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ABSTRACT 
 
Corbin G. Thompson:  Multispecies Evaluation of Antiretroviral Disposition in a Putative Tissue 
Reservoir Of HIV: Implications For Eradication 
(Under the direction of Angela D.M. Kashuba) 
 
Ongoing HIV replication within gut lymphoid tissues may contribute to the persistence of 
HIV despite treatment with antiretrovirals (ARVs). ARVs may have reduced exposure in certain 
tissue areas, but current methods for assessing ARV tissue concentrations cannot test this 
hypothesis. The goal of this project was to characterize how ARVs distribute within gut tissue, 
and determine whether or not they concentrate in areas of local HIV gene expression. Drug 
transporter expression and localization were also evaluated in these tissues to determine what 
factors influence ARV distribution.  
Using mass spectrometry imaging (MSI), the ileum and rectum of humanized mice 
(n=49), non-human primates (NHP, n=12) and humans (n=5) were evaluated for ARV 
distribution. The co-localization of ARV distribution with CD3+ T cells, drug efflux 
transporters, and HIV RNA expression was assessed. ARV correlation with CD3+ T cells ranged 
from -0.09 to 0.32 and was not significantly different between species. HIV RNA was not co-
localized with ARV exposure in any species (r range -0.09-0.2). ARV-transporter co-localization 
was highest for MDR1 in all species, and not significantly different between the ileum and 
rectum. MSI provided previously unobtainable distributional data, showing ARV localization to 
specific tissue sites and no co-localization with HIV gene expression. 
iv 
 
Drug transporters affect ARV tissue disposition and can be exploited to maximize ARV 
exposure, but quantitative measures of drug transporter protein expression across preclinical 
species are not available. Gene and protein expression of ARV efflux and uptake transporters 
were evaluated using qPCR, Western blot, and LC-MS proteomics. Gene and protein expression 
were generally consistent between infected and uninfected animals and between ileum and 
rectum. There was poor correlation between methods, and no single method significantly 
predicted tissue ARV concentrations in a stepwise regression model. We also show that the 
contribution of human transporter isoforms in humanized mice can significantly affect 
interspecies comparisons. Human protein expression data was most consistent with humanized 
mice (1-9 fold different) over NHPs (1-21 fold different). By completing these experiments in 
two animal species and in humans, we can better understand how HIV persists in tissues and 
inform the development of targeted therapies for HIV eradication. 
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Chapter I: HIV Persistence in GALT: Pharmacological Challenges and Opportunities  
Summary 
 
An increasing amount of evidence suggests that HIV replication persists in gut-associated 
lymphoid tissues (GALT) despite treatment with combination antiretroviral therapy (cART). 
Residual replication in this compartment may propagate infection at other sites in the body and 
contribute to sustained immune dysregulation and delayed immune recovery. Therefore, it is 
important to focus efforts on eliminating residual replication at this site. There are several 
challenges to accomplishing this goal, including low antiretroviral (ARV) exposure at specific 
tissue locations within GALT, which might be overcome using the tools of clinical 
pharmacology. Here, we summarize the evidence for GALT as a site of residual HIV replication, 
highlight the consequences of persistent infection in tissues, identify current pharmacologic 
knowledge of drug exposure in GALT, define the challenges that hinder eradication from this 
site, and propose several avenues for pharmacologic intervention.  
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Introduction 
 
The ability to suppress HIV replication with combination antiretroviral therapy (cART) 
permanently changed the landscape of HIV/AIDS. Since the introduction of cART in 1996, the 
life expectancy of HIV-infected individuals has continued to climb to levels near those of non-
HIV infected populations, showcasing the dramatic effect of cART on reducing viral load and 
preventing or reversing AIDS.1 Despite this, studies evaluating the need for continued cART in 
the setting of undetectable plasma virus have demonstrated rebound viremia as soon as 2-3 
weeks after drug discontinuation.2–4 Using ultra-sensitive assay techniques, HIV DNA is 
detectable in resting CD4+ T cells even in patients who have had undetectable plasma viral loads 
for years.5 Utilizing decay rates of HIV RNA in plasma and DNA in peripheral blood 
mononuclear cells (PBMCs), Perelson et al developed a mathematical model which estimated the 
overall half-life of viral decay to be approximately 44 months.6 Given this extremely long rate of 
viral decay , it has been estimated that it would take 73 years of cART to fully eradicate HIV 
from the body.7  Therefore, HIV persistence despite cART is a hallmark of HIV infection and 
represents a significant barrier to cure.  
It is well established that HIV latency is a primary driver of persistence in humans. The 
latent reservoir, comprised of long-lived memory and potentially follicular helper T cells, is 
established early in infection and is unaffected by current antiretroviral (ARV) therapies.8,9 
However, it also has been hypothesized that ongoing viral replication from productively-infected 
CD4+ T cells in certain tissue reservoirs may contribute to persistence. While this hypothesis 
remains controversial, mounting evidence suggests that active replication may be occurring in 
sites such as the central nervous system, genital tract, and lymphoid tissue.10–13 Gut-associated 
lymphoid tissue (GALT) is perhaps the most likely source of ongoing HIV replication given its 
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high concentration of HIV target cells and its role as a site of initial HIV exposure and early 
infection. Given the extensive distribution of GALT and its important role in immune function, 
ongoing replication in this compartment may have clinical consequences not observed from other 
tissue reservoirs. 
As the evidence for ongoing replication in tissue reservoirs continues to grow, so does the 
need for interventions aimed at eradicating HIV from these sites. Clinical pharmacology can play 
a large role in understanding how these reservoirs persist in the face of cART, and in the 
development of targeted interventions for HIV eradication. The tools of pharmacology can also 
help to clarify the mechanisms of persistence in GALT (e.g. active replication, latency, or both). 
The pharmacologic mechanisms influencing HIV tissue reservoirs have been previously 
reviewed14,15, but none have focused on the unique challenges faced in eradicating HIV 
replication in GALT. The purpose of this chapter is to summarize the evidence for ongoing HIV 
replication in GALT, address the challenges associated with current eradication strategies, and 
propose opportunities for pharmacologic intervention. 
 
HIV Persistence in GALT 
 
 GALT is the largest component of the lymphoid system, comprised of the tonsils, Peyer’s 
patches, lymphoid aggregates in the stomach and small intestine, and lymphoid cells in the 
lamina propria.  GALT contains the highest concentration of CD4+ T cells, making it an ideal 
target for HIV infection.16,17 GALT is also one of the first tissues to become infected after 
exposure, with T cell decreases observed as soon as four days after infection.17–19 Given this 
early establishment of infection and the large number of target cells, this compartment may be a 
natural candidate for HIV persistence. Clinical observations support this hypothesis, where HIV 
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RNA shedding from the rectum of HIV positive, STI uninfected men, was reduced but not 
eliminated with cART.20,21 In addition, gut immune activation after initial infection has also been 
shown to persist despite long-term treatment, suggesting persistent exposure to viral antigens.22 
Further, the amount of infectious virus in active CD4+ T cells (many of which are located in the 
GALT) was found to be 1.6-fold higher than in resting CD4+ T cells, suggesting that latently-
infected cells do not account for all of the residual virus.23 
 Given the lymphoid nature of GALT and the corresponding clinical evidence of 
persistent replication at this site, several groups have looked for molecular evidence of HIV 
persistence and compartmentalization in the gut. HIV RNA and DNA have been shown to 
concentrate in the gut compared to PBMCs, and that this distribution changes along the length of 
the GI tract (e.g. unspliced RNA in the ileum and rectum were increased 10.2 and 2.4-fold over 
blood, respectively).24 In addition, the ratio of RNA/DNA (as high as 4.6) throughout the gut 
suggests low level replication.24 Additional work found that HIV DNA concentrations were on 
average 5-fold higher in the gut versus PBMCs in patients on suppressive cART, even after 
correcting for T-cell population differences between these compartments.25 In a study in which 
DNA was isolated from the rectum, PBMCs, and plasma of patients not receiving cART, greater 
diversity was observed among gut-derived HIV variants versus those derived from PBMCs, and 
these variants were interspersed among all three compartments, suggesting movement between 
sites.26 Further, no evidence of compartmentalization was observed in a study using DNA 
isolated from the ileum, colon, and PBMCs of HIV positive patients with undetectable plasma 
viral loads.27 This finding was corroborated in further work showing HIV envelope sequences 
were not significantly different between cells derived from GALT and PBMCs, however the 
authors did not find evidence of HIV evolution in GALT.28 In addition, recent phylogenetic work 
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has shown that viral sequences derived from PBMCs were phylogenetic offspring from 
sequences derived from lymph nodes in patients with undetectable plasma viral loads.29 Though 
this study was not performed in GALT, it demonstrates that focal HIV replication in lymphoid 
tissue can maintain PBMC infection during suppressive therapy. Together, these data support 
persistent HIV replication within the GALT, and that this local replication can maintain infection 
in the plasma through free movement of infected cells or virions between these compartments. 
 Despite these results, several investigations suggest that GALT is not the sole source of 
rebound viremia upon treatment cessation. For example, a cross-sectional evaluation of multiple 
T cell subsets by McBride et al showed that less than 20% of total HIV DNA was found in 
memory T cells with gut migratory capacity.30 Further, sequence analysis of rebound plasma 
virus from three HIV-infected patients who experienced treatment interruption demonstrated that 
the post-interruption viral sequences were not GALT-derived, suggesting an alternative source of 
rebound viremia.31 This hypothesis is supported by a recent study that sampled GALT and lymph 
nodes before and after treatment interruption and found that rebounding HIV variants likely arise 
from many anatomic sites, rather than from a small viral population from a single location (e.g. 
GALT).32  
 Nonetheless, the studies discussed above provide convincing evidence of persistent HIV 
replication in GALT, although the contribution of this replication to viral rebound remains 
unclear. Clinical observations are supported by genetic analyses, which indicate that viral gene 
expression in GALT is maintained even in the setting of undetectable plasma viral loads, and that 
there is likely cross-talk between plasma and tissue that may propagate infection in PBMCs. 
Though direct evidence is still needed (since attempts at isolation of replication competent virus 
6 
 
from durably suppressed patients have failed33), these data provide a foundation for exploring the 
mechanisms of HIV persistence in this tissue compartment. 
 
Consequences of HIV GALT Persistence 
 
 Immune Dysregulation in Acute Infection As an early site of HIV exposure and infection, 
GALT plays an important role in the pathogenesis of HIV infection. The interplay between 
immune cell depletion and activation, local viral dynamics, and systemic immune dysregulation 
is complex and is the focus of thorough reviews.34,35 It was observed early in the HIV epidemic 
that infection resulted in severe GI complications and was associated with increased mortality in 
AIDS patients.36,37 This was caused by severe depletion of specific T cell populations within 
GALT that occur rapidly after infection (27% reduction within 4 weeks).19 Specifically, IL-17 
expressing T helper cell (Th17) populations were found to be preferentially depleted in SIV 
infection, which may lead to decreased immune function and disruption of gut epithelial 
integrity.38 Studies in macaques and humans have shown these T cell decreases to occur within 
the first week of infection.17–19 The importance of T cell depletion within GALT has been 
supported by studies showing that elite controllers do not experience specific depletion of Th17 
cells, suggesting that this immune dysregulation is a main driver of disease progression.39 
 Delayed Immune Reconstitution Persistent replication within GALT also represents a 
large obstacle to restoring immune function in HIV positive patients. It is well documented that 
immune reconstitution is delayed in GALT following initiation of cART19, and that a systemic 
inflammatory state is maintained even after plasma viral loads are undetectable.40 This persistent 
inflammation, likely driven by continued GALT disruption, has been associated with poor 
outcomes and the development of comorbid conditions in these patients.41 The mechanisms 
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responsible for this delay have not been fully determined, but several studies have implicated 
ongoing CD8+ T cell activation, fibrosis, or impaired mucosal homing as contributing 
factors.22,42,43 Importantly, ongoing viral replication in GALT could help explain this delay in 
immune recovery regardless of the specific mechanism(s) involved. Persistent exposure of viral 
antigen to antigen-presenting cells in the gut can increase inflammatory markers44, decrease 
epithelial integrity45, and increase microbial translocation46, continuing the cycle of local 
immune dysregulation and systemic inflammation. Microbial translocation is of particular 
concern, as this is associated with increased incidence of comorbidities and hastened disease 
progression.47,48 The profound immune depletion in GALT, with subsequent clinical 
complications, underscore the importance of eradicating residual viral replication in this 
compartment.  
 
Challenges to Eradicating HIV GALT Replication 
 
 As introduced above, there are a number of factors that make GALT an ideal reservoir for 
HIV. The first line of defense against cART lies in the anatomy and location of GALT. Blood 
perfusion to the GALT via the extensive mesenteric arterial network is more variable than 
perfusion to other sites, and may be reduced in situations where blood is needed in other organs 
(e.g. skeletal muscle during exercise, brain during shock). Further, the proximity of GALT to the 
colorectum, a site of HIV exposure, and the high density of target cells make it a site of initial 
infection and viral propagation. Clinical evidence suggests that the HIV reservoir is established 
within days after infection49, and it is reasonable to expect that this may happen in GALT.  
Clinical studies show that initiation of cART during the acute-phase reduces, but does not 
8 
 
eliminate, the HIV reservoir,49,50 likely due to the very early establishment of the latent reservoir 
before cART can be initiated. Thus, alternative strategies for HIV elimination are required. 
 A critical obstacle to achieving HIV eradication in GALT is the potential for inadequate 
ARV distribution into this compartment. ARV penetration into gut tissues is highly variable, 
both between and within drug classes51, and is not easily predicted based on chemical structure 
or standard pharmacokinetic properties.52 The lack of complete immune restoration in GALT 
following cART administration and the isolation of HIV RNA from tissues in patients with 
suppressed plasma HIV RNA levels provides indirect evidence that ARVs may not achieve 
adequate concentrations in certain areas of GALT.  This is supported by tissue homogenate data 
showing that GI exposures of ARVs such as dolutegravir are 83% lower than plasma.53 
Additionally, studies evaluating the utility of intensified ARV dosing regimens on the size of the 
viral reservoir have shown little effect, suggesting that anatomic or pharmacokinetic barriers may 
exist that prevent ARV penetration into GALT.54,55 A study by Fletcher et al compared ARV 
concentrations between PBMCs and mononuclear cells (MNCs) isolated from the lymph nodes, 
ileum, and rectum.56 It was found that ARV concentrations in gut MNCs were up to 100% lower 
than PBMC concentrations, and that lower concentrations correlated with slower HIV decay rate 
in these tissues. These data suggest that ARVs retain their efficacy provided they are able to 
reach an as-yet unidentified threshold concentration in target cells. However, the interplay 
between active replication secondary to reduced ARV exposure and latent infection remains 
unknown, as does the relative contribution of each of these processes to HIV persistence. 
 Despite the direct and indirect evidence that a lack of ARV tissue penetration contributes 
to HIV persistence, this idea remains controversial. The most frequently cited counterargument is 
the lack of observed drug resistance that would be expected to develop in the setting of 
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subtherapeutic ARV exposure.57 Given that resistance is known to develop rapidly when ARV 
concentrations drop below therapeutic concentrations in plasma, it is reasonable to question this 
pharmacologic assertion. In the absence of widespread resistance developing in patients, some 
have interpreted the continued detection of HIV gene expression as simply random egress from 
latency, having little to do with drug penetration.57 However, it has recently been suggested that 
ARV exposure in tissue reservoirs may be so low that the threshold for resistance development is 
never met.29 In other words, minimal ARV exposure allows for continued replication of wild-
type virus which can outcompete resistance variants that could otherwise emerge. In this way, 
inadequate ARV penetration into tissues may contribute to ongoing replication congruent with 
clinical observations of low level viremia in patients receiving cART. 
In addition to propagating immune dysfunction and systemic inflammation, inadequate 
ARV penetration into target cells may also hinder efforts of latency reversal and blunt the 
corresponding host immune response.22 Reversal of HIV latency in quiescent memory T cells 
using small molecule drugs represents a promising approach for reduction or eradication of the 
HIV reservoir, and several drug candidates are currently undergoing clinical evaluation.58,59 A 
key assumption underlying these efforts is that virions produced from these re-activated T cells 
will be unable to infect nearby healthy cells and stimulate new rounds of HIV replication. 
However, this assumption is valid only if ARVs are present at sufficient concentrations to inhibit 
viral replication. However, if enough healthy T cells remain unexposed to ARVs56 in the setting 
of latency reversal, reactivation of quiescent cells could result in no effect, or possibly an 
increase in the size of the viral reservoir through new rounds of infection. 
There are several barriers that complicate the optimization of ARV therapy for HIV 
eradication in GALT. First and foremost is the limited knowledge of the specific factors that 
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influence ARV disposition in GALT. ARV penetration into tissues is variable and dependent on 
several physicochemical and pharmacokinetic characteristics.51 Volume of distribution and 
plasma protein binding are important variables and vary widely from drug to drug. Drug 
transporters and metabolizing enzymes are also known to affect the absorption and distribution 
of ARVs, and there are many examples of clinically significant drug-drug interactions involving 
these proteins.60 Though the specific transporters or enzymes utilized by ARVs vary between 
drug classes, the metabolizing enzymes of the CYP450 family, particularly CYP3A4, and the 
efflux transporters p-glycoprotein (P-gp), breast cancer resistance protein (BCRP), and the multi-
drug resistance proteins (MRP) are responsible for a significant portion of ARV transport and 
metabolism.61 As such, alterations in the expression and/or activity of these proteins can have a 
dramatic effect on local ARV concentrations. As an example, the penetration of atazanavir 
(ATZ) into the brain was increased by 5.4-fold in P-gp/BCRP knockout mice compared to wild-
type, showing that a lack of functional efflux transporters at the blood brain barrier allows more 
drug to enter tissue.62 Other groups have shown that the expression of the uptake transporter 
family OAT1 at this site also modulates TFV brain penetration.63 These findings have been 
corroborated in other tissues such as the testes, where it was shown that inhibition of P-gp and 
BCRP in human Sertoli cells increases the testicular uptake of ATZ,64 and in in P-gp/BCRP 
knockout mice, where ATZ concentrations in testicular tissues were increased by 4.6-fold 
compared to wild-type mice.62 A recent paper by Bendayan showed that the penetration of 
protease inhibitors into human testes was variable and may be dependent on drug transporter 
expression and localization.65 
Expression and activity of these proteins is variable along the GI tract.66,67 For example, 
protein expression of P-gp and BCRP was found to be 3-fold higher in the ileum versus the 
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colorectum, with the opposite being true for the efflux transporter MRP2 (1.5-fold lower in ileum 
vs colorectum).67 CYP3A4, an enzyme responsible for the metabolism of protease inhibitors,  
has been shown to be expressed at varying levels in GI tissue, and is highest in the 
duodenum.66,68 In combination, these factors may explain the large differences observed in ARV 
exposure in tissues, including the GI tract. For example, the exposure of the P-gp substrate RAL 
in the splenic flexure was shown to be 2.8-fold higher than the terminal ileum or colorectum.69 
This is inversely related to the expression patterns of P-gp in the GI tract,67 suggesting that 
decreased RAL efflux out of enterocytes secondary to focal decreases in efflux transporter 
expression can result in compartment-specific increases in RAL exposure along the GI tract. This 
complicates attempts to achieve maximum drug exposure in tissue, as the local expression of 
drug transporters and enzymes may be the primary driver of tissue concentration. To date there 
has been no evaluation of the relationship between these variables and ARV GALT exposure, 
however given the numerous examples of altered plasma pharmacokinetics secondary to drug 
transporter or metabolizing enzyme interactions in the gut, it is reasonable to expect that changes 
in these variables will also have an effect on local ARV exposure in GALT. 
An additional barrier to ARV optimization in GALT is the lack of target concentrations 
for efficacy in this setting. Plasma target concentrations are well established and are easily 
achievable by standard dosing regimens (derived from early dose finding studies), but similar 
target concentration values for eradication of residual HIV replication in tissues have not been 
determined. HIV RNA has been detected in the GI tract of patients receiving cART who had 
detectable ARV concentrations in these same tissues, providing evidence that current regimens 
are not sufficient to stop residual replication, although these patients had only been receiving 
cART for several months.20 The lack of efficacy observed in ARV intensification studies54,55 
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shows that more sophisticated methods of determining effective concentrations are needed to 
define pharmacokinetic targets in this compartment, as higher concentrations may be needed for 
a longer period of time in tissues compared to plasma. In a study of pre- and post-cART reverse 
transcriptase (RT) sequences in 8 HIV-infected participants, it was found that sequence diversity 
decreased 1.5-2 fold throughout the gut during treatment, and that zidovudine (ZDV)-resistant 
variants were concentrated in the gut versus PBMCs, demonstrating that efficacy targets may be 
different between these compartments.70 The ability to define exposure-response relationships in 
GALT and other tissue reservoirs, as has been done in the female genital tract for HIV 
prevention efforts71, will be critical to overcoming HIV replication in this compartment. Defining 
these relationships is unlikely to change current dosing strategies (though dose intensification 
studies suggests this would have little effect), however a well-defined PK target in tissues would 
inform the development, or selection, of targeted therapies to stop replication. 
The challenges described above highlight the difficulty in eliminating HIV persistence in 
GALT. While some barriers are unavoidable (e.g. high target cell concentration, size and 
complexity of GALT, etc.) others, such as inadequate drug penetration or the contribution of 
drug transporters or metabolizing enzymes, can be acted on in a rational way to improve 
therapeutic success in this area. The next section focuses on ways that clinical pharmacology 
approaches can inform the design of targeted therapies for HIV eradication in GALT.  
 
Opportunities for Pharmacologic Intervention 
 
Emerging Technologies to Understand ARV Distribution 
 The ability to accurately quantify ARV concentrations in tissue reservoirs like GALT is 
critically important in understanding the distribution of these drugs. To date, most evaluations of 
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ARV tissue concentrations have used liquid chromatography-mass spectrometry (LC-MS) 
analysis of tissue homogenates.51 Though traditional LC-MS methodology can provide clinically 
useful quantitative data, it does not have the ability to identify distributional patterns within the 
tissue, as the entire sample is consumed in the homogenization process. This is a critical 
limitation of the technology, as it has been shown for other drugs that distribution across tissue is 
not uniform.72 For example, if the majority of a particular ARV were located in a specific tissue 
compartment (e.g. epithelial layer) with no distribution into the rest of the tissue, LC-MS may 
overestimate the penetrative ability of this ARV. This is particularly concerning if HIV 
replication is occurring in focal areas within a tissue that cannot be reached by ARVs. Further, 
because the majority of ARVs have intracellular sites of action, concentrations within cells are 
the largest determinant of antiviral efficacy. MNC isolation from reservoir tissues overcomes the 
limitations of LC-MS by reporting ARV concentrations only in the cells of interest.56 However, 
this method cannot easily or completely account for drug lost during the isolation process which 
can significantly underestimate true intracellular concentrations,73 nor can it distinguish cell 
populations derived from different areas within a tissue. Therefore, it is crucial to use alternative 
technologies to define ARV distribution into tissues and cells. 
Mass spectrometry imaging (MSI) is a growing field that has numerous potential 
biological applications and is already being implemented in the drug development process.74 
MSI combines the sensitivity and specificity of LC-MS with the ability to visually observe 
distributional patterns within tissue. Using infrared matrix assisted laser desorption/electrospray 
ionization (IR-MALDESI), a novel MSI method, we have demonstrated that the distribution of 
ARVs like efavirenz is heterogeneous within the colorectum, concentrating in the mucosa and 
lamina propria and corresponding to areas of high CD3+ T cell density.75 Tissue drug imaging 
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can be particularly powerful when combined with other techniques such as in situ hybridization 
(ISH) or immunohistochemistry (IHC). Leveraging all of these methods in combination, it is 
possible to compare ARV distribution to that of HIV target cells (IHC) or to HIV itself (ISH) to 
determine whether ARV localization corresponds with areas of local HIV replication.76 Because 
IR-MALDESI is quantitative76–78, it is also possible to determine what local concentrations are 
needed within a tissue compartment to effectively suppress HIV replication, aiding in the search 
for target concentrations in tissues. 
 Raman spectroscopy (RS) is another promising imaging technique that has the potential 
to provide ARV distributional data within unperturbed tissues like GALT. Utilizing the 
principles of Raman scattering and confocal microscopy, RS can identify exogenous substances, 
such as small molecule ARVs, in heterogeneous tissue matrices.79 Like IR-MALDESI, RS can 
potentially identify areas of ARV localization. Unlike IR-MALDESI, however, RS is able to 
temporally analyze small molecule distribution, providing spatial information in real time.80 
Recently, RS has been combined with optical coherence tomography (OCT) technology to 
identify tenofovir distribution in mucosal tissues at various tissue depths.81 Another advantage of 
RS, and one that is shared with IR-MALDESI, is the high spatial resolution these technologies 
can provide. Both technologies have been demonstrated to accurately detect drug at resolutions 
of 100 microns or lower.79,82 This is especially important for distinguishing ARV distribution 
among different cell populations in heterogeneous tissues like GALT. As these technologies 
improve, it may be possible to distinguish ARV concentrations at different cellular locations83, 
providing even more specific PK information in the cytosol (relevant for most ARVs) versus the 
nucleus (relevant for integrase inhibitors).  
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 Droplet microfluidics is a pioneering technology that allows for high-throughput, single 
cell assays.84 In the case of HIV persistence, where proviral DNA may be found in a relatively 
small number of cells, understanding how the exposure of a current or novel therapy exerts its 
PD effect ex vivo would provide a foundation for optimization of therapy. By encapsulating 
single cells inside small volume (1pL) droplets and performing reactions within each droplet, 
microfluidics overcomes the disadvantages of current techniques.85 This technology has been 
used previously to perform cellular screening assays for drug effect and genetic analysis to link 
genotype to phenotype in a single cell population.86,87 Though this technique has not yet been 
used to evaluate small molecule concentrations, it shows promise in the area of cellular ARV 
PK, as differential exposure between and among cell types can be evaluated with high frequency 
(2000Hz), with simultaneous evaluation of PD effects (protein or gene expression changes).  
 Evaluation of small molecule tissue and cellular distribution using novel technologies is a 
burgeoning field. IR-MALDESI and RS have a growing body of evidence demonstrating their 
utility in this arena. Microfluidics shows additional promise for performing cellular PK/PD 
evaluations. The advantages and disadvantages of each of these technologies is summarized in 
Table 1.1. One limitation that is shared by all of these methods is the difficulty in accounting for 
synergy among ARVs, which may result in adequate control of replication despite suboptimal 
exposure of the individual drugs. Additionally, though IR-MALDESI has been used to evaluate 
ARVs from multiple classes88, RS and microfluidics have had limited or no use in ARV 
pharmacology to date and it is unknown whether or not these methods will have widespread 
utility. However, exploring the use of these techniques and others to evaluate ARV distribution 
in GALT is an important step toward HIV eradication.  
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Table 1.1: Potential Technologies to Evaluate Small Molecule Tissue Distribution 
Method Quantitative 
Visual 
Inspection of 
Analyte 
Distribution 
Changes in 
Exposure 
Over Time 
Resolution 
Flexible 
Workflow/Samp
le Preparation 
LC-MS/MS of 
Tissue 
Homogenates
56,89 
Absolute 
quantitation 
possible 
Not possible 
Not possible 
with a single 
tissue 
Averaged 
concentrations 
within an 
isolated cell 
population 
Validated 
methods 
available for 
most tissue or 
fluid matrices 
Mass 
Spectrometry 
Imaging 
75-78,86 
Absolute 
quantitation 
possible 
Yes, across a 
single tissue 
cross-section 
Not possible 
with a single 
tissue 
≤ 100 micron 
spatial 
resolution 
Sample 
preparation and 
imaging 
parameters must 
be optimized for 
each tissue 
Raman 
Spectroscopy
79–81 
Absolute 
quantitation 
possible 
Yes, coupled 
with optical 
coherence 
tomography 
Possible in a 
single 
transwell 
experiment 
≤ 100 micron 
spatial 
resolution 
Requires setup of 
transwell assay 
system and 
optimization of 
analyte detection 
Droplet 
Microfluidics
85 
Quantitation 
possible with 
labelled 
analytes 
Not possible 
in tissue 
Not possible 
with cells 
from a 
single tissue 
Single cell 
resolution 
Requires 
specialized 
cellular isolation 
and preparation 
 
Defining the Factors Influencing ARV Disposition 
 When viewed in isolation, drug exposure in tissues is limited in its ability to inform 
development of HIV therapies targeted at GALT or other tissue reservoirs. Beyond simply 
defining and describing the problem (e.g. a certain drug is sequestered in the gut mucosa, 
allowing for ongoing HIV RNA expression in submucosal T cells), distributional data needs to 
be evaluated from the perspective of improving ARV exposure. As above, ARV disposition in 
the GALT is dependent on many factors affecting absorption and distribution (Figure 1.1). The 
physicochemical characteristics of the ARVs themselves likely play an important role in tissue 
exposure. It has already been shown, for example, that drugs with low plasma protein binding 
penetrate better into mucosal tissues.52 Further, the retention time of these drugs (as a function of 
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their half-life in tissues) is also critical, as it has been shown that ARVs like indinavir are rapidly 
cleared from the lymph compartment despite achieving equilibrium with plasma 
concentrations.90 In addition, there may be certain components of the molecular structure of 
ARVs that favor increased GALT exposure, and these features can potentially be utilized in the 
development of nanoformulations targeted at tissue reservoirs.91,92 Targeted nanoformulations 
have shown success in cancer therapeutics, and several nanoformulated drugs are approved for 
use in breast and pancreatic cancer, achieving increased exposure into tumors and increasing 
survival rates.93 Among ARVs, a nano-formulated version of indinavir was shown to achieve a 
6-fold increase in lymph node concentrations and greater exposure in plasma.94 Additional 
formulations for drugs such as abacavir, rilpivirine, and efavirenz are already in development, 
Figure 1.1: Factors influencing Antiretroviral Disposition and Efficacy in GALT Solubilized 
drugs (green, red, and blue circles) can penetrate into intestinal tissue from peripheral blood supply 
or directly from the intestinal lumen. Penetration arising from blood is dependent on the amount of 
local perfusion as well as pharmacokinetic properties of the drug, i.e. drug bound to plasma protein 
(shown in yellow) cannot enter tissue. Penetration from the gut lumen is dependent on 
physicochemical properties of each drug as well as affinity for drug efflux (blue, green) or uptake 
(red) transporters on the surface of epithelial cells. GALT-specific exposure is also dependent on 
local blood perfusion and drug transporter expression on the surface of lymphocytes. 
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masking unfavorable PK characteristics to maximize ARV tissue exposure.95–97 For example, a 
dimeric prodrug formulation of abacavir, which functions as a P-gp inhibitor when dimerized but 
that can still exert anti-HIV activity when cleaved to its monomer form, has been developed to 
increase abacavir penetration into the CNS.95 Similar approaches for other ARVs to increase 
GALT exposure should be considered. 
Another important step toward eradication is to identify which drug transporters or 
metabolic enzymes either adversely or favorably affect ARV exposure in the GALT. Exploiting 
these factors to increase ARV GALT penetration from the lumen (e.g. P-gp inhibition on 
enterocytes to decrease efflux) or systemic circulation (e.g. CYP3A4 inhibition in the liver to 
increase half-life) may overcome the inherent challenges in treating GALT persistence. Several 
studies have shown drug transporter expression to be inconsistent along the GI tract67, but 
transporter localization in relation to GALT has not been evaluated in this context. A potential 
explanation for this gap in knowledge is the lack of consistency with which transporter 
expression is evaluated and reported, as the methodology used in these studies is highly variable, 
with groups using qPCR, immunoblot, LC-MS proteomics, IHC, or some combination of these 
methods.98–101 Further, there has been no formal analysis of the agreement of these techniques 
with one another. Gene expression has been shown to vary drastically from end protein 
expression, and even measures of transporter proteins may give very different results.101 In order 
to fully characterize which drug transporters or metabolic enzymes affect local ARV 
concentrations in GALT, a consensus should be reached on the best expression measures in 
tissues. Studies formally comparing these methods to each other and examining which method of 
measurement provides the most useful comparisons to ARV distribution are greatly needed.  
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Leveraging ARV distribution data against the biologic factors that influence these 
distribution patterns will provide the most informative data for the design of novel therapies 
targeted at tissue reservoirs, including GALT. In addition to identifying which ARVs achieve the 
highest exposure in GALT and if the exposure occurs where latent and/or reactivated HIV virus 
is located is critical. Further, defining which drug characteristics, transporters, or enzymes should 
be targeted or avoided when developing new therapies or optimizing existing ones would refine 
novel strategies to pursue. Importantly, defining the characteristics that affect ARV exposure in 
GALT is likely to also inform the exposure of LRAs and other small molecules compounds in 
GALT. While specific factors may differ between drug classes, the lessons learned from 
evaluation of ARVs in this tissue can be easily translated to LRAs, for which GALT exposure is 
equally important.  
 
Utilizing Pre-Clinical Models to Streamline Drug Development 
 The location and nature of many active HIV reservoirs make them difficult to sample in 
human participants. Limited repeat sampling can be accomplished in some sites including 
GALT, but extensive evaluation of human GALT tissue remains a challenge, particularly for the 
ability to recover virus from tissue biopsies. These limitations necessitate the use of pre-clinical 
animal models to study HIV persistence. Unfortunately, it has been shown that ARV distribution 
can be variable between species, with tissue ARV penetration varying greatly between 
humanized mice, non-human primates, and humans. This is especially problematic when plasma 
data from animal models are used to select effective doses for humans, potentially adversely 
affecting clinical trials. The reasons for these discrepancies are multifactorial, but species 
differences in drug transport and metabolism are likely contributors.  An extensive review by J. 
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Lin summarizes some of these differences, including that the concentrations of CYP3A and 
CYP2C are increased by 1.8 and 12-fold in rats compared to humans,102 which can lead to 
increased metabolism of substrates (e.g. protease inhibitors, NNRTIs) and decreased plasma or 
tissue exposure over time. Further, our group has shown substantial differences in gene and/or 
protein expression of several drug transporters between humanized mice and non-human primate 
models, which may affect local concentrations of ARVs transported be these proteins, 
particularly those affected by P-gp (e.g. abacavir) and BCRP (e.g. dolutegravir) 101,103 
The challenges in reconciling data from pre-clinical species as it relates to HIV 
persistence have been recognized by the field.104 However, it is obvious that an animal model 
that accurately reflects ARV tissue distribution in humans or that can be accurately scaled to 
predict human distribution would be helpful in the evaluation of candidate ARVs for targeting 
GALT. The generation of reliable interspecies scaling factors for ARV distribution and 
metabolism would streamline ARV development when tissue targeting is required. To 
accomplish this, studies evaluating ARV distribution and metabolism across multiple species 
including humans, and particularly focusing on GALT, should be conducted. These data can 
form the foundation for quantifying the variability of ARV distribution across models and 
developing models to accurately predict these endpoints in humans, and greatly inform 
eradication strategies, including anticipated combination strategies in which drug-drug 
interactions are possible. 
Conclusion 
 
 HIV persistence represents the largest obstacle in the search for a cure. If ongoing 
replication in GALT is to be eliminated, an understanding of how this reservoir propagates is 
needed. Although this compartment presents unique challenges to eliminating replication, the 
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pharmacologic tools described here offer promising solutions. Tissue imaging provides 
distributional data that has been previously unattainable, and will allow the field to assess 
whether or not ARVs have a significant presence in reservoirs by identifying and quantifying 
within-tissue localization. This has enormous implications for HIV persistence; heterogeneous 
ARV distribution in the GALT would provide convincing evidence that current therapies are 
simply not present where they are needed, while reproducibly broad distributional patterns would 
suggest alternative reasons for persistent infection. Demonstrating that HIV replication is 
occurring in areas or cells with low ARV exposure would provide further evidence that 
inadequate ARV tissue exposure contributes to HIV persistence. 
In addition to clarifying the mechanisms driving HIV persistence in GALT, the tools of 
pharmacology can be used to inform the development of targeted therapies for HIV eradication. 
Defining the factors governing ARV exposure in GALT will help to identify which variables to 
target or avoid during the development of novel small molecules, particularly once preferred 
methodologies for measuring these factors are identified. Additionally, performing these 
evaluations in multiple pre-clinical species will provide foundational knowledge of interspecies 
tissue distribution differences. This will be critical for the evaluation of candidate ARVs and 
latency reversing agents for targeting reservoirs by preventing the inappropriate interpretation of 
data from one species to another. Ultimately, these data will allow for a more directed design of 
therapies aimed at eradicating HIV reservoirs and potentially curing HIV. 
  
22 
 
Specific Aims 
 
AIM 1: Define ARV distribution within a putative viral reservoir from 2 animal species 
using IR-MALDESI imaging and LC-MS/MS methods 
1a: Using IR-MALDESI imaging, characterize and quantify the spatial distribution of ARVs 
from 5 therapeutic classes within the gastrointestinal-associated lymphoid tissue (GALT) of non-
human primates (NHP), and 2 humanized mouse models. This will allow for determination of 
whether ARVs concentrate in certain tissue sub-compartments, and whether this differs across 
pre-clinical species. Discussed in Chapter II 
1b: Utilizing tissues collected in Aim 1a, identify the distribution of HIV target cells and HIV 
RNA, and quantify their co-localization with ARV distribution. By co-localizing ARV 
distribution with these variables, deficiencies in exposure at the site of action can be identified. 
This will provide critical data to clarify the mechanisms of HIV persistence. Discussed in 
Chapter II 
AIM 2: Identify the physiologic factors that influence ARV distribution and activity in 
tissues suspected of being active viral reservoirs.  
2a: Quantify the gene and protein expression of relevant drug transporters in the GALT of 
humanized mice and NHPs using qPCR, Western blotting, and LC-MS proteomics. Quantify 
cross-species variability and identify any species-specific features which may influence drug 
transporter activity. This will be the first comprehensive comparison of commonly-used 
methodologies for drug transporter expression across species. Discussed in Chapter III 
2b: Utilizing tissues collected in Aim 1a, evaluate the potential effect of drug efflux transporters 
on ARV distribution by quantifying ARV/transporter co-localization along the gastrointestinal 
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tract. Determine whether or not these effects are differential between transporters, between 
species, or between anatomic sites. Discussed in Chapter III 
AIM 3: Identify ARV regimens that concentrate within active viral reservoirs and assess 
their impact on HIV persistence in humans. 
3a: Characterize and quantify the distribution of four commonly used ARV regimens within the 
GALT of virologically suppressed HIV positive patients using IR-MALDESI quantify co-
localization with target cells and HIV RNA. Define the relationship between data from humans 
and animal models. These interspecies comparisons will inform the development of novel 
targeted therapies. Discussed in Chapter IV 
3b: Using tissues collected in Aim 3a, quantify drug transporter gene and protein expression by 
qPCR and LC-MS proteomics, and assess co-localization of drug efflux transporters with 
observed ARV distribution. Quantify the agreement in transporter expression data between 
species and identify differential effects of drug transporters on ARV distribution between 
animals and humans. Discussed in Chapter IV 
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Chapter II: Mass Spectrometry Imaging to Determine Antiretroviral GALT Exposure in 
Preclinical Models of HIV Infection  
Summary 
 
HIV replication within the gut may be propagated by reduced antiretroviral (ARV) 
exposure. Mass spectrometry imaging (MSI) provides biodistribution data that LC-MS cannot. 
Here, we use MSI to visualize ARV distribution within gut tissues from two species, and assess 
co-localization with HIV target cells, HIV RNA, and drug efflux transporters. Two humanized 
mouse (n=49) and one primate (NHP, n=12) models were given combination ARVs. One 10µm 
slice from frozen ileum and rectum was analyzed by MSI.  Serial slices were analyzed for CD3+ 
T cell and efflux transporter localization by IF/IHC, and HIV RNA by ISH. Co-localization of 
ARV and IF/IHC/ISH imaging was performed in Matlab using Pearson correlation (r). ARV 
distribution was heterogeneous in NHP tissues with 2-fold greater mucosal accumulation in NHP 
vs mice, where the majority of ARV detection was secondary to heme. ARV-T cell correlation 
ranged from -0.09 to 0.32, was consistent between species and up to 4-fold higher in the NHP 
ileum versus the rectum. HIV RNA was preferentially detected in areas of low TFV and MVC 
exposure in both species (overall range -0.09-0.2). ARV-transporter co-localization was variable 
between ARVs and highest for MDR1 (range -0.09-0.54) in both species. Co-localization 
suggests efflux transporter expression results in lower ARV exposure in HIV target cells in the 
ileum, which may contribute to low level HIV replication. This is supported by HIV RNA 
detection in the absence of ARV signal. These data support the hypothesis that GALT may act as 
an HIV reservoir, and will inform the development of targeted therapies for HIV eradication.  
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Introduction 
 
 
 The persistence of HIV despite treatment with combination antiretroviral therapy (cART) 
is the major obstacle to eradication of this disease, necessitating lifelong therapy in infected 
individuals. Rebound plasma viremia after treatment cessation is thought to be secondary to 
reactivation of multiple latently-infected memory T cell populations.4,5,8,9 The elimination of this 
latent cellular reservoir has received most of the focus of HIV eradication research to date, 
however it has been hypothesized that residual HIV replication from active T cells within tissue 
reservoirs may also contribute to viral rebound upon treatment interruption.  
 The evidence for continued production of replication-competent virions within certain 
anatomic sites continues to grow and has been extensively reviewed.14,15 Several tissue 
compartments, such as the central nervous system10, male and female genital tracts11,12, gut-
associated lymphoid tissue, and peripheral lymph nodes13 have been implicated as potential 
tissue reservoirs. The contribution of these tissue reservoirs to persistent replication was recently 
investigated by Lorenzo-Redondo et al, who showed that viral sequences isolated from the 
lymph nodes of suppressed patients were genetic descendants of peripheral blood mononuclear 
cell (PBMC)-derived variants and vice versa, demonstrating viral evolution during cART and 
supporting the active reservoir hypothesis.29 Additionally, several groups have used in situ 
hybridization to show localized HIV RNA expression in tissues from cART-treated 
individuals.32,56 While it is unlikely that all of this RNA represents replication-competent 
virus105, these data suggest that the latent reservoir is not the sole contributor to HIV persistence.  
 The extensive immune network contained within GALT and its role as a site of early 
infection make it an important target for HIV eradication efforts. The consequences of HIV 
persistence in GALT, such as prolonged immune dysregulation and delayed reconstitution during 
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cART, are unique from other anatomic compartments and have been previously reviewed in 
Chapter I.106 The mechanism(s) underlying propagation of tissue reservoirs like GALT is 
unclear, but suboptimal antiretroviral (ARV) penetration into tissues has been suggested as a 
potential cause.56 Inadequate ARV exposure at the site of action would help explain the 
persistence of HIV replication and provide an avenue to develop targeted therapies. 
Unfortunately, traditional methods of analyzing small molecule penetration into tissues are 
limited in their capacity to measure within-tissue distribution. Liquid chromatography-mass 
spectrometry (LC-MS) of tissue homogenates has been the gold standard for ARV tissue 
analysis, but provides only an averaged concentration over the entire tissue. If HIV replication is 
occurring focally (e.g. in a single lymphoid follicle), this method may misrepresent ARV 
exposure at the site of action. Some groups have isolated the mononuclear cell (MNC) 
population from tissues before performing LC-MS.56 While this method is an improvement over 
homogenate analysis, it does not account for drug lost during MNC isolation73 and cannot 
distinguish between MNCs from different sites within the tissue.  
 Mass spectrometry imaging (MSI) allows for the visual inspection of small molecule 
analytes within a tissue section, while simultaneously providing absolute quantitation.77,107 We 
have previously demonstrated our ability to detect efavirenz (EFV) distribution within several 
putative tissue reservoirs, including gastrointestinal tissues, and showed that its distribution was 
heterogeneous.75 An advantage of MSI that has yet to be explored is the ability to co-localize 
ARV distribution with other targets from adjacent tissue slices. Understanding ARV disposition 
as it relates to HIV target cells, drug transporters, and HIV RNA expression would greatly 
inform the eradication field, as focal HIV RNA expression in areas of low ARV exposure would 
provide convincing evidence that suboptimal ARV penetration propagates tissue reservoirs. In 
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addition to the lack of within-tissue distributional data, there is a paucity of data on how ARV 
distribution differs among pre-clinical species and between animals and humans. The 
development of any new therapeutic agent requires testing in animal models, but efficacy 
measures for these studies can be greatly skewed if within-tissue distribution is different from 
humans. Defining the differences in ARV distribution, if any exist, between animal models will 
inform the development of novel therapies for use in humans.  
 In this study, we use MSI to visualize the distribution of ARVs from multiple therapeutic 
classes in two GI tissues from three animal models. We quantify concentration in the mucosal 
compartment, and assess the co-localization of ARVs with HIV target cells and with viral RNA 
expression. Additionally, we assess whether ARV localization is correlated with HIV RNA 
expression, or whether focal RNA expression occurs in the absence of ARV exposure. Finally, 
we evaluate the effect of drug transporters on observed distribution patterns, and quantify the 
differences between species. The data generated here provide insight into the mechanisms of 
HIV persistence in GALT, and will form the basis of studies aimed at optimizing cART to 
eradicate HIV. 
 
Methods 
 
Animal Models 
Uninfected Animals 
 Three commonly used animal models from two species were employed in this study: the 
hu-HSC-Rag (n=20) and bone marrow-liver-thymus (BLT; n=6) humanized mouse models and a 
rhesus macaque non-human primate model (NHP; n=6). Humanization protocols used to 
generate both mouse models have been described previously.108,109 Female hu-HSC-Rag mice 
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aged 3-6 months underwent humanization as previously described, and were then dosed with one 
of several ARV regimens for 10 days: EFV 10mg/kg (n=6) alone; atazanavir (ATZ) 140mg/kg 
(n=6) alone; or tenofovir (TFV) 208mg/kg, emtricitabine (FTC) 240mg/kg, raltegravir (RAL) 
56mg/kg, maraviroc (MVC) 62mg/kg (n=6) in combination.  Each drug was given once per day 
(QD). A single cohort of female BLT mice also underwent humanization and received a 
combination of TFV, FTC, RAL, ATZ, and MVC at equivalent doses for 6 days (toxicity has 
been observed with longer dosing periods). All drugs were administered by oral gavage, and 
dosing solutions were prepared by solubilizing formulated drug. Dosing regimens for each 
animal model are summarized in Table 2.1.  
Table 2.1: Sample size and ARV administration schematic 
Dosing 
Regimen 
MICE MACAQUES 
BLT hu-HSC-
Rag 
TFV/FTC/ATZ/
MVC 
TFV/FTC/EFV/
RAL 
+ - + - + - + - 
EFV   N=6 N=6     
ATZ   N=6 N=6     
TFV/FTC/RAL/
MVC 
  N=6 N=6     
TFV/FTC/RAL/
MVC/ATZ 
N=7 N=6       
CONTROL N=2 N=2 N=3 N=2     
TFV/FTC/ATZ/
MVC 
    N=3 N=3 N=3 N=3 
TFV/FTC/EFV/
RAL 
    N=3 N=3 N=3 N=3 
 
The extent of humanization for both mouse models was assessed by quantifying human T 
cell populations using flow cytometry as previously described.109 Male rhesus macaques 
(Macaca mulatta) between 3 and 7 years of age were dosed for 10 days with TFV 30mg/kg 
subcutaneously (SubQ), FTC 16mg/kg (SubQ) and one of the following regimens: MVC 
270mg/kg twice daily (BID) with ATZ 150mg/kg BID OR EFV 200mg QD with RAL 100mg/kg 
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BID. Doses for all drugs in all animal models were chosen based on commonly used treatment 
doses for HIV infection in these models.110–114 Two animals from each mouse model were not 
dosed with ARVs and used as controls.  Dosing periods for all animals were chosen to achieve 
pharmacokinetic steady-state in tissues based on known half-lives of the drugs used and previous 
studies with these models.  
Infected Animals 
 To assess the effect of infection on drug distribution and transporter expression, three 
additional cohorts of animals (n=21 hu-HSC-Rag, n=18 BLT, n=6 macaques) were infected and 
dosed with identical ARV regimens. Flow cytometry was used to quantify the extent of 
humanization at baseline and at 4 weeks post-infection. The hu-HSC-Rag animals were infected 
intraperitoneally with 200µL 2.1 x 106 IU/mL of HIVBal D7. Plasma HIV RNA was measured 
weekly beginning two weeks after inoculation and continuing for 4 weeks. ARV dosing 
commenced once 4 weeks of durable HIV infection was established, and a final viral load was 
measured during therapy. BLT mice were infected intravenously with 200µL 90,000 TCIU of 
HIVJRcsf, with plasma HIV RNA being measured 1, 2 and 4 weeks after inoculation to confirm 
durable infection, and once after starting therapy. Macaques were infected intravenously with 
104.5 TCID50 of RT-SHIVmac239, with viral loads measured weekly after inoculation. 
  
 
Tissue Collection 
 
 
 One day after the final ARV dose was administered, animals were euthanized and 
underwent necropsy. Whole blood was collected via retroorbital or cardiac puncture for mice and 
venipuncture for macaques. Several tissues suspected of being HIV reservoirs were collected 
from all animals, including the ileum and rectum. After removal from the body, tissues were cut 
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into two approximately equal sized pieces (~100mg for the mice ileum, ~10mg for the mice 
rectum, and ~2g for non-human primate (NHP) ileum and rectum), placed into separate 
aluminum foil pouches and snap frozen on dry ice. Total time from euthanization to tissue 
freezing was less than 60 minutes for all tissues. After freezing, tissues were stored at -80˚C for 
further analysis. All animal experiments were performed in accordance with locally-approved 
IACUC protocols.  
 
Tissue Slicing 
 
 
 To generate serial sections for multi-modal analysis, tissues were sliced frozen at 10µm 
thickness using a cryostat (Leica Biosystems, Wetzlar, Germany) and thaw mounted onto glass 
microscope slides in the following order: 8 slices for immunohistochemistry (IHC), 2 slices for 
MSI (one for analysis and one backup), 2 slices for LC-MS, 15-20 slices for ISH. NHP tissues 
were mounted on optimal cutting temperature (OCT) compound and sliced individually, however 
the small size of the mouse tissues (3-5mm cross sections) precluded this method. Instead, mouse 
tissues were grouped by dosing cohort and mounted within a 50:50 gelatin 
carboxymethylcellulose gel block, which was snap frozen and stored at -80°C. Each frozen gel 
block was mounted on OCT, sliced and thaw mounted, allowing for mounting and analysis of up 
to 6 mouse tissues simultaneously.  
 
Mass Spectrometry Imaging and Absolute Quantitation 
 
 
 ARV distribution within each tissue was assessed using infrared matrix-assisted laser 
desorption electrospray ionization (IR-MALDESI) as previously described.75,107 The glass 
microscope slide containing the thaw mounted tissue was placed into the source chamber and 
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maintained at -10˚C. Relative humidity inside the chamber was reduced to <6% to allow for 
sample cooling without condensation of water vapor, then humidity was increased to deposit a 
layer of ice across the entire stage. Tissues were ablated with two pulses of a mid-IR laser (IR-
Opolette 2371, Opotek, Carlsbad, CA) with a 100um spot-to-spot distance. Ablated molecules 
were ionized by orthogonal electrospray using 0.2% formic acid in 50:50 methanol water as an 
electrospray solvent and sampled into a Thermo Fisher Scientific Q Exactive mass spectrometer 
(Bremen, Germany) for analysis in positive ion mode. Raw data from each voxel were converted 
to the mzXML format with MSConvert (ProteoWizard), then to the imzML format for 
interrogation using MSiReader, which allows for generation of images of ARV distribution 
across the tissue slice.115  
 Absolute quantitation of ARV concentration was achieved by spotting a series of 
calibration standards (of known ARV concentration) onto a non-dosed “blank” NHP tissue slice 
from identical tissue matrices (ileum or rectum; Bioreclamation IVT, Baltimore, MD). 100nL of 
each calibration standard was spotted onto the tissue, allowed to air dry, then placed inside the 
source chamber and analyzed in an identical manner to the samples. A new calibration tissue was 
analyzed every day that sample analysis occurred to account for inter-day variability run 
conditions (electrospray stability, relative humidity, thickness of ice layer, etc.). Calibration 
tissues were analyzed in MSiReader, where the summed pixel intensity over each calibration 
spot was plotted against the known ARV concentration to generate a calibration curve. The slope 
and intercept of this curve was applied to the summed pixel intensity value for each ARV over 
the entire area of the corresponding sample to generate an absolute concentration.77 To quantify 
ARV concentration in mouse tissues, a single calibration spot was applied to a blank mouse 
tissue and analyzed in tandem with NHP calibration tissues. The pixel intensity value for the 
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mouse calibration spot was used to adjust the slope and intercept of the NHP calibration curve 
(to account for response differences between tissues from different species), and the adjusted 
calibration curve was applied to mouse samples. Resulting ng/slice concentrations were 
converted to µg/g using the known area of each tissue slice, depth of each tissue (10um), and an 
assumed tissue density of 1.06g/mL.  
 
LC-MS Analysis and Comparison to MSI 
 
 
Plasma and tissue ARV quantitation of each sample was performed using LC-MS 
methods as described previously.75  Plasma samples, calibration standards, and quality control 
samples underwent protein precipitation followed by LC-MS/MS. Internal standard was added to 
plasma and mixed with 600μL of acetonitrile. Samples were vortexed and centrifuged, then the 
supernatant was diluted with 50:50 methanol:water. For tissues, 1 mL of ice cold 70:30 
acetonitrile-water was added to sample tubes containing a serial 10µm section from each sample. 
Samples were sonicated for 10 minutes with calibration standards and quality control samples. 
Separation for both matrices occurred on a Shimadzu high-performance liquid chromatography 
system, and an AB SCIEX API 5000 mass spectrometer (AB SCIEX, Foster City, CA, USA) 
equipped with a turbo spray interface was used as the detector. The dynamic range of the plasma 
assay ranged from 1-20,000ng/mL for TFV, ATZ and EFV, 1-8,000ng/mL for MVC, 8-
20,000ng/mL for FTC and RAL. The dynamic range for tissues range from 0.1-50ng/mL. The 
precision and accuracy of the calibration standards and QC samples were within the acceptable 
range of 15%. Tissue concentrations were reported as ng/slice and converted to µg/g using an 
assumed tissue density of 1.06 g/mL.  
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In order to assess the agreement of the experimental MSI and reference LC-MS methods, 
tissue ARV concentrations from both methods were normalized for the corresponding plasma 
concentrations to generate tissue penetration ratios (TPRs; duplicate LC-MS samples were 
averaged before normalization). Bland-Altman plots were used to evaluated the agreement 
between methods for each ARV evaluated.  
 
Immunofluorescence (IF)/Immunohistochemistry(IHC) 
 
 
 Dual IF on frozen humanized mouse and NHP sections were performed in the Bond 
fully-automated slide staining system (Leica Microsystems) using Bond Polymer Refine 
Detection kit (DS9800). Slides were allowed to sit at room temperature for 15 minutes, then 
fixed in 10% NBF for 15 minutes. They were then placed in Bond wash solution (AR9590). 
Antigen retrieval was done at 100°C in Bond-epitope retrieval solution 2 pH9.0 (AR9640) for 10 
minutes. Staining was performed first using CD4 1F6 antibody (Abcam clone BC/ 1F6) at 1:50 
dilution for 1h with Bond Polymer and Post-Primary reagents and Cy5 fluorochrome (Perkin 
Elmer) for 15 minutes.  Antigen retrieval was done at again 100°C in Bond-epitope retrieval 
solution 2 pH9.0 (AR9640) between protocols. Slides were then stained with CD3 (Leica clone 
LN10) Ready-to-Use antibody for 15 minutes and Dako Envision mouse secondary for 30 
minutes. Cy3 fluorochrome (Perkin Elmer) was applied for 15 minutes.  IF slides were 
counterstained with Hoechst 33258 (Invitrogen, Carlsbad, CA) and mounted with ProLong Gold 
antifade reagent (P36934, Life Technologies).  
Drug efflux transporter localization was analyzed using IHC. Frozen serial sections were 
stained with primary antibody for MDR1 (1:50; Abcam, Cambridge, MA), MRP2 (1:50, Kamiya 
Biomedical, Seattle, WA), MRP1 (1:100, Santa Cruz Biotechnology, Santa Cruz, CA), or BCRP 
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(1:50; Santa Cruz) for 15-60 minutes followed by pH antigen retrieval (Leica). DAB (3,3’-
diaminobenzidine) was used as a substrate-chromagen for detection. All staining was performed 
on a Leica Bond automated tissue stainer (Leica). Mouse and NHP liver tissues were used as a 
positive control for all antibodies, and negative staining was performed using secondary antibody 
only. Samples were visually evaluated for transporter localization.   
 
In Situ Hybridization (ISH) 
 
 
 15-20 serial sections from each tissue were evaluated for HIV/SHIV RNA expression 
using RNAscope.116 Before beginning the RNAscope procedure, slides were fixed in 4% 
paraformaldehyde at 4˚C for 15min followed by dehydration with graded ethanol washes (50%, 
70%, 100% ethanol for 5 minutes each). Detailed methodology for the RNAscope procedure is 
described elsewhere117, but briefly, slides were boiled to retrieve epitopes in P2 ACD buffer for 
30 minutes followed by peroxidase blocking for 10 minutes at room temperature, rinsing with 
double distilled water, dehydrating with 100% ethanol for 5 minutes, then air drying.  Slides 
were then incubated for 20 minutes at 40˚C with protease digestion solution from ACD (P3). 
After protease digestions, slides were rinsed with double distilled water and incubated with HIV 
clade B or SIVmac239 ACD probes for 2 hours at 40˚C. Slides were then washed in 0.5X ACD 
wash buffer and incubated in amplification reagents according to RNAscope 2.5 HD detection 
protocol117. All reagents used in the hybridization process were obtained from Advanced Cell 
Diagnostics (ACD, Newark, CA) and used according to manufacturer’s protocol with some 
minor adaptations. After counterstaining slides with Hematoxylin, slides were mounted in clear 
mount and cover slipped. 
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Image Co-localization 
 
 
 Image manipulation and co-registration was performed using the Matlab v. R2015a 
Image Processing Toolbox (Mathworks, Natick, MA). A schematic of the co-localization 
workflow is shown in Figure 2.1. For a given sample (Figure 2.1a), MSiReader was used to 
export pixel intensity matrices for cholesterol, heme, and each ARV of interest across the entire 
tissue slice into Matlab; IF and IHC samples were scanned as described above and downsampled 
to match the resolution of the MSI data.  Off-tissue response was eliminated by using cholesterol 
signal to mask ARV response, such that only on-tissue signal was shown. To eliminate the 
confounding effect of ARVs contained within the vasculature, ARV responses were again 
masked based on heme distribution (Figure 2.1b) to show only the ARV signal that localized 
outside the microvasculature. To ensure that MSI-derived images and IF/IHC/ISH images were 
appropriately 
aligned 
before co-
localization, 
co-
registration 
was 
performed on 
the 
cholesterol 
image using 
the 
Figure 2.1: Image Co-localization Workflow Representative raw IR-MALDESI 
and IF (a). Total ARV signal is masked based on corresponding heme distribution 
(b). (c) Co-registration of cholesterol and DAPI image. (d) Overlay of ARV and 
variable of interest (CD3 in figure) to form fused image of ARV (red) and CD3 
(green), with correlation coefficient shown.  
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background DAPI stain as a reference (Figure 2.1c). The resulting transform variable was 
applied to all ARV images so that every ARV image was identically-oriented. Finally, the heme-
corrected transformed ARV images were overlayed with the variable of interest (CD3, MDR1, 
etc.) to generate a fused image (Figure 2.1d) containing both the ARV (in red) and the variable 
of interest (in green). After image overlay was performed, Pearson’s correlation was performed 
to assess the co-localization of both variables. 
 
Statistical Analysis 
 Descriptive statistics (median, range) of plasma and tissue concentrations as well as 
correlation coefficients were generated for each drug in each animal model. Pearson correlation 
was performed only on tissues where both variables were detected. Comparisons between animal 
models and between anatomic compartments were performed using Kruskal-Wallis ANOVA on 
ranks. p<0.05 was considered statistically significant. 
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Results 
 
Plasma Exposure of Antiretrovirals  
 
ARV concentrations in plasma collected at necropsy were measured to verify absorption 
of oral doses and to ensure consistency across animal models. ARV plasma concentrations were 
detectable in >90% of samples. Figure 2.2 compares plasma exposure between infected and 
uninfected animals from each model. No significant differences were observed between these 
groups. Given the overall lack of differences in plasma exposure, data were combined in Figure 
2.3, which 
shows plasma 
data across all 
animal models. 
There were no 
statistically 
significant 
differences 
between the 
two humanized 
mouse models except for RAL, where plasma exposure showed a 10-fold increase in BLT mice 
over hu-HSC-Rag mice   (p=0.03). Despite receiving different ARV dosing, the NHPs had 
plasma concentrations that were not significantly different than the humanized mice, with the 
exception of RAL which was 2-logs higher in NHPs over humanized mice (p<0.001).  
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Quantitative Comparison 
of LC-MS and MSI 
 
We have published 
LC-MS tissue concentrations 
from these animals using 
larger tissue samples  (three 
50 micron slices)118, 
however here we utilize 
concentrations obtained 
from a single 10 micron 
serial slice to make a more 
direct comparison. In mice, tissue concentrations from serial slices were detected with far less 
frequency than larger samples, ranging from 8% detection for EFV to 77% detection for TFV. 
MVC was not detected in any hu-HSC-Rag tissue sample despite detection in plasma, but did 
achieve measurable concentrations in BLT ileum and rectum. Detection of ARVs in tissue slices 
by MSI was also sporadic in mice, with detection largely mimicking LC-MS results (ranging 
from 4% detection for EFV samples to 55% detection for TFV). Unlike LC-MS, MVC was 
detected in 50% of samples using MSI in both hu-HSC-Rag and BLT mice. Conversely, the 
NHP samples had detectable ARV concentrations in >85% of samples for every ARV evaluated 
by LC-MS, and 100% of samples by MSI.  
Figure 2.3: ARV Plasma Concentrations Across Animal 
Models Plasma concentrations are shown for hu-HSC-Rag mice 
(gray), BLT mice (red), and NHPs (blue) for each ARV. Solid line 
represents median, box ends represent IQR, and whiskers 
represent range. Solid dots are outlier values. *p<0.05 
* 
* 
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We have previously demonstrated our ability to obtain absolute quantitation of ARVs in tissue 
slices using IR-MALDESI and showed good agreement (with 15%) with LC-MS75, however this 
was performed on tissues from a single animal. Here, we performed a more comprehensive 
comparison between these methods using Bland-Altman plots, which are shown in Figure 2.4. 
Mean bias between methods ranged from -0.06 for MVC to -8.65 for ATZ. TFV (Figure 2.4a), 
FTC (Figure 2.4b), and MVC (Figure 2.4e) did not demonstrate bias toward one method over 
another, with concentrations spread evenly above and below zero.  For RAL (Figure 2.4c), ATZ 
(Figure 2.4d), and EFV (Figure 2.4f), the bias favored higher LC-MS concentrations over MSI as 
the average concentration increased, potentially indicating saturation of MSI detection at higher 
concentrations.  
Figure 2.4: Comparison of LC-MS and IR-MALDESI Methods Comparison of paired tissue 
sample concentrations generated using each method are shown for each ARV (a-f), with method 
average along the x-axis and method difference along the y-axis. Middle dashed line represents mean 
bias; upper and lower dashed lines represent the upper and lower limits of agreement (i.e. confidence 
intervals). Red circles are NHP data; black circles are humanized mouse data.   
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Heterogeneous ARV Distribution in Gastrointestinal Tissues and Co-localization  
with HIV Target Cells 
 Figure 2.5 showcases representative images of differential ARV distribution from a 
single NHP tissue slice.  TFV (Figure 2.5b) and FTC (Figure 2.5c) showed disparate distribution 
patterns, with TFV giving the highest signal in the lumen, with low but consistent penetration 
into the mucosa and muscularis, while FTC was minimally detected in the mucosa. Consistent 
with previously published data75, EFV distribution was not homogenous throughout the NHP 
ileum or rectum, instead localizing in the mucosal layer with little penetration into the muscularis 
(Figure 2.5d). RAL, on the other hand was localized to the lumen and showed less penetration 
into the mucosa (Figure 2.5e). The potential effect of these differences in ARV distribution on 
exposure in HIV target cells is reflected by the ARV-CD3+ T cell correlation coefficients in 
Figure 2.5g-
j. For 
example, 
although 
RAL 
showed 
greater 
Figure 2.5: Differential ARV Localization Within a Single NHP Tissue Slice 
Representative heme-corrected IR-MALDESI and IF images from a NHP ileum (a-f). 
Overlay images (g-j) show ARV in red and CD3+ T cells in green.   
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sequestration to the luminal 
area of the tissue versus EFV, 
the co-localization of these 
drugs was not markedly 
different, with RAL showing a 
3-fold increase compared to 
EFV.  Further, when 
comparing T-cell co-
localization between TFV and 
FTC in this tissue, the relative 
lack of FTC detection and 
subsequent lack of T-cell 
exposure results in no 
correlation with CD3+ T cells. 
TFV, on the other hand, 
demonstrated low but 
quantifiable correlation with an r value of 0.06.  
 Representative images from humanized mouse tissue are shown in Figure 2.6. As 
previously mentioned, ARV detection by MSI of single slices was sporadic compared to NHP 
tissues. We were unable to detect RAL or FTC in any tissue slice from both mouse models, 
despite detection in plasma and tissue by LC-MS, and robust detection in NHP tissues. Figure 
2.6a-c shows the distribution of cholesterol, heme, and ATZ, respectively. As shown in Figure 
2.6b, we observed extensive heme distribution throughout these tissue cross-sections (IF slice 
Figure 2.6: ARV Localization in Humanized Mouse 
Tissues Representative images from a single humanized 
mouse rectum. Raw IR-MALDESI and IF images are shown 
in a-d. (e) shows heme-corrected ATV distribution, with 
overlay of ARV (red) and human CD3+ T cells (green) 
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shown in Figure 2.6d), contrary to NHP results where heme was localized to discrete tissue 
areas. As a consequence, ARV detection was greatly reduced upon heme correction (compare 
Figure 2.6c to 2.6e), showcasing the importance of this step. We observed a large decrease in 
detectable CD3+ T cells in the humanized mouse samples (Figure 2.6d), probably owing to the 
fact that staining was specific for T cells of human origin only. Figure 4f shows the overlay for 
this tissue, where decreases in CD3+ detection and ARV signal result in low correlation (r=0.02).  
T-cell co-localization for all animal models in both the ileum and rectum is summarized 
in Table 2.2. Co-localization with CD3+ T cells was variable but generally low, with r values 
ranging from -0.09 to 0.32.  Lack of detection of many ARVs complicated within-species 
comparisons, however co-localization values were similar between BLT and hu-HSC-Rag mice 
for all detected ARVs.  For NHPs, TFV co-localization with HIV target cells was 2-fold higher 
in the rectum over the ileum, with FTC and RAL also showing a similar trend. Conversely, EFV 
r values were 4-fold higher in the ileum.  Interspecies comparisons were limited, but tended to 
show similar co-localization between mice and NHPs. The exception was EFV in the ileum, 
which showed some of the highest r values in NHPs despite being undetectable in hu-HSC-Rag 
mice after heme correction. MVC was also undetectable in hu-HSC-Rag mice despite detection 
in both BLT mice and NHPs, although correlation coefficients were low.  
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Table 2.2: Summary of ARV-CD3+ T Cell Correlation Coefficients Across Species 
Drug 
Ileum Rectum 
Mice 
All 
Macaques 
Mice 
All Macaques BLT hu-HSC-
Rag 
BLT hu-HSC-Rag 
TFV - - 
0.02  
(-0.06,0.08) 
0 
(-0.04,0.29) 
0 
(-0.03-0.09) 
0.04  
(0,0.15) 
FTC - - 
0  
(0,0) 
- - 
0.02  
(-0.01,0.11) 
RAL - - 
0  
(-0.09,0.08) 
- - 
-0.08 
 (-0.09,-0.03) 
EFV  - 
0.20  
(-0.04,0.28) 
 
0 
(n=1) 
-0.07  
(-0.08,-0.04) 
MVC 
-0.01 
(-0.09,0.13) 
0 
(0,0) 
0.01  
(0.01,0.02) 
-0.01 
(-0.09,0.11) 
- 
0.05 
 (0.04,0.06) 
ATZ 
0.02 
(-0.02,0.32) 
-0.01 
(-0.03,0) 
0.03  
(-0.03,0.12) 
0 
(-0.05,0.07) 
0 
(-0.03,0.02) 
0.05  
(0.01,0.08) 
*data shown are median and range 
Mucosal Accumulation of Antiretrovirals Between Species 
 To determine the percentage of total ARV signal within each tissue slice that localized in 
the mucosal layer, an overlay workflow similar to Figure 2.1 was employed, where a region of 
interest was manually defined surrounding the mucosal layer and summed pixel intensities from 
this ROI were divided by the summed pixel intensity from the entire tissue slice. Results are 
reported in Table 2.3. Overall, mucosal accumulation was extremely variable within tissue slices, 
ranging from 0-100% of total ARV signal. Accumulation was similar between the humanized 
mouse models with the exception of ATZ in the rectum, which was 1.7-fold higher in hu-HSC-
Rag versus BLT mice. ARV accumulation in NHP mucosa was 2-3 fold higher than mice in the 
ileum, but similar in the rectum.  
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Table 2.3: Summary of Mucosal Accumulation Across Species 
Drug 
Ileum Rectum 
Mice 
All 
Macaques 
Mice 
All Macaques BLT hu-HSC-
Rag 
BLT hu-HSC-Rag 
TFV - - 
70 
(34, 80) 
58 
(48, 70) 
49 
(28, 73) 
45 
(5, 77) 
FTC - - 
61 
(50, 84) 
- - 
38 
(27, 99) 
RAL - - 
55 
(6, 97) 
- - 
46 
(20, 100) 
EFV  - 
53 
(33, 96) 
 
100 
(n=1) 
45 
(1, 100) 
MVC 
18 
(4, 27) 
22 
(20, 25) 
57 
(18, 80) 
39 
(28, 77) 
- 
56 
(30, 65) 
ATZ 
20 
(3, 39) 
25 
(0, 49) 
45 
(6, 69) 
37 
(35, 38) 
66 
(32, 38) 
58 
(11,100) 
*data shown are median percent accumulation and range  
HIV RNA Expression in Areas of Low ARV Signal  
To determine whether or not low ARV-T cell co-localization translated to ongoing HIV 
gene expression in these cells, MSI images were co-localized with HIV RNA localization 
obtained from ISH. In NHPs, HIV RNA expression was detected preferentially in areas of low or 
no ARV signal (Figure 2.7). As shown in Figure 2.7k, detected HIV RNA was not diffusely 
distributed throughout tissues, but instead localized into discreet clusters within the submucosa 
(see insert of Figure 2.7k). These discreet areas of RNA expression tended to be observed only in 
tissue areas that corresponded to high T cell density (compare Figure 2.7k to 2.7f), showing that 
detected RNA likely represents real gene expression rather than non-specific response. The 
NRTIs TFV and FTC, though detected at low levels in this tissue, did not co-localize with RNA 
(r=0 for both). MVC and ATZ showed very similar distributions and were more readily detected 
in this sample, however even these ARVs showed poor correlation (r= -0.01 for both) when 
compared to HIV RNA. In mice (Figure 2.8), HIV RNA was again detected in tissue areas that 
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corresponded to CD3+ T cells (Figure 2.8d & f). After correction for heme signal, ARVs were 
found to be poorly co-localized with detected RNA and resulting correlation coefficients were 
low. 
When compared across species, corresponding correlation coefficients were low for 
every ARV evaluated (Table 2.4), and were not significantly different between species or 
between the ileum and rectum. HIV RNA was not detected several tissues where we had 
previously observed CD3+ T cell distribution (marked NV in table), resulting in a small number 
of samples available for analysis within each cohort. This was especially true in mice, where 
RNA was detected with greater frequency in BLTs versus hu-HSC-Rag animals, consistent with 
CD3+ T cell expression data. Though the range of correlation coefficients was wide (-0.09-0.20), 
TFV and MVC showed poor correlation with HIV RNA in both species. FTC and ATZ 
coefficients were more variable but still low. We were unable to detect SHIV RNA expression in 
Figure 2.7: HIV RNA Localization in Areas of Low ARV Signal Representative images from a 
single NHP rectum. Raw IR-MALDESI images are shown in a-e. IF images showing CD3+ T cell 
distribution (green; f) were overlayed with ARV images in g-j. Raw ISH image is shown in k, with 
positive staining in red (insert in k provided to show positive cells). Co-localization of ARV images 
(red) and HIV RNA (cyan) are shown in l-o, with corresponding correlation coefficients. 
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the three infected animals receiving EFV & RAL, 
however further analysis of RNA expression by qPCR of 
these tissues revealed that RNA expression in these 
animals was 2-3 logs lower than those receiving ATZ & 
MVC, which may explain the lack of detection (data not 
shown). 
 
 
Table 2.4: Summary of ARV-HIV RNA Correlation Coefficients Across Species 
Drug 
Ileum Rectum 
Mice 
All 
Macaques 
Mice 
All Macaques BLT hu-HSC-
Rag 
BLT hu-HSC-
Rag 
TFV - - 
0 
(0,0) 
-0.02 
(-0.04, 0.03) 
-0.01 
(n=1) 
0 
(0, 0.12) 
FTC - - 
0.01 
(0, 0.02) 
- - 
0 
(0, 0) 
RAL - - NV - - NV 
EFV  - NV  NV NV 
MVC 
-0.03 
(-0.09, 0.16) 
-0.02 
(-0.04, 0) 
-0.01 
(-0.02, 0.10) 
-0.04 
(-0.06, 0.03) 
- 
-0.01 
(-0.02, 0.08) 
ATZ 
0.06 
(-0.03, 0.24) 
-0.06 
(n=1) 
0 
(-0.02, 0.09) 
-0.01 
(-0.04, 0.05) 
0.20 
(n=1) 
0 
(-0.01,0.07) 
*data shown are median and range; NV=no virus detected 
 
 
Figure 2.8: HIV RNA Localization in Areas of Low 
ARV Signal (Mice) Representative images from a single 
humanized mouse ileum. Heme-corrected IR-MALDESI 
images are shown in a & b. IF image showing CD3+ T cell 
distribution (green; c) was overlayed with ATZ in d. Raw 
ISH images is shown in e, with positive staining in red. Co-
localization of ARV image (red) and HIV RNA (cyan) is 
shown in f, with corresponding correlation coefficient. 
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Drug Efflux 
Transporter 
Localization and 
Effect 
 Figure 2.9 
shows 
representative 
images of ARV-
efflux transporter 
co-localization, 
which 
demonstrates the 
potential influence 
of these 
transporters on 
observed 
distribution 
patterns. Figure 2.9a-e show raw MSI images with differential distribution between ARVs. 
Heme-corrected images are shown in Figure 2.9f-j, where a large decrease in ARV response is 
observed, though tissue localization patterns remain intact. EFV, for example, distributes through 
the mucosa and accumulates in the adipose layer of tissue (Figure 2.9i).  When overlayed with 
MDR1, it does not appear that EFV disposition is significantly affected by the expression or 
localization of this transporter, as the two variables are not co-localized (Figure 2.9n). 
Conversely, RAL concentrates on the luminal surface of this tissue, with limited penetration into 
the submucosa (Figure 2.9j). Unlike EFV, MDR1 is highly co-localized with RAL (Figure 2.9o), 
Figure 2.9: Efflux Transporter Correlation with ARV Localization 
Representative images from a single NHP ileum. Raw IR-MALDESI images are 
shown in a-e. (f-j) shows heme-corrected ARV distribution. Raw transporter IHC 
and subsequent ARV-transporter overlays are shown for MDR1 (k-o), BCRP (p-
t), and MRP2 (u-y), with ARV in red and transporter in green.  
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suggesting that this 
efflux transporter 
may act as a barrier 
to RAL penetration 
into the submucosa 
from the gut lumen. 
Similarly, TFV 
(Figure 2.9g) and 
FTC (Figure 2.9h) 
show differential 
distribution in this 
tissue slice with 
corresponding differences in MDR1 co-localization (Figure 2.9l and 2.9m, respectively). BCRP 
(Figure 2.9p) and MRP2 (Figure 2.9u) were not extensively expressed in these tissues and thus 
significant differences on co-localization between drugs was not observed. 
 A summary of correlation coefficients with all efflux transporters in all animals is shown 
in Appendix 2.1. Again correlation coefficients were low, ranging from -0.09 to 0.55, with most 
values below 0.2. ARV-efflux transporter co-localization was lower on average in NHPs 
compared to humanized mice for every transporter evaluated, though species comparisons could 
only be made for TFV, MVC, and ATZ. To compare the effect of drug transporters at different 
sites in the GI tract, animal models were pooled and compared between the ileum and rectum in 
Figure 2.10. No significant differences were observed in ARV-transporter co-localization 
between the ileum and the rectum for any of the transporters evaluated.  
Figure 2.10: ARV-Efflux Transporter Co-localization Across 
Compartments Correlation coefficients for pooled ARVs-efflux transporters 
in the ileum (blue) and rectum (red). Solid lines represent medians, box ends 
represent IQR, and whiskers represent range. Solid black dots are outlier 
values. 
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Discussion 
 
 This is the first study to demonstrate heterogeneous ARV distribution within tissues 
across pre-clinical models and relate this distribution to HIV RNA expression. Using mass 
spectrometry imaging, we show that ARV disposition in the NHP ileum and rectum is 
differential between drug classes. In particular, EFV and RAL localized to completely distinct 
tissue subcompartments despite being dosed orally and at the same time. Similarly, the relatively 
homogenous detection of TFV across NHP tissue slices was not observed with FTC, despite 
identical routes of administration. Co-localization with relevant biologic variables such as CD3+ 
T cells allowed us to interpret the implications of these differences. For instance, when looking 
at the tissue slice in Figure 2.5, the nearly 3-fold decrease in EFV-CD3 co-localization compared 
to RAL-CD3 suggests that, at standard treatment doses for these animals, EFV may not achieve 
adequate exposure at the site of action compared to RAL, which concentrates more in the 
mucosa.  
 Despite the large differences observed on an individual tissue level, aggregate T-cell 
correlation coefficients were not significantly different between ARVs in the NHP tissues (Table 
2.2), with a large amount of intra-species variability in T cell co-localization. There are several 
potential explanations for this observation, namely the large variation in CD3+ T cell expression 
from animal to animal. Further, the differences in tissue slice morphology and approximate 
location along the GI tract likely contribute to observed variability. ARV localization into tissue 
subcompartments may not be consistent along the length of the GI tract, and even small 
variations in the local tissue environment can alter the disposition of drugs at these sites. This 
may help explain why EFV co-localization with CD3+ T cells was much higher in the NHP 
ileum than any other ARV.  
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 In stark contrast to the NHP data, ARV distribution in both humanized mouse models 
initially appeared to be more homogenous in GI tissues, though heme-correction greatly 
decreased ARV detection (Figure 2.6) and subsequently lowered correlation coefficients (Table 
2.2). Low ARV-T cell co-localization in mice suggests that these drugs may not achieve 
adequate exposure at the site of action. This suggestion is tempered, however, by the fact that 
CD3+ T cell detection was extremely low compared to NHPs, thus correlation coefficients are 
falsely lowered to some extent. The relative lack of detection in humanized mice can be 
explained by the fact that we stained only for human T cells rather than the entire T cell 
population. Though the gut tissues are known to substantially reconstitute human lymphocyte 
populations in humanized mouse models, particularly in the BLT model, the relative decrease 
compared to NHPs was not unexpected.  
Low co-localization with T cells across animal models was a surprising result given that a 
large percentage of heme-corrected ARV signal was detected in the mucosal layer (Table 2.3), 
where the majority of activated T cells in the gut are localized.119 Although few differences were 
observed between animal models with regard to T-cell co-localization, we observed higher 
mucosal accumulation in the NHP tissues versus either mouse model, though these differences 
were not statistically significant. Serial slicing revealed high-quality cross-sectional slices for 
most mouse tissues, so severely altered morphology cannot explain these differences. A possible 
explanation may be that the mucosal layer represents a greater proportion of the total tissue size 
in mice compared to NHPs (compare 2.5f to 2.6d), and that the very low ARV detection in mice 
after heme-correction drove these values down.  
Importantly, we show that low ARV-T cell co-localization may result in continued HIV 
replication in this cell population. As shown in Figures 2.7 and 2.8 , HIV RNA was localized to 
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areas of low ARV exposure in both NHP and mouse tissues, with median correlation coefficients 
suggesting a low amount of drug exposure at the site of action. These findings agree with the low 
ARV-T cell co-localization previously observed, especially given that RNA detection was co-
localized with only a small percentage of CD3+ T cells, consistent with viral gene expression in 
the smaller CD4+ T cell population. Given that only a small proportion of detectable HIV RNA 
from ARV-treated subjects represents replication-competent virus, and that these animals had 
only been receiving cART for 7-10 days, this pharmacodynamic endpoint is likely an 
overestimation of the true magnitude of persistent infection during treatment. Nevertheless, these 
findings provide support for the hypothesis that ongoing HIV replication in tissues like GALT is 
driven by low ARV penetration to the site of action, and that strategies to achieve therapeutic 
concentrations at these sites are needed.  
The ultimate goal in generating these data are to develop target concentrations for 
efficacy at the site of action. Although concentrations within certain tissue sites (e.g. mucosa) 
can be estimated based on accumulation and total concentration of the entire slice, a reasonable 
first step may be to base efficacy target estimates on the limit of detection (LOD) for the ARVs 
that were not well correlated with RNA. Because we observed HIV gene expression almost 
exclusively in locations where no TFV or MVC signal was co-localized, we can assume that 
concentrations above the LOD for each drug are sufficient to suppress RNA expression at these 
sampling sites. Using maximum LOD estimates from calibration experiments run in tandem with 
our infected samples, these values are as follows: TFV, 4,503fg/voxel; MVC, 708fg/voxel. 
Importantly, these total drug values represent the most conservative estimate, as there may be 
ARV exposure in other tissue sites that is below current LODs, but still high enough to suppress 
viral gene expression. However, we provide a starting framework for defining exposure-response 
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at the site of action, as improvements in sensitivity will likely decrease the LOD in the future. 
Future work will refine this pharmacodynamic endpoint, with particular focus on translating per-
voxel drug amounts to per-gram concentrations to generate specific target concentrations for 
HIV suppression in tissues, especially for those ARVs where HIV RNA expression was detected 
despite detectable signal (e.g. ATZ).  
The potential contribution of drug efflux transporter localization to differences in ARV 
tissue distribution are substantial. MDR1 in particular demonstrated drastically different extents 
of co-localization depending on the ARV evaluated (2.8k-o), which may have implications for 
exposure at the site of action. For example, the higher MDR1 co-localization observed with RAL 
suggests that this transporter may act as a barrier to RAL distribution into the mucosa from the 
gut lumen. MDR1 appears less important for EFV distribution, as evidence by the lower co-
localization values and concentration of EFV signal in the tissue submucosa. Importantly, these 
trends are supported by data showing that RAL, but not EFV, is a substrate for MDR1.120 
Further, existing transporter substrate data also support observed distribution of TFV, which is 
not an MDR1 substrate.121  
Similarly to the T cell co-localization and mucosal accumulation comparisons, large 
variability in transporter co-localization data resulted in most comparisons within and between 
models showing non-significant differences (Appendix 2.1). This was particularly true for 
BCRP, which showed the largest range of any transporter, and MRP2, which was not detected in 
the mouse gut. MRP1 was more ready detected in tissues, and co-localization with this 
transporter was 2 to 4-fold higher in the mouse ileum versus NHPs. This is particularly important 
for drugs like ATZ or FTC, which may have decreased exposure in the mouse ileum secondary 
to increased efflux by MRP1. When ARV-transporter co-localization was compared across 
53 
 
efflux transporters and anatomic compartments, no significant differences were observed (Figure 
2.9), suggesting that the four efflux transporters evaluated here contribute equally to ARV 
disposition, and that this contribution is continuous along the GI tract.  
Importantly, we did not observe any significant difference between infected and 
uninfected animals for any variable measured in this study. Previous work has shown that HIV 
infection can alter the protein expression of drug transporters by as much as 3-fold99, and that 
infection can alter several PK variables such as intestinal absorption and metabolism that may 
affect ARV disposition in tissues.122 The ARVs examined here are known to utilize several of the 
drug transporters shown to be altered during infection (e.g. RAL by MDR1, TFV by BCRP), and 
we showed that these transporters may influence exposure in gut tissues (Figure 2.7). 
Nevertheless, it does not appear that HIV infection substantially contributes to ARV disposition 
in these tissues. A possible explanation for the disparity in results may be that the animals were 
not infected for a long enough time for these changes to become apparent, as previous work has 
utilized biopsy samples from humans that were infected for >12 months before tissue 
collection.99 It may be the case that transporter or metabolic changes only manifest during 
chronic HIV infection, and we were unable to capture those changes here.  
There are several limitations of this study which should be addressed, the primary one 
being lack of information gained from a single 10 micron tissue slice. As previously mentioned, 
the relative lack of ARV detection in many of these tissues despite detection with traditional LC-
MS can be explained by the small amount of tissue available for analysis. It may be the case that 
because we analyzed such a small portion of tissue, we simply missed where drug is actually 
distributing. It is not unreasonable to expect that sampling at additional points along the GI tract 
of these animals would yield better detection of ARV and perhaps differential distribution 
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patterns. In other words, the distribution we observe in a single slice from the ileum may not 
reflect the distribution several centimeters, or even several millimeters, away. A related 
limitation is the lack of information on distributional changes over time. Because all of these 
tissues were collected during the plasma PK trough, it is unknown whether the tissue penetration 
of ARVs would be different at other PK time points. We attempted to minimize this possibility 
by dosing animals to plasma steady-state, and we have shown that tissue concentrations during 
PK steady-state have little variability and are unlikely to significantly differ based on sample 
collection time.123,124  
The use of Pearson correlation on image overlays is a further limitation of this study. 
While T-cell or RNA co-localization is a crude measure that provides a general idea of ARV 
exposure at the site of action, this method cannot account for potency differences between drugs, 
and how this affects exposure-response relationships in tissue. For example, though in some 
cases EFV co-localization with CD3+ T cells was higher than RAL, this difference may not 
matter due to the potency differences between these drugs. This is supported by the fact that 
there is no clinical evidence that treatment with EFV delays viral rebound after treatment 
cessation more than RAL, or that RAL treatment results in greater tissue replication versus other 
therapies. To overcome these limitations, future work will focus on generating new image 
overlay workflows to account for potency differences between drugs and provide a more relevant 
pharmacodynamics endpoint.  
As we demonstrated in Figure 2.6, masking ARV response on the basis of corresponding 
heme distribution resulted in drastic decreases in ARV signal, particularly in mouse and human 
tissues. This is an important step to reduce confounding from ARVs contained in the 
microvasculature or from blood contamination during tissue collection which could falsely 
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elevate correlation with biologic variables; however, this process of data censoring is imprecise 
and has several important limitations in its implementation. Application of this step 
underestimates true ARV tissue signal as there are likely cases where ARVs are present in tissue 
but happen to co-localize with a micro-vessel, making their masking unnecessary and falsely 
lowering correlation coefficients. Though we attempted to correct for this by applying heme 
masks to both MSI and IHC/ISH images, the true correlation values between these variables 
remain unknown. 
The use of viral RNA as a surrogate of viral replication is another important limitation. 
As previously mentioned, RNA expression does not necessarily represent downstream protein 
expression or completion of the viral life cycle, thus detected RNA may be secondary to random 
egress from latency rather than productively infected T cells. Further, though the RNAscope 
method used here has improved specificity to detect HIV-specific genes versus traditional ISH116 
it may be the case that some of the RNA detected here originated from non-HIV sources, further 
overestimating the actual amount of potential viral replication. Future studies should examine 
downstream components of the HIV life cycle (e.g p24) by IHC, or potentially by IR-MALDESI 
itself. 
Importantly, the ARV responses observed in this study represent total rather than 
unbound drug. As the efficacy of these agents is driven by free drug concentrations at the site of 
action, we are limited in our ability to estimate target concentrations in these tissues from total 
drug alone. It has been shown that the extent of protein binding, and thus free drug 
concentrations, can differ between plasma and tissues for anti-infective agents.125,126 In some 
cases, estimates of the free drug in tissues can be accurately extrapolated from plasma data127,128; 
however, direct measurement of unbound tissue concentrations provide the most useful data for 
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comparison to IC50 values for a given pathogen.  Strategies such as ultrafiltration or 
microdialysis have been utilized by others to measure unbound tissue concentrations directly and 
have been previously reviewed.72 Performing similar analyses in replicate tissues from this study 
can provide insight into how much of the total ARV signal observed is due to unbound drug, as 
well as provide a framework for estimating target concentrations for efficacy at this site. 
The resolution of ARV distribution images generated by MSI is the limiting factor in 
obtaining data at the cellular level. Despite the availability of high-resolution IHC/ISH images 
for HIV target cells, drug transporters, and RNA, the final image overlays are capped at 100 
micron resolution, precluding our ability to observe ARV distribution within cells. Although 
understanding the distribution of these agents on a macro level in tissues is helpful, and still 
provides data that would otherwise be unobtainable with traditional LC-MS, the fundamental 
question of exposure in reservoirs is whether or not ARVs can achieve adequate concentration in 
cells to suppress viral replication. The lack of ARV signal in areas of HIV RNA detection would 
suggest this is not the case, but the limitation remains. A related limitation was our inability to 
detect the active metabolites of TFV (TFVdp) or FTC (FTCtp). These phosphorylated moieties 
act as chain terminators in reverse transcription rather than the parent compounds, and are 
sequestered within lymphocytes. Though analysis of parent TFV and FTC can show in general 
where these compounds distribute, it may be the case that the specific distribution of the 
metabolite differs drastically from that of the parent compound. We have demonstrated rapid 
degradation of these metabolites back to the parent compounds in tissue samples, and are 
currently optimizing methods to stabilize these metabolites for increased detection in this setting.  
Despite these limitations, this work provides novel data demonstrating that the 
assumptions made when analyzing LC-MS concentrations from tissue homogenates may not be 
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valid, and that ARV distribution in tissues is not homogenous. ARV localization was similar 
between animal models, with low T-cell co-localization in all species despite a 1.5-fold increase 
in mucosal accumulation in NHPs that was not observed in humanized mice. We show that HIV 
RNA is expressed in areas of low TFV and MVC exposure, providing support for the hypothesis 
that suboptimal ARV tissue penetration may propagate tissue reservoirs. Drug transporter effects 
were differential between ARVs, but consistent between the ileum and rectum. Quantitatively, 
we observed good agreement between IR-MALDESI and the gold standard LC-MS, but 
showcased the advantage of visualizing drug distribution. Ultimately, these data can be used to 
inform the design of targeted therapies for HIV eradication. 
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Chapter III: Multimodal Analysis of Drug Transporter Expression and Localization in 
Gastrointestinal Tissue and Implications for Antiretroviral Disposition 
 
Summary 
 
HIV persistence in tissue reservoirs like the GI tract may be reduced with optimized 
exposure of antiretrovirals (ARVs). Drug transporters affect ARV tissue disposition, but 
quantitative measures of drug transporter protein expression across pre-clinical species are not 
available. Our objective was to use proteomics to obtain absolute transporter concentrations and 
assess agreement with corresponding gene and immunometric protein data. Ileum and rectum 
were collected from two ARV-dosed humanized mouse (hu-HSC-Rag (n=41); BLT (n=13)) and 
one primate (rhesus macaque, (NHP, n=12)) models and analyzed for gene (qPCR) and protein 
(LC-MS proteomics and Western blot) expression and localization (immunohistochemistry) of 
ARV efflux and uptake transporters. Drug concentrations were measured by LC-MS/MS.  
Multivariable regression was used to determine the ability of transporter data to predict tissue 
ARV penetration. We observed little agreement between analytical methods, with interspecies 
comparisons showing different trends for gene and protein expression. For example, qPCR 
analysis showed a 2-fold increase in permeability glycoprotein (Pgp) expression in NHPs versus 
mice, however proteomics analysis showed a 200-fold difference in the opposite direction. 
Proteomics results were supported by IHC staining showing extensive efflux transporter 
localization on the luminal surface of these tissues. ARV tissue concentration was variable 
between species, and multivariable regression showed that QTAP data best predicted these 
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values.  Lack of agreement between analytical techniques, and better agreement between drug 
and transporter concentration in tissue, suggests that resources should be focused on generating 
downstream measures of protein expression to predict drug exposure. Taken together, these data 
inform the use of pre-clinical models for studying ARV distribution and the design of targeted 
therapies for HIV eradication. 
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Introduction 
 
The introduction of combination antiretroviral therapy (cART) in the mid-1990s 
permanently altered the landscape of HIV infection, saving millions of lives and helping to 
increase the lifespan of HIV-infected individuals to levels near their uninfected counterparts.1 
However, early studies of cART showed persistent infection and rapid rebound viremia after 
drug removal even from patients with undetectable viral loads, necessitating lifelong therapy.4,49 
Today, viral rebound upon cART cessation is a well-established clinical phenomenon which has 
been shown to be secondary to the establishment of an HIV reservoir early in infection.49  The 
latent reservoir, consisting of quiescent memory T cells containing proviral DNA, has been well 
characterized and has received the focus of most eradication research over the past 15 years.  
However, there is also evidence that HIV can persist within certain anatomic sites, or tissue 
reservoirs, including the central nervous system, lymphatic system, gut-associated lymphoid 
tissue (GALT), and genital tract.129,130,29 Both latent and tissue reservoirs represent a substantial 
barrier to HIV eradication from the body, and an understanding of the factors that contribute to 
the propagation of these reservoirs, particularly in GALT (see Chapter I), is a necessary step 
toward HIV cure.  
 There is a growing body of evidence to support the existence of tissue HIV reservoirs. 
For example, several studies have demonstrated continued viral shedding from the 
gastrointestinal (GI) and genital tract despite undetectable plasma viral loads,12,131,132 and 
additional studies have shown that replication-competent virus can be isolated from the tissues of 
patients long after cART initiation.133 More recent work has demonstrated viral genetic evolution 
within the lymph nodes of patients fully suppressed on cART.29 Given that this persistence has 
been observed in the setting of suppressive cART, it is reasonable to suspect that inadequate 
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antiretroviral (ARV) penetration into certain tissues may contribute to HIV persistence. It has 
been shown by our group and others that ARV tissue penetration is highly variable between 
anatomic sites and between ARVs within a single tissue.51 Further, Fletcher et al demonstrated 
that higher tissue ARV concentrations were significantly associated with faster HIV decay within 
the lymph nodes and GI tract.56 More recently, we have shown our ability to image ARVs within 
a tissue, and found heterogeneous efavirenz (EFV) distribution in several anatomic sites, 
particularly in the GI tract.75 Further investigation into what factors govern these distribution 
patterns is critical for understanding how to increase ARV exposure in tissue reservoirs.  
 Drug transporters are known to play an important role in the disposition of many drugs, 
including ARVs. Not only does their activity help define a drug’s pharmacokinetic profile (e.g. 
absorption in the intestine, excretion in the kidney), but they play a major role in drug 
interactions, particularly for ARVs.60,61 Using tissue penetration data from multiple classes of 
drugs, including ARVs, we have previously shown that the likelihood of being a substrate for the 
efflux transporters MRP1 and MRP4 was significantly predictive of drug penetration into the 
female genital tract52, suggesting a role for these transporters in overall ARV tissue exposure. 
Several groups, including our own, have published studies evaluating the expression and 
localization of drug transporters in tissues relevant for HIV prevention98,134 and, more recently, 
cure.65 However, there has been no consensus in the field on the optimal way to measure 
transporter expression. There is little agreement between publications with regard to what is 
being measured (i.e. gene vs protein expression), and there has been no assessment of the level 
of agreement between techniques (e.g. qPCR vs Western blot vs immunohistochemistry (IHC)). 
Further, although proteomics-based methods have been used to obtain absolute concentrations of 
specific proteins including drug transporters135,136, this technology has not been compared against 
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other methods in the context of HIV infection.  A comprehensive evaluation of transporter 
expression and localization using multiple techniques within the same study is greatly needed to 
inform the field as to the best way to measure transporter expression for their effect on ARV 
penetration into tissues.  
 In addition to methodological considerations, another important variable to address is 
expression differences between species. Animal models are commonly used to study HIV 
infection, and any evaluation of the tissue exposure of a new or existing ARV must first be 
performed in animals before moving into humans. While there are some data showing 
similarities in ARV exposure between humans and animals114, there is a relative lack of data 
comparing important variables for drug distribution, such as drug metabolizing enzymes, drug 
transporters, and PK properties between animal models or between animals and humans. Further, 
the effect of HIV infection on these variables has not been elucidated. Identification and 
quantitation of these differences, if they exist, will help to prevent the inappropriate extrapolation 
of data from one species to another, determine whether pharmacokinetic information should be 
obtained during infection, and streamline the drug development process.  
 In the present study, we perform a comprehensive evaluation of drug transporter 
expression and localization in two tissues of the GI tract24,130 using multiple methodologies and 
three animal models from two species. These data will help identify important variables for ARV 
exposure into tissue reservoirs, while at the same time identifying the best way to measure drug 
transporter expression. Finally, the generation of novel inter-species data can help determine the 
applicability of animal models to future ARV development.  
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Methods 
 
 
ARV Dosing and Tissue Collection 
 Animal dosing and tissue collection were described in detail in Chapter II, but briefly, 
three commonly used animal models were employed in this study: the hu-HSC-Rag (n=41) and 
bone marrow-liver-thymus (BLT; n=13) humanized mouse models and a non-human primate 
model (n=12), with half of each cohort infected with HIV or SHIV as described 
previously.108,137,138 Mice were dosed orally with one of several ARV regimens for 10 days: EFV 
10mg/kg (n=6) alone; atazanavir (ATZ) 140mg/kg (n=6) alone; or tenofovir (TFV) 208mg/kg, 
emtricitabine (FTC) 240mg/kg, raltegravir (RAL) 56mg/kg, maraviroc (MVC) 62mg/kg (n=6) in 
combination. Male rhesus macaques (Macaca mulatta) were dosed for 10 days with TFV 
30mg/kg subcutaneously (SubQ), FTC 16mg/kg (SubQ) and one of the following regimens: 
MVC 270mg/kg twice daily (BID) with ATZ 150mg/kg BID OR EFV 200mg QD with RAL 
100mg/kg BID. Doses for all drugs were chosen based on commonly used treatment doses for 
HIV infection in these models.110–114 ARV dosing combinations were chosen based on the 
limited resources available (i.e. NHPs) or on toxicity (e.g. EFV in BLT mice). Two animals from 
each mouse model were not dosed with ARVs and used as controls.  Ileum and rectum were 
collected at necropsy and snap frozen. All animal experiments were performed in accordance 
with locally-approved IACUC protocols.  
 
 
Gene Expression 
 Transporter gene expression was analyzed by quantitative polymerase chain reaction 
(qPCR) on five efflux and four uptake transporters (Table 3.1). These transporters were chosen 
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based on their relevance to ARV disposition and expression in the GI tract, though this is not an 
exhaustive list.61 Approximately 30mg of tissue was homogenized in lysis buffer using a 
Precellys Tissue Homogenizer (Bertin Technologies, Montigny-le-Bretonneux, France) and 
RNA was extracted using a Qiagen RNAeasy Mini Kit (Qiagen, Valencia, CA) per 
manufacturer’s protocol. RNA concentrations were measured using a NanoDrop 2000c (Thermo 
Fisher Scientific, Waltham, MA), and 200ng of RNA was reverse transcribed to cDNA using the 
VILO Superscript cDNA Synthesis Kit (Thermo Fisher). RNA integrity was confirmed using the 
260/280 ratio for each sample. In order to obtain a large enough volume of cDNA to perform 
PCR in triplicate for 10 genes, cDNA was pre-amplified for 10 cycles using Taqman Pre-
amplification Master  
Table 3.1: Drug Transporters Evaluated for Gene and Protein Expression 
Gene Name Protein Name ARV Substrates ARV Inhibitors ARV 
Inducers 
ABCB1 MDR1 TFV, RAL, ATZ, 
MVC 
TFV, FTC, EFV, 
ATZ, MVC 
FTC, EFV, 
ATZ 
ABCC1 MRP1 FTC, ATZ TFV, FTC, EFV, 
ATZ 
ATZ 
ABCC2 MRP2 ATZ TFV, FTC, EFV RTV, NFV, 
MVC 
ABCC4 MRP4 TFV   
ABCG2 BCRP TFV EFV, ATZ RTV, NFV 
SLCO2A1 OATP2A1   DRV 
SLC29A1 ENT1 TFV, FTC   
SLC22A2 OCT2 3TC ABC,FTC,TFV  
SLC22A3 OCT3    
 
Mix (Life Technologies, Carlsbad, CA) and Taqman Gene Expression Assays (Appendix 3.1) 
and then diluted 5-fold with Tris-EDTA buffer. Forty cycles of qPCR were performed on the 
pre-amplified cDNA using Taqman primers and probes on a QuantStudio6 (Life Technologies). 
Raw CT values were calculated based on a threshold value of 0.2, and expression for all 
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transporters was normalized to the housekeeping gene GAPDH (which showed lower variability 
after pre-amplification versus beta-actin; data not shown) using the 2-ΔCT method.139  
  
Protein Extraction and Western Blot 
 Protein used for Western blot and LC-MS proteomics was isolated using a modified 
version of an extraction method optimized for proteomics as described previously.140,141 Briefly, 
tissues (10-100mg) were homogenized in 1.3mL hypotonic buffer containing 10mM NaCl, 
1.5mM MgCl2, 10mM Tris HCl pH 7.4, and 150uL of Complete Protease Inhibitor Solution 
(Sigma-Aldrich, St. Louis, MO) using the Precellys tissue homogenizer. Tissue homogenate was 
left on ice for 30 minutes, then sonicated for 5 minutes and centrifuged for 10min at 10,000g. 
Supernatant was saved and subjected to high-speed centrifugation at 55,000rpm for 1 hour. 
Supernatant was discarded and the pellet was resuspended in Complete Protease Inhibitor 
Solution. Protein concentrations were quantified using the BCA protein assay (Pierce, Rockford, 
IL). The total protein isolated from each tissue was split between Western blot and proteomics. 
At least 10 and up to 50µg was reserved for proteomics, with the remaining protein (up to 10µg) 
being used for Western blot. 
 For Western blot, up to 10µg of protein was combined with 7.5µL sample buffer 
(NuPage, ThermoFisher) and 0.5M dithiothreitol (DTT, Sigma-Aldrich) and heated at 70˚C for 
10 minutes before being loaded onto a 4-12% electrophoresis gel (NuPage) and run for 110 
minutes at 180V. Transfer onto a PVDF membrane (NuPage) occurred over 90 minutes at 30V. 
Once transfer was completed, membranes were rinsed with Tris-buffered saline with Tween-20 
(TBS-T) and blocked for 1 hour at room temperature in 5% milk. After blocking, primary 
antibody was added for one of the five following proteins: MDR1 (1:4000, ab170904, Abcam, 
Cambridge, MA), MRP2 (1:200, ALX-801-037-C125, Enzo Life Sciences, Farmingdale, NY), 
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MRP1, (1:200, ALX-801-007-C125, Enzo), BCRP (1:1000, ab3380, Abcam), and GAPDH 
(1:2000, sc-25778, Santa Cruz Biotechnology, Dallas, TX). Membranes were incubated in 
primary antibody for 1-3 hours, then rinsed with TBS-T and incubated in secondary antibody 
(anti-rabbit, 1:2000, ab16284, Abcam; anti-mouse, 1:10000, ab112458 Abcam; anti-goat, 
1:5000, sc2020, Santa Cruz) for 1-2 hours, then rinsed again with TBS-T. Development occurred 
using Clarity ECL reagents (Bio-Rad, Hercules, CA) with a Chemi-Doc XRS+ Imager (Bio-
Rad). All developments were performed using a 5 min exposure, and densitometry relative to 
GAPDH was calculated using ImageLab 5.2.1 (Bio-Rad). MDR1 and GAPDH were analyzed 
during the same exposure, then each membrane was stripped and re-probed for MRP2 and 
BCRP, then MRP1, with all densitometry being compared to the initial 5 min GAPDH exposure. 
A combination of 15µg each of mouse brain extract, liver extract, and T98G cell lysate (Santa 
Cruz) was used as the positive control sample.  
 
Quantitative Targeted Absolute Proteomics (QTAP) 
 Protein isolation and quantitation occurred as described above, with between 10 and 50µg 
being used for this analysis. Methods for protein digestion and proteomic analysis have been 
described in detail elsewhere140,141, but briefly, proteins were dried down and reconstituted in 
50mM ammonium bicarbonate buffer with 40mM DTT, 10% sodium deoxycholate (Sigma-
Aldrich), and 10µL β-casein (0.1µg/µL). Samples were reduced for 40min at 60°C, then 135mM 
iodoacetamide (Sigma-Aldrich) was added and samples were incubated for ~30min at room 
temperature in the dark. 1 pmol stable isotope labeled (SIL) peptide standards (Theracode JPT 
Inc., Acton, MA) for each transporter of interest (Table 3.1) were added to each sample along 
with 25µL Trypsin (0.1µg/µL) (Promega, Madison, WI). Samples were digested for at least 18 
hours at 37°C after which point the digestion was stopped with 10% trifluoroacetic acid (Sigma-
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Aldrich). Samples underwent solid phase extraction using Strata-X 33µm polymeric reversed 
phase extraction cartridges (Phenomonex, Torrance, CA), then were dried down and 
reconstituted in modified Mobile Phase (98% formic acid 0.1%, 2% acetonitrile) and transferred 
to silinized inserts for injection.  
 Analysis was performed using a nanoACQUITY system (Waters, Milford, MA) coupled 
to a QTRAP 5500 mass spectrometer (AB SCIEX, Framingham, MA) equipped with Nanospray 
III source. An injection amount of ~0.2-1µg of total membrane microsomal protein was loaded 
onto a C18 trap column (180µm x 20mm, 5µm particle size, Waters). Positive ion mode was 
used for MS analysis with ion spray voltage of 4000. Target scan time was set at 1.5sec with a 
scheduled MRM detection window of 90 seconds and a 3 millisecond pause time between 
MRMs. Analyst 1.5 (AB SCIEX) was used for MS control, and MRM analysis was performed 
using MultiQuant 2.0 (AB SCIEX). Peaks were smoothed prior to integration and area ratios of 
unlabeled/SIL peptides were determined using the sum of MRMs monitored. The lower limit of 
detection for the peptides was ~0.2pmol/mg protein. 
Immunohistochemistry 
 Tissues were sliced frozen at 10µm thickness using a cryostat (Leica Biosystems, 
Wetzlar, Germany) and thaw mounted onto glass microscope slides. The frozen slides were then 
stained with primary antibody for MDR1 (1:50; Abcam), MRP2 (1:50, Kamiya Biomedical, 
Seattle, WA), MRP1 (1:100, Santa Cruz), MRP4 (1:20, Abcam) or BCRP (1:50; Santa Cruz) for 
15-60 minutes followed by pH antigen retrieval (Leica). DAB (3,3’-diaminobenzidine) was used 
as a substrate-chromagen for detection. All staining was performed on a Leica Bond automated 
tissue stainer (Leica). Mouse and NHP liver tissues were used as a positive control for all 
antibodies, and negative staining was performed using secondary antibody only. Samples were 
visually evaluated for transporter localization.   
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 ImageJ software (www.imagej.net) was used to quantify observed transporter staining, as 
extensive staining for several transporter precluded traditional counting of positive cells. Raw 
images of scanned slides loaded into ImageJ. The IHC toolbox was used to threshold the image 
to show only positive staining. The thresholded image was then converted to 8-bit greyscale. The 
image adjust tool was used to maximize the intensity of positive staining, then the image was 
converted to black and white. The selection tool was used to measure the total area of positive 
staining (white), then the selection was inverted to measure the total area of negative staining 
(black). The ratio of positive (white) to negative (black) staining was used as the quantitative 
endpoint. 
 
Human Transporter Analysis 
 The humanization process for both mouse models results in extensive reconstitution of 
human lymphocytes.109,142 As drug transporters that affect ARV flux have been shown to be 
present on the surface of human lymphocytes, and these transporters may contribute to ARV 
disposition in the GI tract, an analysis of human gene and protein expression was completed in 
parallel to mouse expression in samples from both humanized mouse models. For gene 
expression, cDNA preamplification and qPCR was performed with human-specific Gene 
Expression Assays (Appendix 3.1). Western blot analysis used human specific primary 
antibodies on the same membranes to assess human protein expression. For QTAP, human 
proteotypic peptides were optimized in addition to those used for quantitation of mouse proteins. 
Non-humanized mouse samples were used as negative controls to confirm the specificity of both 
the Gene Expression Assays and antibodies.  
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Antiretroviral Plasma and Tissue Concentrations 
Plasma samples were extracted by protein precipitation with methanol containing stable, 
isotopically-labeled internal standards. Samples were vortexed and centrifuged, then the 
supernatant was diluted with water prior to LC-MS/MS analysis. A Shimadzu high-performance 
liquid chromatography system with a Waters Atlantis T3 (50mm x 2mm, 5µm particle size) 
HPLC column was used for separation, and an AB SCIEX API 5000 mass spectrometer (AB 
SCIEX, Foster City, CA, USA) equipped with a turbo spray interface was used as the detector. 
The lower limit of quantitation was 1ng/mL for each analyte. The precision and accuracy of the 
calibration standards and QC samples were within the acceptable range of 15%.  
Tissue ARV concentrations were also quantified by LC-MS/MS. Briefly, tissue samples 
were placed in a tube (Precellys 2mL Hard Tissue Metal Beads Kit) containing 1mL of ice cold 
70:30 acetonitrile-water. Samples were homogenized using a Precellys 24 benchtop 
homogenizer.  A portion of the homogenate was then mixed with methanol containing stable, 
isotopically labeled internal standards.  Following centrifugation, the supernatant was evaporated 
to dryness and reconstituted with water (for TFV/FTC analysis) or 25:75 methanol:water (for 
ATZ/EFV/MVC/RAL analysis) . LC-MS analysis was performed using the same system as 
described above except the HPLC separation for ATZ/EFV/MVC/RAL was performed using an 
Agilent Pursuit XRs Diphenyl (50mm x 2mm, 5µm particle size) column. The lower limits of 
quantitation for the tissue analysis were 0.002 ng/mL (FTC and MVC), 0.005ng/mL (ATZ, EFV, 
and RAL), and 0.01ng/mL (TFV).  Tissue concentrations were ultimately converted into ng/g 
tissue units for comparison to plasma. 
Statistical Analysis 
 For both gene and protein expression, comparisons between dosing cohorts were made 
using one-way Kruskal-Wallis ANOVA on ranks, which was also used to make comparisons 
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between species and anatomic compartments. Dunn’s post-test was used for pairwise multiple 
comparisons when significant differences (p<0.05) were detected. LC-MS concentrations were 
normalized to paired plasma concentrations to generated tissue:plasma ratios (TPRs) for 
reporting. Pearson correlation was used to determine the relationship between gene expression 
and protein expression by each method for all combined samples. 
 To determine which transporter evaluation method best predicted tissue ARV 
penetration, univariate regression analysis was performed using log-transformed TPR values as 
the dependent variable. Transporter expression values (as measured by qPCR, Western blot, 
QTAP, or IHC) for the efflux transporters were included as independent variables. Those 
variables achieving p<0.05 in the univariate analysis were included in a multivariable analysis 
using stepwise linear regression to identify combinations of variables significantly predicting 
TPR.  R2 values from each resulting model were compared across methods to determine which 
method best predicted tissue penetration for each drug. Descriptive statistics and between-group 
comparisons were conducted using SigmaPlot 13.0 (Systat Software Inc., San Jose, CA), and the 
univariate and multivariable analyses were performed using SAS 9.3 (Cary, NC); p<0.05 was 
considered significant.  
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Results 
 
Human Engraftment and Viral Load in Animal Models 
 The extent of human engraftment of total lymphocytes (CD45+), total T cells (CD3+), 
and HIV target cells (CD4+) in both humanized mouse models is shown in Figure 3.1a. At 
baseline, CD45+ and CD4+ engraftment was similar between the two models and is consistent 
with what has previously been observed (>50% engraftment),108,143 and human CD3+ cell 
percentage was 3-fold lower in the hu-HSC-Rag model compared to the BLT model. At week 4 
post-infection, there was a 2.5-fold decrease in the total lymphocyte population in hu-HSC-RAG 
(week 4 data was not available for the BLT mice) likely driven by drops in human CD4+ T cells. 
Figure 3.1b shows the plasma viral load from both mouse models as well as the NHP model over 
the course of infection. Peak viral loads were observed at week 2 post inoculation and ranged 
from 105 copies/mL in the hu-HSC-Rag to 107 copies/mL in NHPs. Plasma viremia was 
sustained over the course of infection.  
Figure 3.1: Extent of Human Engraftment and Viral Load Among Animal Models Human 
lymphocyte populations were quantified for the hu-HSC-Rag (black) and BLT (gray) mouse models 
at baseline and week 4 post-infection (A). Plasma viral loads for both humanized mouse (gray and 
red) and macaque models (black) are shown over time in (B). Data shown are mean and standard 
deviation. 
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Transporter Gene Expression in Humanized Mouse Intestine 
 Evaluable rectum and ileum tissues were available from all mice that completed dosing. 
Comparisons between individual dosing cohorts for the ileum and rectum are shown in Appendix 
3.2 and 3.3, respectively. These comparisons demonstrate the agreement between uninfected and 
infected mice and show a significant 2.5-3 log increase in ABCC4 expression in the hu-HSC-Rag 
mice versus BLT mice (Appendix 
3.2d and 3.3d) which was observed in 
both the ileum and rectum.  There 
was also a trend for lower ABCB1 
expression in the ileum and rectum of 
BLT mice, but this did not reach 
statistical significance (Appendix 
3.2c and 3.3c). ARV dosing did not 
significantly modulate gene 
expression for any transporter with 
the exception of ABCC2 in the ileum, 
for which gene expression was nearly 
3-fold higher in the non-dosed control 
mice (Appendix 3.2b) compared to 
all other mice evaluated.  
Because there were no 
significant differences observed 
between individual dosing cohorts, 
these data were combined to assess total gene expression (Figure 3.2). In the ileum (Figure 3.2a), 
Figure 3.2: Mouse Transporter Gene Expression in 
Humanized Mouse Gut Combined transporter 
expression from all humanized mice (all hu-HSC-Rag and 
BLT) is shown relative to GAPDH for infected and 
uninfected animals in the ileum (a) and rectum (b). Data 
shown are median and range. * represents p<0.05.  
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transporter expression ranged from 10-6 to 1-fold of GAPDH expression, with detectable gene 
expression in every sample. These expression levels were consistent with the rectum (Figure 
3.2b), with similar trends between transporters. Importantly, gene expression was generally 
consistent between uninfected and infected mice with the exception of ABCC4, which had 
significantly higher expression in infected mice versus uninfected mice (p<0.05).  
   
Interspecies Comparison of Transporter Gene Expression 
 Pooled ileum and rectum data from mice and macaques were compared in Figure 3.3, 
which shows inconsistent agreement between compartments and between species. Among the 
efflux transporters, ABCC2 (Figure 3.3b) showed agreement between species in both the absolute 
level of expression (10-1 fold GAPDH in the ileum) and expression between compartments (3-
log increase in ileum vs rectum).  ABCB1 demonstrated a significant 2-fold increase in 
expression in macaques vs mice (Figure 3.3c), while ABCC1 and ABCG2 did not differ 
significantly between species or tissue site. The significant differences in ABCC4 expression 
between uninfected and infected mice are again demonstrated here (Figure 3.3d), but otherwise 
no significant differences were observed. The uptake transporters SLCO2A1 and SLC29A1 did 
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not differ between species, but SLC22A2 was increased 0.5-fold in mouse rectum versus ileum 
and was not detected at all in macaque tissues (Figure 3.3h). Conversely, SLC22A3 was 2-3 logs 
more highly expressed in mice ileum and rectum compared to macaques (Figure 3.3i).  
 
 
 
 
 
 
Figure 3.3: Multispecies Comparison of Transporter Gene Expression Gene expression is 
represented as fold change of GAPDH for uninfected (gray) and infected (red) animals from multiple 
dosing cohorts. Data shown are median and range. SLC22A2 was observed in mouse tissues only. 
NHP=non-human primate. * represents p<0.05 
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Interspecies Comparison of Transporter Protein Expression by Western Blot Analysis 
 Figure 3.4 showcases transporter protein expression as measured by Western blot, with 
representative blots shown in 3.4a-e. Densitometry data from all mouse samples are shown in 
Figure 3.4f and 3.4g, which demonstrates large variability in protein expression, ranging from 
0.2 fold GAPDH in some MRP1 samples to >100 fold GAPDH for MDR1. Densitometry 
analysis of individual mouse dosing cohorts is shown in Appendix 3.4, and did not indicate 
significant differences between dosing cohorts or mouse models. Figure 3.4h-k compares mouse 
and NHP Western blot data. Relative protein expression trends were similar between mice and 
macaques for MRP1, MRP2, and BCRP. Interestingly, MDR1 protein expression showed a 
Figure 3.4: Transporter Protein Expression Humanized Mice Ileum and Rectum Representative 
Western blots for four efflux transporters from the ileum of each humanized animal cohort (a-e). + 
represents the positive control sample. Samples with no detectable GAPDH were not included in 
subsequent analyses. Densitometry data from each blot was quantified for each transporter in mice 
(f[ileum]&g[rectum]), where protein expression is represented as a fold change over GAPDH for 
uninfected (gray) and infected (red) animals. Zero values were imputed at 10-4 (dashed line) for 
graphing purposes. Comparison of all mice and macaques is shown in h-k, where data are median and 
range. Solid line represents equal protein expression to GAPDH. * represents p<0.05 
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significant opposite trend compared to the ABCB1 gene expression between species, with 
relative MDR1 protein expression 1-2 logs higher than macaques in both the ileum and rectum. 
Interspecies Comparison of Transporter Protein Expression by Targeted 
 Quantitative Proteomic Analysis 
 Proteomics analysis of absolute transporter protein concentrations for individual mouse 
dosing cohorts is shown in Appendix 3.5 and 3.6, where there was good agreement between 
dosing cohorts with no significant differences observed between infected and uninfected animals. 
Ileac and rectal QTAP data from all cohorts of mice were combined and compared to those 
generated in macaques (Figure 3.5). MDR1 protein concentrations were 2 logs higher in the 
mouse ileum compared to macaques (Figure 3.5c), which is the opposite of observed ABCB1 
gene expression trends. Further, the significant differences in ABCC4 expression between 
infected and uninfected mice were not replicated in the protein analysis (Figure 3.5d). The 3-log 
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increase in SLC22A3 gene expression in mice over macaques was also not replicated here 
(Figure 3.5h). There were also several significant differences in protein concentrations that were 
not present in the qPCR analysis. SLCO2A1, for example, was not significantly different between 
species in gene expression, however a significant increase in OATP2A1 concentrations was 
observed in macaques compared to mice (Figure 3.5f).  
 
 
 
 
 
Figure 3.5: Multispecies Comparison of Transporter Protein Expression by QTAP Absolute 
protein concentrations are represented as pmol/mg protein for uninfected (gray) and infected (red) 
animals from multiple dosing cohorts. Solid lines represent 1pmol/mg; dashed lines represent the 
lower limit of quantitation.  Data shown are median and range. * represents p<0.05 
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Transporter Localization in the Ileum and Rectum  
 IHC staining revealed distinct localization of several drug transporters within the GI tract 
(representative images in Figure 3.6). In both the ileum and rectum, MDR1 was found to localize 
on the luminal surface of the gut mucosa in tissues from all three animal models, and was readily 
expressed. Conversely, MRP2 was not detected in any tissue from any animal, though protein 
was sporadically detected with Western blot (Figure 3.4) and QTAP (Figure 3.5). BCRP was 
detected in the ileum of both mouse models, and showed a similar localization profile to MDR1. 
Interestingly, BCRP expression in the rectum of these animals was much lower, with only a few 
positive-staining cells detected, and was not detected at all in the macaque tissues despite low 
levels of detection in the macaque ileum by QTAP. MRP1 localized to the luminal surface in a 
similar fashion to MDR1 and was expressed in all tissues. MRP4 was localized to the lamina 
Figure 3.6: Efflux Transporter Localization Within the Macaque and Mouse Gut. 
Immunohistochemical staining for MDR1, BCRP, MRP2, MRP1 and MRP4 in NHP, hu-HSC-Rag 
mice, and BLT mice. Positive cells (brown staining) are indicated with black arrows. Lumen is 
labelled in each image.   
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propria in all three species, with extensive positive staining on the basolateral surface of mucosal 
cells.  
Human Transporter Expression in Humanized Mice 
 Figure 3.7 provides an overview of human transporter gene expression as it relates to 
mouse gene expression in the same tissues. Human gene expression was observed for more than 
half of the transporters evaluated. 
Expression was in general 1-5 
logs lower than the mouse genes, 
with the notable exceptions of 
ABCB1 and ABCC4, which in 
some samples was 2 logs higher 
than mouse expression. Trends 
were similar between ileum and 
rectum, with no significant 
differences detected between 
infected and uninfected animals. 
Human genes were not detected in 
any sample for ABCC2, SLC22A2, 
or SLC22A3. The Gene 
Expression Assay for human 
SLCO2A1 was found to be cross-
reactive to mouse genes and was 
therefore not included in the 
analysis. An analysis of the 
Figure 3.7: Human Transporter Gene Expression in 
Humanized Mouse Gut Combined transporter expression 
from all humanized mice (all hu-HSC-Rag and BLT) is 
shown relative to mice for infected and uninfected animals 
in the ileum (a) and rectum (b). Data shown are median 
and range. SLC22A2 and SLC22A3 were not observed in 
any animal, and the SLCO2A1 primers were found to be 
cross reactive and thus were not included. 
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relationship between the extent of humanization and the amount of human transporter gene 
expression did not show any significant relationship (data not shown). Western blot analysis 
using human-specific antibodies showed detectable bands for MDR1 only, which had fold-
GAPDH values that were within 50% of mouse protein expression (data not shown). However, 
QTAP analysis using human-specific SILs did not detect any MDR1 in any humanized mouse 
sample, nor did it detect human protein from any other transporter (data not shown). To 
demonstrate that earlier interspecies comparisons for ABCB1 and ABCC4 were not confounded 
by a lack of accounting for human gene expression, we re-analyzed these data after accounting 
for the contribution of human gene expression of these transporters (Appendix 3.7). Our ABCB1 
results were not significantly altered, however median ABCC4 expression in the uninfected 
mouse rectum greatly increased (p<0.01) over corresponding data in NHPs.   
Antiretroviral Tissue Penetration 
 Tissue:plasma ratios for each ARV investigated in both the ileum and rectum are shown 
in Table 3.2 for all three animal cohorts. No significant differences were seen between infected 
and uninfected animals so these data were combined for analysis. 
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Table 3.2: Tissue:Plasma Ratios for Evaluated Antiretrovirals in Intestinal Tissue 
 Ileum Rectum 
Drug 
Mice 
All 
Macaques 
Mice 
All 
Macaques 
BLT hu-HSC-
Rag 
BLT hu-HSC-
Rag 
TFV 
12  
(1,28) 
17 
 (0,56) 
13  
(3,58) 
52  
(1,448) 
160  
(0,628) 
32  
(2,145) 
FTC 
2 
(0.3,5) 
2 
(0,16) 
23  
(5,133) 
4  
(1,717) 
0.6 
(0,2) 
76 
 (9,496) 
RAL 
1  
(0.4,3) 
3 
(1,26) 
32  
(2,49) 
0.7 
 (0.2,279) 
3  
(2,4) 
753  
(137,1163) 
EFV  
0.7 
(0,509) 
6  
(4,42) 
 
13 
(0,156) 
9 
 (0.1,328) 
MVC 
24 
 (5,131) 
9 
(0.9,31) 
135 
(8,422) 
29 
 (5,81) 
6 
(1,18) 
385 
(17,2831) 
ATZ 
12  
(0.1,87) 
25  
(0.2,749) 
2709 
(9,30000) 
11  
(0.2,1239) 
15  
(0.6,183) 
8763 
(0.1,19812) 
 *data shown are median and range 
In mice, quantifiable concentrations of ARVs were detected in most plasma samples, 
ranging from 65% detection for MVC to 100% detection for TFV and FTC. Tissue 
concentrations were detected more frequently, ranging from 79% detection for RAL to 100% 
detection for TFV and FTC. Among the ARVs evaluated, TFV showed the highest penetration 
into both the ileum and rectum. TFV penetration was similar between BLT and hu-HSC-Rag 
mice in the ileum, but was increased by 3-fold in the hu-HSC-Rag rectum vs BLTs (160 vs 52). 
FTC, RAL, and ATZ TPRs were not significantly different between mouse models or 
compartments, while EFV achieved 18-fold higher TPR values in the hu-HSC-Rag rectum 
versus the ileum. MVC penetration was similar between the ileum and rectum, but was 3-fold 
and 5-fold higher in BLTs versus hu-HSC-Rag mice in these respective compartments.  
 The NHP samples had detectable ARV concentrations in >85% of samples for every 
ARV evaluated in both plasma and tissue. TPRs in NHP tissues were significantly increased 
(p<0.05) over both mouse models for FTC, RAL, MVC, and ATZ, ranging from 9-fold (MVC 
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ileum) to 150-fold (ATZ ileum) higher in NHPs. TFV penetration between animal models was 
not significantly different. EFV penetration was 8.5-fold higher in the NHP vs. mouse ileum 
(p<0.05), but this difference was not observed in the rectum. MVC and ATZ achieved the 
highest exposure of any drugs in both species, and median TPR values were increased by 3-fold 
in the rectum versus the ileum for both of these drugs. These large ratios were driven by high 
tissue exposure rather than low plasma concentrations, which were consistent with previously 
published data in non-human primates. 
Methodology Comparison for Drug Transporter Evaluations 
 To determine whether or not the three methodologies used here to evaluate drug 
transporter expression 
agree with one 
another, correlation 
matrices were 
generated for the four 
efflux transporters 
evaluated by all three 
methods using 
combined data from 
all animals (Figure 
3.8). Correlation 
coefficients were low 
for all comparisons, 
ranging from 0.01 
(MRP2 QTAP vs Western) to 0.42 (MRP1 qPCR vs Western) and showcasing the lack of 
Figure 3.8: Lack of Agreement Between Transporter Evaluation 
Methods Correlation matrices are shown for the four efflux transporters 
evaluated by all three methods. 
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agreement between techniques. Comparison of qPCR and QTAP for BCRP showed the strongest 
correlation, and reaches statistical significance (r=0.34, p<0.01), however the large amount of 
variability in the data does not provide convincing evidence that these methods are in high 
agreement. 
 Results from the multivariable analysis are shown in Table 3.3. Predictive ability was 
generally low, with R2 values ranging from 0.09 (TFV TPR predicted by qPCR) to 0.51 (FTC 
TPR predicted by WB). qPCR data was able to generate significantly predictive regression 
models for each drug evaluated, though the resulting R2 values tended to be lower than those 
generated by WB. QTAP data generated significant models for TFV, FTC, and RAL only, and 
R2 values were lower than qPCR or WB in every case. IHC quantitation poorly predicted TPR 
values and did not offer improvement over qPCR or QTAP. There was little agreement between 
methods regarding which specific efflux transporters were found to significantly contribute to 
each model, though BCRP and MRP1 expression were the most commonly implicated 
transporters. 
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Table 3.3: Multivariable Regression Analysis of Drug Transporter Expression Methods on TPR 
Drug Method MDR1 BCRP MRP2 MRP1 MRP4 R2 
TFV 
qPCR - - 0.01 - - 0.09 
WB - 0.01 - 0.05 - 0.38 
QTAP - 0.01 - - - 0.11 
IHC - - - - - n/a 
FTC 
qPCR - 0.007 - 0.008 - 0.41 
WB - 0.01 - 0.002 - 0.51 
QTAP 0.04 - 0.05 - - 0.15 
IHC - - - - - n/a 
RAL 
qPCR 0.56 0.002 - 0.002 - 0.43 
WB - 0.03 - 0.01 - 0.51 
QTAP - - - 0.58 0.008 0.16 
IHC - - - - - n/a 
EFV 
qPCR - 0.004 - 0.07 - 0.39 
WB - 0.12 - - - 0.22 
QTAP - - - - - n/a 
IHC - - - - - n/a 
ATZ 
qPCR - - - - 0.06 0.17 
WB - - - - - n/a 
QTAP - - - - - n/a 
IHC - - - - - n/a 
MVC 
qPCR - - - 0.002 - 0.23 
WB - - - - - n/a 
QTAP - - - - - n/a 
IHC - - - - - n/a 
 
 
 
 
Discussion 
 
 
 This is the first study to comprehensively compare drug transporter expression in the GI 
tract across animal models, and has demonstrated several novel findings with important 
implications for drug development and HIV eradication research. Transporter gene expression in 
mice was shown to be similar regardless of drug regimen and mouse model. There were, 
however, a few notable exceptions. ABCB1 expression tended to be lower in the BLT mice than 
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in hu-HSC-Rag animals. Though this difference did not reach statistical significance due to the 
high variability of these data, it may be the case that GI exposure of MDR1 substrates (including 
most ARVs) may be increased in the BLT model. This is supported by the LC-MS data 
generated here, where MVC and RAL (two MDR1 substrates) were undetectable in the hu-HSC-
Rag animals but readily detected in BLT mice (Table 3.1). Conversely, TFV and ATZ 
concentrations showed the opposite trend despite also being MDR1 substrates. 
 Additionally, we observed significant multiple log increases in ABCC4 expression in 
infected mice, which was found in both the ileum and rectum and was consistent between the 
drug regimens and mouse models (Figure 3.2). Given that MRP4 is known to transport TFV,61  
higher levels of ABCC4 expression and MRP4 efflux activity during infection may mean that 
TFV exposure is reduced in tissues with high amounts of HIV replication, contributing to the 
propagation of tissue reservoirs. These changes also have implications for the development of 
novel ARVs that are also MRP4 substrates. For example, the observed tissue exposure of an 
investigational agent may depend solely on whether or not the animals used were infected or not, 
potentially changing the course of a drug’s development. Though we did not observe these same 
differences in MRP4 protein expression with QTAP or Western blot, overall detection of this 
protein was low and it may be that lower detection limits would have yielded more conclusive 
results. TFV tissue concentrations evaluated here by LC-MS were not significantly different 
between infected and uninfected animals after adjustment for plasma concentrations, casting 
doubt on whether or not the observed differences in gene expression have any clinical 
implication. Lack of agreement between mRNA expression and protein expression and function 
(discussed in more detail below) or the effect of numerous drug transporters acting in concert 
may help explain this disconnect.  
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 When gene and protein expression data were pooled to investigate differences between 
anatomic compartments and between species, several important differences were observed. The 
multiple log differences observed between mice and macaques for ABCB1/MDR1 and 
ABCC4/MRP4 indicate ARV PK data generated in one model may not easily be extrapolated to 
the other. Given that several of these transporters have been shown to efflux numerous ARVs, 
the species used in investigations of ARV disposition into tissues, whether for prevention or 
eradication, is a critically important variable. RAL, for example, has been shown to reach rectal 
concentrations that are 35-fold greater than plasma in macaques.144 We have also recently shown 
that RAL distributes readily throughout the macaque rectum, but that distribution in humanized 
mouse rectum is lacking.76 In this study, RAL NHP ileum and rectum concentrations were 
increased over mice by 16- and 376-fold, respectively. Given that RAL is known to be effluxed 
by MDR1, it may be the case that RAL distributes into the intestinal mucosa in both species, but 
is effluxed back into the intestinal lumen by MDR1 to a greater extent in mice versus macaques, 
helping to explain the decreased tissue concentrations in this model. The distinct differences 
observed here provide support that transporter expression may also differ between animal models 
and humans. 
 When compared to data generated by others using human tissues, the animal data 
generated here shows several striking differences. De Rosa et al evaluated the gene and protein 
expression of five efflux transporters in the sigmoid colon of 16 HIV negative and 9 HIV 
positive men.100 The authors found the highest level of gene expression for ABCC2 (0.76-fold vs 
cyclophilin) and the lowest expression level for ABCG2 (0.17-fold). We observed comparatively 
lower expression levels in both mice and NHPs, with a maximum median expression level of 0.5 
(ABCG2 in infected mice), though we normalized to a different housekeeping gene. Protein 
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expression by Western blot in their study showed relative expression ranging from 40-100-fold 
higher than the loading control (actin), again higher than what we observed. Of note, we failed to 
observe any MRP2 and little BCRP from the rectum of both animal species despite expression in 
human colon of 60-70-fold that of loading control. Further, analysis of human data showed a 
significant downregulation of ABCB1 and ABCC2 genes in HIV infection, and significant 
alterations in protein expression during cART, neither of which were observed here. Studies of 
human tissue done by our group (described in Chapter IV) provide additional insight on 
interspecies differences and minimize inter-lab variability effects that may be confounding these 
comparisons.  
 Not only does the current study provide important information on transporter expression 
between animal models, we also are the first to formally compare methodologies for measuring 
transporter expression in tissues relevant for HIV research. The extent of agreement between 
methods was generally poor, with ABCG2/BCRP showing the only significant relationship. 
There are several possible explanations for this lack of correlation, including the fact that, 
compared to the robust qPCR data, protein expression was highly variable and was not observed 
in all samples. Conditions for these experiments have been optimized by our lab, however lot-to-
lot antibody variability and lack of an accepted standard for quantifying densitometry data are 
persistent challenges with the Western blot technique.145 Further, mRNA inhibition by native 
micro-RNAs or post-translational protein modifications are known to affect the relationship 
between gene and protein expression and may be influencing the observed results. Additionally, 
differential rates of mRNA degradation between GAPDH and transporters may falsely lower 
observed expression despite correction for this housekeeping gene. 
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The lack of agreement between qPCR and Western blot data even after correction for 
GAPDH expression is concerning, as there is currently no accepted standard in the field for 
measurement of transporter expression. Several groups have published data generated using both 
methods100,65, however the utility of Western blot data is limited due to narrow dynamic range 
and often possible antibody cross reactivity. Further, relative gene expression data should be 
interpreted with caution, as the high sensitivity may lead to false positives. Using DNA 
standards, we have determined that 8-10,000 copies of GAPDH were present in each mouse 
sample, with 60-100,000 GAPDH copies present in each NHP sample (data not shown). Based 
on these values, relative transporter expression values of 10-4 or greater represent biologically-
plausible expression of these genes in our samples, however lower relative expression values 
may simply mean that the gene is not expressed at all.  
Proteomics analysis of the same tissues showed much more robust data compared to 
those generated by Western blot in terms of overall frequency of detection (80% for QTAP vs 
71% for WB). However even these data showed little agreement when compared to qPCR data. 
The transporters with statistically significant relationships between the methods (BCRP and 
MRP1) did not demonstrate a significant predictive ability, with R2 values of 0.34 and 0.42, 
respectively. Despite the lack of agreement with qPCR data, QTAP tended to agree with 
transporter localization data determined by IHC, where MDR1 and BCRP were the most highly 
expressed throughout the ileum and rectum, with decreased expression of MRP1 and almost no 
expression of MRP2. The ability of QTAP to provide robust, downstream protein expression 
data with high sensitivity and specificity for multiple transporters from a single sample make this 
an appealing technology. The lack of agreement between QTAP and WB is inconsistent with 
previous reports showing good correlation between these methods146.  However, those results 
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have been generated using recombinant enzymes, which do not represent the complex biological 
tissue matrices studied here. To our knowledge, ours is the first study to compare these data 
using tissue homogenates.  While this technology requires specialized equipment and expertise 
its use has become more widespread in recent years.147–149  
Despite these advantages, the multivariable regression analysis found that QTAP data did 
not provide a significant increase in predicting observed TPR values over data derived from 
other techniques (Table 3.3). Further, the efflux transporters identified as significantly predicting 
TPR were not consistent between methods. The biologic plausibility of the observed results is 
also variable. For example, BCRP expression measured by WB showed a moderate predictive 
capacity (R2= 0.38) for the TPR of TFV, a BCRP substrate. MRP1 was found to significantly 
affect the TPR of FTC using qPCR and WB data (R2=0.41 and 0.51, respectively), supporting 
studies that show FTC as an MRP1 substrate. Conversely, there are several instances where 
significant prediction was unexpectedly not found given existing substrate data (e.g. MDR1 for 
RAL, MRP4 for TFV). These results may be explained in part by the large amount of 
undetectable samples for Western blot and QTAP, which may have reduced the ability to detect 
significant relationships. Further, the possibility of drug-drug interactions affected tissue ARV 
exposure, particularly in the NHPs receiving EFV, must be considered.  
The negative results of this regression analysis may indicate that drug transporters alone 
do not govern ARV tissue concentrations in a significant way, but must be measured in the 
context of additional variables such as drug metabolizing enzyme expression or drug PK 
properties, which were not examined here. It is possible that consideration of these variables in 
tissue accumulation would have improved the predictive ability of the model. Given the high 
sensitivity and low variability of qPCR data compared to other methods, it is surprising that these 
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models did not identify expected transporters, however qPCR was able to identify at least one 
significant variable for every drug. The fact that gene expression is not always reflected by 
protein expression could be seen as an issue with the qPCR technique. 
One of the most notable findings of this analysis is the characterization of human drug 
transporter expression in the tissues of both humanized mouse models. The extent of peripheral 
immune humanization observed here was consistent with previous studies using these models108, 
but this is the first study to quantify human transporter expression in these animals. The detection 
of some human transporter gene expression should not be surprising given that many of these 
transporters are expressed on the surface of human lymphocytes, which are abundant in the 
humanized mouse GI tract, particularly in the ileum. We observed human gene expression from 
nearly every transporter evaluated, and found that ABCB1 and ABCC4 were expressed at an 
extent equal to or greater than mouse transporters in tissues from five mice (Figure 3.7). This 
implies some amount of underestimation of the size of the total transporter pool, and when 
human transporter isoforms were accounted for (Appendix 3.8), ABCC4 results significantly 
changed.  However, ABCB1 results remained consistent and the use of species-specific 
antibodies and SILs for Western blot and QTAP, respectively, preserved the validity of our 
protein results. 
This finding is particularly relevant to intracellular ARV exposure in the context of 
infection. As the majority of ARVs have intracellular sites of action, drug transporters on the 
surface of lymphocytes (e.g. ENT1, MRP1, MPR4, BCRP)150 are equally important to those 
regulating overall exposure in the tissue. Human lymphocytes are the only cells infected in these 
chimeric mice, and the contribution of human transporters on the surface of these cells to the 
overall transporter population cannot be ignored. Though species differences in the specificity of 
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these transporters for the ARV substrates studied here have yet to be quantified, protein sequence 
homology is high compared to mice (78-88%), and it is reasonable to expect that ARVs utilize 
transporters from both origins. Evaluations that quantify transporters from only one species or 
the other may underestimate the effect of some transporters for ARV disposition, as we have 
demonstrated here. Future studies of drug transporters and/or drug metabolizing enzymes in 
these mouse models should include the analysis of both mouse and human-derived proteins.  
As the body of evidence for persistent HIV replication within tissue reservoirs continues 
to grow, so does the need to define and quantify the factors influencing ARV disposition within 
these tissues. Targeting new or existing ARV therapies to these sites will require a knowledge of 
the specific variables that favor increased exposure at the site of action. To that end, this analysis 
is the first to formally compare drug transporter expression between commonly used animal 
models, and to assess the effect of HIV infection on transporter expression. We also 
demonstrated that the methods commonly used to evaluate transporter expression have little 
agreement with each other, and that robust downstream measures may have the most utility. 
Finally, we are the first to quantify the contribution of human transporters to the overall 
transporter pool in the GI tissue of these humanized mouse models. These data can inform the 
development of future therapies targeted toward HIV reservoirs and, when coupled with within-
tissue ARV distribution data, represent an important step toward HIV eradication. 
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Chapter IV: Clinical Assessment of Antiretroviral GALT Distribution and Drug 
Transporter Expression with Interspecies Comparisons to Inform Drug Development 
 
Summary 
 
Inadequate antiretroviral (ARV) exposure within gut-associated lymphoid tissue (GALT) 
may contribute to HIV persistence, but traditional LC-MS techniques cannot fully address this 
hypothesis. Mass spectrometry imaging (MSI) shows heterogeneous ARV distribution in GALT 
in animal models, which may be affected by drug transporters. However, application of these 
findings are limited without comparing these data to humans. Here, we assess ARV localization 
and drug transporter expression in HIV-infected subjects and make novel inter-species 
comparisons. Ileum and rectum biopsies (n=10 each) were collected from five HIV-infected 
females receiving combination ARVs (Truvada® + raltegravir (RAL), efavirenz (EFV), 
atazanavir (ATZ), or maraviroc (MVC)). Co-localization analysis of ARVs (measured by MSI) 
and T cells (measured by immunofluorescence) was performed in Matlab using Pearson 
correlation (r). Drug transporter protein concentration was measured from replicate biopsies by 
LC-MS/MS proteomics. Human data were compared to our previously generated animal data in 
non-human primates (n=12) and humanized mice (n=49) using ANOVA on ranks. ARV 
localization was heterogeneous within tissue and across therapeutic classes. After correction for 
heme signatures, MVC and EFV showed the best ARV-T cell co-localization, which was 5-fold 
higher in the rectum versus ileum, and not significantly different (p>0.05) from data in primates 
or mice. HIV RNA localization was anti-correlated to the distribution of all ARVs except MVC 
93 
 
and ATZ and was consistent with animal data. Human drug transporter concentration was in 
better agreement with mice (1 to 9-fold difference) versus primates (1 to 21-fold difference), 
with 4-fold lower P-gp expression in primates. We show that ARV distribution within biopsies is 
heterogeneous and may not co-localize with HIV target cells. This is consistent with animal data 
and may implicate ARV tissue exposure in the propagation of HIV GALT replication. Human 
drug transporter concentrations agreed with humanized mice better than primates, suggesting that 
the former may be a better animal model for developing novel ARV therapies targeted at GALT, 
particularly for P-gp substrates.  
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Introduction 
 
 Despite advancements in treatment and prevention strategies, HIV continues to present an 
enormous global health burden, and remains a top ten cause of death worldwide.151 The inability 
to cure this disease is a direct consequence of HIV persistence in cellular and tissue reservoirs 
despite treatment with combination antiretrovirals (ARVs).5,7,14 Although the latent cellular 
reservoir remains the primary obstacle to HIV eradication, ongoing replication in certain tissue 
sites, including gut-associated lymphoid tissue (GALT), may represent an additional barrier to 
cure.10–13 The consequences of HIV persistence in GALT (described in Chapter I) are distinct 
from other tissue reservoirs and make this site a priority for understanding the mechanisms 
underlying this persistence (e.g. reduced ARV exposure).  
The generation of PK/PD relationships at the site of action is critical to optimizing 
therapy for HIV eradication, and must be performed before testing interventions in late-phase 
development. Several studies have attempted to circumvent this process by simply intensifying 
existing ARV regimens to reduce the reservoir size, with limited success.54,55 Given that these 
studies have been unsuccessful to date, and the fact that viral rebound upon treatment cessation is 
observed in nearly all patients, it is reasonable to assume that novel therapies will need to be 
developed that target tissue reservoirs specifically. A novel small molecule that achieves 
increased exposure at the site of action and subsequently reduces or eliminates HIV replication in 
tissues would be an important step toward eradication. 
The development of any novel therapy will require initial characterization in pre-clinical 
models of HIV infection. In addition to traditional safety and efficacy measures, it is critical to 
define the exposure-response relationship in tissues to maximize the likelihood of clinical 
success. The mixed success of pre-exposure prophylaxis (PrEP) trials in the HIV prevention field 
95 
 
is due, in part, to the lack of pre-clinical PK/PD to inform Phase III trial design.51,152 Several 
variables required to define this relationship, such as ARV distribution within tissues and drug 
transporter expression and localization, were described in Chapters II and III of this dissertation, 
respectively. Significant differences were found between animal models (i.e. 1.7-log increase in 
TFV-CD3+ T-cell co-localization in NHPs vs mice, 2-fold decrease in MDR1 expression in BLT 
vs hu-HSC-Rag mice), but the utility of these data are limited without appropriate comparison to 
human tissues. 
The use of pre-clinical data to predict human PK/PD is complicated by a paucity of data 
directly comparing animals to humans, despite evidence that factors influencing drug disposition 
may be substantially altered between species. For example, drug metabolizing enzymes such as 
the CYP2C family can be as much as 12-fold higher in rats versus humans.102 Further, the gene 
and protein expression of drug transporters quantified in Chapter III does not agree with existing 
data from human subjects (e.g. lower gene and protein expression of ABCG2/BCRP and 
ABCC2/MRP2 in animals compared to humans100). In order to prevent inappropriate 
extrapolation of data from one species to another, formal interspecies comparisons must be 
performed.  
In this study, we characterize ARV distribution within several putative viral reservoirs 
from HIV positive subjects, and measure drug transporter expression and localization from these 
same sites. We compare these data to those generated using similar methods in humanized mice 
and non-human primates to determine which pre-clinical species best predicts results from 
humans. These data address whether or not current therapies achieve adequate exposure at the 
site of action, and identify specific variables to target or avoid to maximize efficacy. By directly 
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comparing animals to humans, we can also inform the development of inter-species scaling 
factors to streamline the development of targeted therapies for HIV eradication. 
Methods 
Trial Design 
 This was a single-center, open label, observational study of ARV localization within 
GALT (terminal ileum & rectum), vaginal, and cervical tissues (for future analysis) in the setting 
of undetectable plasma HIV. This study enrolled 5 of a planned 22 HIV positive women between 
18 and 65 years of age with intact gastrointestinal and genital tracts, who had an undetectable 
viral load within 3 months preceding the study. Participants were recruited from the infectious 
disease clinic at UNC Hospitals on the basis of receiving one of the study regimens as part of 
their ongoing HIV care. The primary objective of the study was to quantify the distribution of 
ARVs in the GALT of HIV positive women receiving one of four ARV regimens and identify 
tissue compartments in which ARV exposure is lacking or concentrated. 
 Participants were excluded if they had any clinically significant comorbidities or 
abnormal screening laboratory tests; untreated sexually transmitted infections (rectal or vaginal 
chlamydia or gonorrhea, syphilis, trichomonas); were pregnant or lactating; had an abnormal Pap 
smear result within the previous 36 months or previous hysterectomy or cervical resection; or 
tested positive for any drugs of abuse that would complicate sedation. Additional exclusion 
criteria included receiving CYP3A4 inducers or inhibitors (other than those contained in their 
HIV regimens) in the previous 6 months; receiving any investigational drug in the last 4 months; 
history of inflammatory bowel conditions (IBD, Crohn’s); or not using an approved method of 
contraception (systemic hormonal contraception, IUD, bilateral tubal ligation, vasectomized 
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male partner, condom plus spermicide, female-only sex partners, or 3 months of abstinence 
before enrollment). A complete list of inclusion and exclusion criteria is listed in Appendix 4.1.  
After participant education, informed consent, and screening for study eligibility, 
participants were assigned to the treatment arm associated with the HIV regimen they were 
receiving (Figure 4.1). Within 42 days of screening, participants were admitted to the UNC 
HealthCare Clinical Trials Research Center (CTRC) for a 36-hour inpatient pharmacokinetic 
visit (Figure 4.2). For the 7 days prior to admission, participants were asked to follow a strict 
low-fiber diet in preparation for a colonoscopy. Once admitted, participants were given only 
clear liquids until 4 hours prior to the colonoscopy. On day 1 of the visit (within 3-4 hours of 
admission), each participant provided 2 biopsies each from the cervix and vaginal wall and a 
paired blood sample. After genital tract biopsies were taken, participants were given an oral 
laxative (two 5mg bisacodyl tablets) followed by a colonic preparation with a PEG solution   
Figure 4.1: Treatment Arms Evaluated Subjects were analyzed by treatment arm according to 
their current cART regimen.   
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(Golytely).  The preparation was divided into 2 separate 2-hour blocks; the first beginning 18 
hours before the scheduled procedure, and the second half beginning 6 hours pre-procedure.  
Participants were NPO for the immediate pre-colonoscopy period. Before the procedure, a single 
paired blood sample was taken. During the procedure, 10 biopsies each were taken from the 
terminal ileum and rectum. After the colonoscopy procedure, subjects were monitored for 6 
hours and then discharged home, with follow-up visits within 14 days of discharge. 
Safety assessments were conducted on each day of the inpatient visit and during follow-
up. Adverse events were evaluated using a standard questionnaire, with grading according to the 
DAIDS adverse events grading table.153 Women were screened for pregnancy at each visit. This 
study was conducted using Good Clinical Practice procedures and was approved by the UNC 
Institutional Review Board. All participants provided written informed consent before study 
procedures were performed. 
Sample Collection and Analysis 
 Cervical and vaginal biopsies were collected using sterilized Tischler forceps (Cooper 
Surgical, Trumbull, CT). Ileac and rectal biopsies were collected during colonoscopy with Radial 
Jaw 4 large capacity biopsy forceps (Boston Scientific, Boston, MA). All tissues were 
immediately snap frozen on dry ice, then placed in aluminum foil pouches and stored at -80˚C 
until analysis. Whole blood was collected in 3mL EDTA tubes and centrifuged at 3000rpm for 
10 minutes at 4˚C. Plasma was aliquoted into a 2mL cryovial and stored at -80˚C until analysis.  
Figure 4.2: Study Design Schematic After screening, subjects underwent a 36 hour inpatient visit 
where tissues were collected (represented by black arrows on Day 1 and 2   
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LC-MS 
 Plasma and tissue samples were analyzed as described in Chapter III. Briefly, plasma 
samples were extracted by protein precipitation with methanol containing stable, isotopically-
labeled internal standards. Samples were vortexed and centrifuged, then the supernatant was 
diluted with water prior to LC-MS/MS analysis. Tissue samples were placed in a tube (Precellys 
2mL Hard Tissue Metal Beads Kit) containing 1mL of ice cold 70:30 acetonitrile-water, 
homogenized, then mixed with methanol containing stable, isotopically labeled internal 
standards. Following centrifugation, the supernatant was evaporated to dryness and reconstituted 
with water (for TFV/FTC analysis) or 25:75 methanol:water (for ATZ/EFV/MVC/RAL 
analysis). A Shimadzu high-performance liquid chromatography system with a Waters Atlantis 
T3 (50mm x 2mm, 5µm particle size) HPLC column was used for separation, and an AB SCIEX 
API 5000 mass spectrometer (AB SCIEX, Foster City, CA, USA) equipped with a turbo spray 
interface was used as the detector. The lower limit of quantitation was 1ng/mL for plasma, and 
0.002 ng/mL (FTC and MVC), 0.005ng/mL (ATZ, EFV, and RAL), and 0.01ng/mL (TFV) for 
tissue samples. 
Tissue Imaging 
 Tissue biopsies underwent IR-MALDESI (for detailed methods, see Chapter II), with one 
additional step during sample processing. Due to the small size of the tissue biopsies, samples 
were embedded in groups of 4 tissues in a 50:50 gelatin carboxymethylcellulose gel block, which 
was snap frozen and stored at -80°C (in an identical fashion to the mouse tissues described in 
Chapter II). Briefly, tissues were sliced frozen at 10µm thickness using a cryostat (Leica 
Biosystems, Wetzlar, Germany) and thaw mounted onto glass microscope slides. Thaw mounted 
tissues were placed into the source chamber and maintained at -10˚C while an ice layer was 
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deposited. Tissues were ablated with two pulses of a mid-IR laser (IR-Opolette 2371, Opotek, 
Carlsbad, CA) with a 100um spot-to-spot distance, ionized, and analyzed using a Thermo Fisher 
Scientific Q Exactive mass spectrometer (Bremen, Germany). Because the detection of certain 
analytes (e.g. TFV, EFV) was found to be increased by probing for negative ions, polarity-
switching was used during these experiments using 5mM ammonium acetate in 50:50 methanol 
water as the electrospray solvent. Raw data were converted to the imZML format for analysis 
with MSiReader, interrogating both positive and negative ions.  
 IHC, IF, and ISH were performed as described in Chapter II using identical reagents and 
antibodies. Image co-localization proceeded using MatLab vR2015 (Mathworks, Natick, MA). 
Pixel intensity matrices for each ARV of interest, plus cholesterol and heme, were imported into 
MatLab along with downsampled IHC/IF/ISH images. Cholesterol and heme masks were applied 
as described in Chapter II, then images were co-registered. Co-localization of each ARV and 
biologic variable of interest (CD3, HIV RNA, MDR1, etc.) was performed using Pearson 
correlation to quantify distributional overlap.  
Drug Transporter Analysis 
With the remaining ileac and rectal tissue, drug transporter gene and protein expression 
were measured by qPCR, WB, and LC-MS proteomics as described in Chapter III. Drug 
transporters evaluated were identical to those described in Chapter III (Table 3.1). For qPCR 
analysis, 200ng of extracted RNA were reverse transcribed to cDNA, then pre-amplified and 
diluted to ensure adequate volume for qPCR. 40 PCR cycles were performed on a QuantStudio 6 
(Life Technologies) using human-specific gene expression assays (Appendix 3.1). Raw CT 
values were calculated based on a threshold value of 0.2, and expression for all transporters was 
normalized to the housekeeping gene GAPDH using the 2-ΔCT method.139  
101 
 
Protein extraction for Western blot and QTAP analysis occurred similarly to the methods 
described in detail in Chapter III. Briefly, whole tissue biopsies were homogenized in 1.3mL 
hypotonic buffer containing 150uL of Complete Protease Inhibitor Solution (Sigma-Aldrich, St. 
Louis, MO), and underwent differential centrifugation to isolate protein. Protein concentrations 
were quantified using the BCA protein assay (Pierce, Rockford, IL). For WB, up to 10µg of 
protein was loaded onto a 4-12% electrophoresis gel (NuPage) and run for 110 minutes at 180V. 
Transfer onto a PVDF membrane (NuPage) occurred over 90 minutes at 30V. After blocking in 
5% milk, membranes were incubated in primary antibody for 1-3 hours, then rinsed and 
incubated in secondary antibody for 1-2 hours. Development occurred using Clarity ECL 
reagents (Bio-Rad, Hercules, CA) with a Chemi-Doc XRS+ Imager (Bio-Rad), and densitometry 
relative to GAPDH was calculated using ImageLab 5.2.1 (Bio-Rad). A combination of 15µg 
each of mouse brain extract, liver extract, and T98G cell lysate was used as the positive control 
sample.  
 For proteomics, protein extracts were reconstituted in 50mM ammonium bicarbonate 
buffer with 40mM DTT, 10% sodium deoxycholate (Sigma-Aldrich), and 10µL β-casein 
(0.1µg/µL). Samples were reduced for 40min at 60°C, then incubated for ~30min in the dark 
with 135mM iodoacetamide (Sigma-Aldrich). 1 pmol stable isotope labeled (SIL) peptide 
standards (Theracode JPT Inc., Acton, MA) for each transporter of interest (Table 3.161,154,155) 
were added to each sample along with 25µL Trypsin (0.1µg/µL) (Promega, Madison, WI). 
Digestion occurred for at least 18 hours at 37°C and was stopped with 10% trifluoroacetic acid 
(Sigma-Aldrich). Samples underwent solid phase extraction using Strata-X 33µm polymeric 
reversed phase extraction cartridges (Phenomonex, Torrance, CA). Analysis was performed 
using a nanoACQUITY system (Waters, Milford, MA) coupled to a QTRAP 5500 mass 
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spectrometer (AB SCIEX, Framingham, MA) equipped with Nanospray III source. An injection 
amount of ~0.2-1µg of total membrane microsomal protein was loaded onto a C18 trap column 
(180µm x 20mm, 5µm particle size, Waters). Analyst 1.5 (AB SCIEX) was used for MS control, 
and MRM analysis was performed using MultiQuant 2.0 (AB SCIEX). Peaks were smoothed 
prior to integration and area ratios of unlabeled/SIL peptides were determined using the sum of 
MRMs monitored. The lower limit of detection for the peptides was ~0.2pmol/mg protein. 
Statistical Analysis 
Descriptive statistics (median, min-max) were generated for the concentration of each ARV 
in each tissue site as determined by LC-MS and MSI. Tissue concentrations were divided by the 
plasma concentration of each ARV, corresponding to the time when the tissue sample was taken 
to correct for variability in plasma exposure between individuals (i.e. tissue/plasma ratio,TPR). 
To perform inter-compartmental comparisons, plasma-corrected ARV concentrations in tissue 
were compared between rectal and ileal tissue using an exact Wilcoxon signed-rank test.  To 
compare ARV localization and drug transporter gene and protein expression between species, the 
human data generated here was plotted against the pooled data from mice and non-human 
primates (as there were no significant differences observed between infected and uninfected 
animals). One-way Kruskal-Wallis ANOVA on ranks was used for inter-species comparisons; 
p<0.05 was considered significant. 
Results 
Subject Demographics and Adverse Events 
 As of February 10th, 2017 a total of 5 women have completed the study, with summary 
demographics shown in Table 4.1. Participants had a mean age of 52 and a mean BMI of 37.2, 
and 4 of 5 were African-American. Menopause status was evenly distributed (2 pre-, 3 post). All 
5 participants had been HIV-positive for >5 years (mean 18 years) and had been on their current 
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regimen for a mean of 8 years. Participants had well-controlled HIV infection as evidenced by 
undetectable plasma viremia and high CD4 counts (mean 786 cells/mm3). A single adverse event 
(Grade I headache) was observed. 
Table 4.1: Subject Demographics 
 EFV 
(n=1) 
RAL 
(n=1) 
ATZ 
(n=2) 
MVC 
(n=1) 
Age (years) 55 49 50 (47, 53) 56 
Race     
     Caucasian   1  
     African- 
     American 
1 1 1 1 
Menopause 
Status 
    
     Pre 1  1  
     Post  1 1 1 
BMI (kg/m2) 39.1 44.8 37.7 (35.6, 39.8) 26.7 
CD4 
(cells/mm3) 
782 753 862 (651, 1074) 672 
Time on 
Current 
Regimen 
(years) 
7 5 9.5 (8, 11) 8 
Time Since 
Diagnosis 
(years) 
26 6 20.5 (17, 24) 18 
*data shown are median and range 
 
ARV Localization in Gastrointestinal Tissues 
 Table 4.2 shows the results of LC-MS analysis on these tissues. Pooled TPR values for 
all ARVs in the ileum and rectum are shown in Figure 4.3, where a significant 3-fold increase in  
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Table 4.2: Tissue Penetration Ratios 
ARV ILEUM RECTUM 
TFV (n=5) 131 
(78, 297) 
46 
(14, 52) 
FTC (n=5) 8 
(6,12) 
4 
(1, 8) 
RAL (n=1) 189 242 
EFV (n=1) 5 6 
MVC (n=1) 74 31 
ATZ (n=1) 55 43 
 
median ARV penetration into the ileum is observed. To show that this difference is not driven by 
a single ARV, individual values from both compartments are shown in Figure 4.3b. With the 
exception of RAL, all ARVs had higher penetration into the ileum versus the rectum, with TFV 
showing the greatest difference (3-fold higher penetration into the ileum).  
Figure 4.3: ARV Penetration into Human Gut Biopsies Pooled ARV penetration ratios into the 
ileum and rectum (a). Individual plots for each ARV between these two compartments (b).  
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Representative images of ARV localization as determined by MSI are shown in Figure 
4.4. Despite detectable concentrations of TFV and FTC and in the plasma and tissue by LC-MS, 
these two drugs were only sporadically detected in these samples by MSI, even before heme 
correction (Figure 
4.4b&c). In contrast, 
the remaining ARV 
in each regimen 
(EFV, RAL, ATZ, 
MVC) were 
detected in every 
ileum and rectum 
sample and showed 
broad distribution 
throughout the 
mucosa and 
submucosa of 
biopsy sample 
(Figure 4.4d). Heme 
was extensively 
distributed in many 
tissue slices (Figure 
4.4e), resulting in 
large decreases in 
Figure 4.4: ARV Localization in Human Gut Biopsies Representative 
images of ARV localization in a rectal biopsy from an HIV+ subject. a-d 
show raw MSI images. Heme distribution (e) was corrected for in f-h. ARV 
image overlay with IF stain (i) is shown in j-l, with CD3 in green and the 
ARV in red.  
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ARV response after heme correction (Figure 4.4f-h). As a result, co-localization with CD3+ T 
cells by IF (Figure 4.4j-l) was low. T-cell co-localization was 2-5 fold higher in the rectum 
versus the ileum, with EFV and MVC showing the best co-localization overall.  
Figure 4.5 compares ARV-T cell co-localization from human biopsies to data generated 
in similar tissues from humanized mice and NHPs (Chapter II). In the ileum (Figure 4.5a), 
human data was in better 
agreement with co-
localization values generated 
in humanized mice versus 
NHPs for every ARV except 
MVC and EFV. MVC 
correlations in hu-HSC-Rag 
mice were 5-fold higher than 
humans, though this was not 
significantly different. 
Median EFV co-localization 
was higher in NHPs than any 
other species, but ranged 
from -0.04 to 0.28. In the 
rectum (Figure 4.5b), NHP 
Figure 4.5: Interspecies comparison of ARV-CD3+ T cell 
Correlation Median (dot) and range (whiskers) correlation 
coefficients for each animal model and humans are shown for 
the ileum (a) and rectum (b). Some data points are offset to 
ease interpretation.  
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MVC and EFV co-localization was much lower, with EFV and RAL trending toward anti-
correlation with CD3+ T cells. In 
humans, MVC and EFV 
correlation was 4 and 3-fold 
higher than mice or NHPs, 
respectively, though ultimately 
no inter-species differences were 
statistically significant.  
HIV RNA Localization and 
Co-registration with ARVs 
 HIV RNA was detected 
in all ileum samples, but was 
only detected in the rectum of 
two subjects. A representative 
image of HIV RNA and ARV 
co-localization is shown in 
Figure 4.6. Similar to the NHP 
and mice tissues, RNA was 
detected in discreet tissue areas 
that corresponded to CD3+ T cell 
localization. When overlayed with 
heme-corrected ARV images, it was 
found that HIV RNA was localized to 
Figure 4.6: ARV-HIV RNA Co-localization in Human 
Gut Biopsies Representative images from the ileum of a 
single HIV+ subject. Raw IR-MALDESI images are 
shown in a-c. IF image showing CD3+ T cell distribution 
(green; d) were overlayed with ARV images in e & f. 
Raw ISH image is shown in g, with positive staining in 
red. Co-localization of ARV images (red) and HIV RNA 
(cyan) are shown in h & i, with corresponding correlation 
coefficients. 
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areas of low ARV signal 
(Figure 4.6h & j), and 
corresponding correlation 
coefficients indicated anti-
correlation of these variables. 
This was true for every ARV 
with the exception of MVC 
and ATZ, which showed 
positive correlation with HIV 
RNA (r=0.07 and 0.05, 
respectively), though these 
values are very low.  
 Figure 4.7 compares 
ARV-HIV RNA co-
localization values in humans 
to those generated in NHPs 
and mice (reported in Chapter 
II). Because 30% of mouse 
samples did not have detectable 
HIV RNA, the two humanized mouse models were combined for analysis. There were no 
statistically significant differences between species in either the ileum or the rectum.  Median 
coefficients for all models trended toward anti-correlation, though maximum values were as high 
as 0.26. ATZ tended to co-localize best with HIV RNA in animals, and this was consistent with 
Figure 4.7: Interspecies comparison of ARV-HIV RNA 
Correlation Median (dot) and range (whiskers) correlation 
coefficients for each animal model and humans are shown for 
the ileum (a) and rectum (b). Some data points are offset to 
ease interpretation.  
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human data, where ATZ in the rectum also showed a positive correlation. In contrast, TFV 
showed the strongest anti-correlation with HIV RNA in mice, NHPs, and humans.  
ARV Co-localization with Drug Transporters  
 Figure 4.8 shows representative images of ARV co-localization with several drug efflux 
transporters. Similar to the trends observed in the animal models, MDR1 showed the largest 
disparity in co-localization between ARVs, with r values ranging from -0.05 with TFV to 0.21 
with MVC (Appendix 4.2). Again, MRP2 was not readily detected in these tissues despite 
previous studies showing its expression in the gut.99,100 BCRP and MRP1 staining were more 
Figure 4.8: Efflux Transporter Localization and Effect on ARV Distribution Representative 
images from a single ileum sample. Raw MSI (a,g,m,s) and heme-corrected (b,h,n,t) images are 
shown from a single subject. Overlays for MDR1, BCRP, MRP2, and MRP1 are shown with ARV in 
red and transporter in green. 
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apparent, but not 
differential between 
ARVs, with similar 
co-localization values 
for each of the drugs 
evaluated.  
 A quantitative 
comparison of 
transporter co-
localization between 
tissues is shown in 
Figure 4.9. Unlike results in animals (Chapter II), ARV-transporter co-localization tended to be 
higher in the rectum than the ileum when data were pooled. This was especially true for BCRP 
and MRP2, which showed 5-fold and 17-fold higher co-localization in the rectum versus ileum, 
respectively (p=0.02). While MDR1 and MRP1 showed similar trends, these differences were 
not statistically significant.  
 
Interspecies Comparison: Transporter Gene Expression 
 Drug transporter gene expression from human samples is compared to pooled animal data 
in Figure 4.10, which shows variable agreement between species. Among the efflux transporters, 
human ABCB1 expression (Figure 4.10a) was in better agreement with NHP data (8-fold 
difference) than humanized mouse data (2.6-log increase in humans; p<0.001) in both the ileum 
Figure 4.9: Efflux Transporter Co-localization Across Compartments 
Correlation coefficients for pooled ARV-transporters in the ileum (blue) and 
rectum (red). Solid lines represent medians, box ends represent IQR, and 
whiskers range. * denotes p<0.05  
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and the rectum. 
Conversely, mouse 
ABCG2 expression 
was closer to 
observed human data 
than NHP expression, 
which was 4-fold 
lower than humans in 
the ileum (Figure 
4.10d; p=0.01). 
ABCC2, ABCC1, and 
ABCC4 expression 
were similar between 
humans and animals. 
Human uptake 
transporter expression 
was in better 
agreement with 
mouse data, showing 
multi-log increases in 
the expression of 
SLC22A3 over NHPs in the ileum and rectum (Figures 4.10f and 4.10h; p<0.001). 
  
Figure 4.10: Interspecies comparison of Transporter Gene 
Expression Median (box) and range (whiskers) of gene expression in 
humans (light gray), mice (white), and NHPs (dark gray) in the ileum 
and rectum.  
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Interspecies 
Comparison: 
Transporter 
Protein 
Expression 
 Figure 4.11 
shows an inter-
species comparison 
of efflux 
transporter protein 
expression as 
measured by 
Western blot. 
Interestingly, 
protein expression of MDR1 (Figure 4.11a) showed the opposite trend of ABCB1 gene 
expression results, with human data in better agreement with humanized mice data (2-10 fold 
difference) over NHPs (6-19 fold difference). The protein expression of BCRP (Figure 4.11C) 
was not significantly different between species in the ileum, and was undetectable in all species 
in the rectum. MRP2 (Figure 4.11B) MRP1 (Figure 4.11D) were only detected by WB in NHPs 
and humanized mice, respectively, despite detection in human and mouse control tissues (data 
not shown).  
Figure 4.11: Interspecies comparison of Transporter Protein Expression 
by Western Blot Median (box) and range (whiskers) of protein expression in 
humans (light gray), mice (white), and NHPs (dark gray) in the ileum and 
rectum.  
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QTAP results 
between 
species are 
shown in 
Figure 4.12. At 
the protein 
level, 
transporter 
concentrations 
were generally 
consistent 
between 
species, with 
several 
important 
exceptions. 
Human MDR1 
concentrations 
were similar to 
humanized 
mouse 
concentrations in 
both the ileum and rectum, and were 5-fold higher than NHP MDR1, though this was not 
Figure 4.12: Interspecies comparison of Transporter Protein Expression 
by Proteomics Median (box) and range (whiskers) of gene expression in 
humans (light gray), mice (white), and NHPs (dark gray) in the ileum and 
rectum.  
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statistically significant. As previously reported in Chapter III, MRP2 concentrations were 1.5-
logs higher in the NHP versus humanized mouse ileum (Figure 4.12c). Median human MRP2 
concentrations fell in between mice and NHPs, and was not significantly different from either 
species. Among the uptake transporters, only OATP2A1 showed a statistically significant 
difference between species, with NHP concentrations 1-log higher than humans in the ileum and 
rectum (Figure 4.12f).  
Discussion 
 The preliminary analyses conducted here provide new insight into ARV distribution in 
the human GI tract, and reveal interspecies differences that may be important in the development 
of novel ARVs targeted to these tissues. A particular strength of this study was the use of MSI 
technology to visualize ARV tissue distribution, which provides detailed data not possible by 
traditional LC-MS. TPR values observed here were consistent with previous studies of these 
drugs in GI tissues.69,156,157 Importantly, plasma concentrations were also consistent with 
previously reported steady-state values69,156,157, demonstrating that the use of bowel preparation 
prior to colonoscopy did not significantly alter drug absorption or local PK in gut tissues. The 
use of plasma-corrected tissue concentrations to understand tissue distribution and has been the 
gold-standard for ARV tissue pharmacology to this point, but we show here how limited these 
data can be.  
 Initial evaluations of these biopsy samples appeared to show extensive ARV distribution 
with no evidence of localization (Figure 4.4d). After correcting for the large amount of heme 
present in each sample, however, ARV detection sharply decreased and T-cell co-localization 
values declined as a result. The extensive heme present in these biopsy samples (which was not 
present in whole NHP tissues; Chapter II) is likely a function of the biopsy procedure and the 
large amount of vasculature present in the gut mucosa, both of which are unavoidable when 
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collecting human tissues. However, the sharp contrast in results before and after heme correction 
not only shows the importance of this step when analyzing biopsy samples by IR-MALDESI, but 
also showcases the advantage of this technology over LC-MS. ARV concentrations generated in 
tissue homogenates are unable to distinguish between drug within cells/extracellular space and 
drug in blood, whether contained in the microvasculature or from contamination secondary to 
tissue procurement. This is an especially important distinction in the setting of HIV eradication, 
where drug localization within tissue reservoirs may have a direct effect on residual HIV 
replication.  
 The importance of drug localization is highlighted by the low correlation between the 
ARVs investigated here and CD3+ T cell distribution. Similar to the results discussed in Chapter 
II, inadequate exposure in this cell population may lead to reservoir propagation. This hypothesis 
was directly tested in the ISH experiments, which show HIV RNA expression occurring 
preferentially in areas of low or no ARV exposure, with subsequently low co-localization 
between these two measures (Figure 4.6). Not only does this support data generated previously in 
human gut and lymph nodes29,56, but shows that novel ARVs will need to be developed in order 
to totally eradicate residual replication at this site. An important distinction from the animal 
experiments is that these human subjects had been on their current regimen for at least 5 years 
with undetectable plasma viral loads, yet HIV RNA was still detected in many of their tissues. 
Though much of this HIV RNA is defective and does not represent replication-competent 
virus105, this analysis shows that current therapies are insufficient to clear infected cells from this 
site.  
Evaluation of the effect of drug transporters on the disposition of these drugs did not 
reveal any significant relationships. Though transporters (particularly MDR1 and BCRP) were 
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readily detected on the epithelial surface of most samples, but we did not observe any examples 
of ARV sequestration and co-localization with a specific transporter. This is in direct contrast to 
results from NHPs (Chapter II), where it appeared that the MDR1 substrate RAL was 
sequestered to the mucosa with relatively high co-localization with this transporter. Similarly, the 
apparent differential influence of MDR1 on TFV and FTC distribution was not observed here. 
This may be partially explained by the small sample size in this study, and it is possible that we 
would have observed similar results with samples from a larger population. It is unlikely that 
these conflicting results represent a true difference in transporter effects, as these human and 
macaque transporters have high sequence homology (>80%), though it may be the case that these 
drugs have lower affinity for human transporters versus NHPs.  
 This study was also the first to make direct, prospective interspecies comparisons 
between humans, NHPs, and humanized mice using similar methodology. ARV co-localization 
with CD3+ T cells in humans was not significantly different from any pre-clinical model, with 
low correlation coefficients across the board. Consistent with these results were the ISH data, 
which showed detectable HIV RNA in every species, which was not co-localized with any ARV. 
These results are consistent with the fact that that HIV latency137 and persistent replication on 
cART138 have both been observed in humanized mice and NHPs, and suggest that lack of ARV 
localization in GALT is consistent across species. EFV and MVC showed the largest difference, 
particularly in NHPs versus humans or humanized mice, and it may be that these drugs achieve 
better exposure in NHPs, though the observed differences were not statistically significant.  
 As in Chapter III, we observed little agreement between methodologies to evaluate drug 
transporter expression and localization, with interspecies comparisons of gene and protein 
expression giving variable and inconsistent results. Results were especially disparate for 
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ABCB1/MDR1 and SLCO2A1/OATP2A1, for which gene expression suggested that NHPs more 
closely represented human transporter expression, and QTAP results suggesting the opposite. As 
discussed in Chapter III, the downstream nature of QTAP over qPCR and the fact that QTAP 
more closely mimics IHC results suggest that QTAP is a more appropriate measure of 
expression. This is supported by the fact that TPR values for MDR1 substrates (TFV, RAL) 
humans were lower than what was observed in NHPs, consistent with more efflux by MDR1. 
Given that many ARVs are MDR1 substrates, these results have important implications for the 
development of novel ARVs. For example, results of pre-clinical studies of a novel MDR1 
substrate ARV may depend on the species utilized, as studies performed in NHPs may show 
higher exposure in GALT than what would be achieved in humans, as was observed here. 
 The close agreement between humans and humanized mice for co-localization measures 
(with CD3 T cells, transporters, and HIV RNA) and drug transporter protein expression suggest 
that extrapolation of results generated using this pre-clinical model to predict human data is 
appropriate. While much of the NHP data was not significantly different from either humans or 
humanized mice, the large increases in CD3+ T cell co-localization with TFV and MVC in 
NHPs, and the multi-log differences in protein expression of MDR1 and OATP2A1, show that 
results generated in this model may not accurately predict human data. However, the presence of 
detectable HIV RNA in areas of low ARV exposure in NHPs provides strong support for 
observed results in humanized mice and humans. Additional advantages to the humanized mouse 
model are the lower cost, higher availability, and use of non-chimeric HIV strains for infection 
(though infection status did not appear to significantly affect ARV tissue distribution; see 
Chapter II). One caveat to these advantages is the need to quantify the effect of both human and 
118 
 
mouse drug transporters or drug metabolizing enzymes when considering local ARV PK, as 
discussed in Chapter III.  
 The interpretation of these results is limited by the small sample size of this study, which 
resulted in an n=1 for all ARVs except TFV and FTC. Since the inception of these experiments, 
many novel ARVs have been introduced to market and have quickly been adopted by 
practitioners, which greatly reduced the number of eligible patients for this study. Although we 
were able to make direct comparisons between humans and animals by studying identical ARV 
regimens, it may be that newer small molecule ARVs behave differently in GALT, especially 
given that at least one novel formulation (tenofovir alafenamide fumurate (TAF)) was developed 
to exploit PK differences.158 Additionally, our view of GALT in these humans was limited to the 
small biopsy samples we collected here. IF analysis showed that mucosal tissue was captured in 
each biopsy sample, but this is a very limited viewpoint compared to complete tissue cross-
sections that were available with humanized mice and NHPs. These biopsies may not be 
representative of the entire ileum or rectum, or even the entire mucosa, thus results should be 
interpreted with appropriate caution.  
 Despite these limitations, these data are the first to formally compare pre-clinical and 
clinical data of this kind within a single set of experiments. This type of study is critical for 
reducing inter-lab variability that has made inter-species comparisons difficult in the past. We 
show that, as in our pre-clinical studies, HIV RNA continues to be expressed in areas of low 
ARV exposure in the ileum and rectum. We also show that human co-localization and 
transporter expression data best agrees with those generated from humanized mice versus NHPs. 
By placing the human data in the context of pre-clinical models, we can inform the development 
of novel ARVs targeted at GALT. 
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Chapter V: Impact and Future Directions 
 
Challenges to Characterizing Antiretroviral Exposure in GALT 
 The data generated in this dissertation are the first of their kind, and address many of the 
current limitations of using clinical pharmacology to target tissue HIV reservoirs. As discussed 
in Chapter I, HIV persistence in GALT has substantial clinical consequences and presents unique 
challenges to eliminating replication.106 The inability to determine whether or not suboptimal 
ARV penetration results in ongoing viral replication using traditional LC-MS, the lack of 
established best practices for evaluating the factors influencing ARV tissue disposition, and the 
scarcity of interspecies comparisons of these factors hinder the development of targeted therapies 
for HIV eradication.  
 In Chapter II, we provide confirmation of our earlier work showing that distribution 
throughout GI tissues is not homogenous for many ARVs, and show that HIV RNA expression 
occurs preferentially in areas of lower ARV exposure, providing strong support for the 
hypothesis that optimizing ARV exposure to these sites may reduce or eliminate ongoing 
replication. We also show that distribution may be influenced by drug transporter localization, 
and that this effect can be differential between the ileum and rectum. Importantly, these data 
would not have been possible using traditional LC-MS techniques, suggesting that MSI-based 
technologies should be further utilized for evaluation of small molecule tissue disposition. This is 
especially true for tissues with a high amount of blood contamination, as our imaging results in 
mice show that correction for this variable greatly reduces ARV signal from tissues. When 
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leveraged with other imaging modalities (e.g. IHC, ISH, etc.), MSI can be a powerful tool to 
generate PK/PD relationships in specific tissue sites. These data will not only clarify the 
mechanisms behind HIV persistence in GALT, but will inform the design of novel therapies with 
increased GALT exposure. 
 The primary limitation of this aim is the lack of cellular resolution in tissues. The 100 
micron resolution of the IR-MALDESI images necessitated the down-sampling of high-
resolution IHC and ISH images to allow for co-localization. Because of this, we are unable to 
determine ARV concentrations within individual cells, or between cell populations. General co-
localization with CD3+ T cells provides a crude estimate of exposure at the site of action, but 
limits the ability to generate site-specific target concentrations for efficacy. Additionally, the use 
of HIV RNA as a PD endpoint is an overestimation of true replication, as it has been shown that 
much of this RNA is defective and unable to produce viral proteins.105 Thus, the gene expression 
endpoint provides a “worst-case scenario” for ongoing replication and should be interpreted with 
appropriate caution. Finally, we observe ARV distribution in a single slice from a single point in 
time, and did not collect tissues across a dosing interval. It is possible that, although the animals 
were dosed to steady-state, ARV localization varies with plasma concentrations, or that 
localization is inconsistent even in small portions (microns-millimeters) of the GI tract. Future 
evaluations of ARV tissue distribution using IR-MALDESI are warranted, but should include 
multiple slices from a single tissue site as well as tissues from multiple points along a dosing 
interval. 
 Chapter III summarizes a comprehensive comparison of methods for evaluating drug 
transporter expression, and defines for the first time expression differences between preclinical 
models of HIV infection. The relevance of drug transporters for ARV disposition in GALT is 
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supported by the findings in Chapter II, as well as previous work by us and others implicating 
transporters as significant variables for ARV tissue penetration.52,98,100 The lack of agreement 
between gene and protein expression observed in all animal models is compelling, as there is 
currently no standard for reporting this type of data. Although we were unable to conclusively 
show the superiority of one method over another in predictive tissue ARV penetration, the 
quantitative downstream protein data generated by QTAP may provide the best measures moving 
forward. Observed expression differences between species for transporters like P-gp or BCRP 
will be important in selecting appropriate animal models for the development of novel ARVs 
which are utilized by these proteins. The outcomes of this aim demonstrate that careful 
consideration should be given to the method and model used to evaluate transporter expression, 
and provide important interspecies comparisons to inform drug development. 
 Quantifying transporter gene and protein expression and localization using four methods 
was challenging in a single piece of tissue. This was particularly true in mice, where in many 
cases <10mg of tissue material was available for analysis, resulting in limited protein available 
for WB and QTAP analysis. It may be the case that increasing protein would have resulted in 
fewer BLQ/BLD values (particularly among WB results) and provided stronger agreement 
between these techniques, which has previously been reported.146 An additional obstacle in this 
aim was the inability of any method to reliably predict tissue penetration makes it difficult to 
advise the field on best practices for transporter evaluations.  The extensive staining for 
transporters like P-gp and BCRP precluded traditional IHC quantitation, forcing us to evaluate 
positive staining as a function of tissue area. This may explain why IHC results were the least 
predictive measure in the regression model despite being the most downstream and relevant 
transporter measurement. In the future, emphasis should be placed on maximizing protein yield 
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for WB and QTAP, and optimizing IHC staining to allow for traditional quantitation methods. 
Moreover, we show that the contribution of human transporter isotopes to the total transporter 
population in humanized mice must be considered, as interspecies comparisons of ABCC4 were 
significantly altered after accounting for human genes.  
 In addition to drug transporters, there are many other factors that influence small 
molecule penetration into tissues.51 Characteristics such as protein binding, drug-metabolizing 
enzymes, blood perfusion, and physicochemical properties (e.g. molecular size, lipophilicity, 
ionization state) were not addressed in this study but likely play a role in ARV distribution 
within the gut. However, the ARVs chosen for evaluation span a large range of values for many 
of these variables and can provide a qualitative starting point for future analysis. For example, 
differences in EFV and RAL localization in NHP tissues (illustrated in Figure 2.5 and 2.9) may 
be explained by the lipophilic nature of EFV, which could allow it to penetrate further into 
tissues versus RAL. Quantitative measures of these variables and incorporation into our 
regression analysis may provide improved predictive capacity. Previous attempts to incorporate 
these features into a global QSAR model to predict female genital tract penetration were only 
modestly successful; however, the use of a stepwise linear regression model may represent a 
more focused approach to identifying additional variables for GALT exposure. 
  The clinical study performed in Chapter IV provided insight into how well data from 
preclinical models translates to humans. The ARV distribution and HIV RNA results observed 
supported observations from Chapter II and show that humanized mice data more closely 
mimicked human results for most ARVs. The lack of agreement between transporter expression 
measures confirms the importance of choosing the appropriate method; however, we show again 
that humanized mice transporter protein expression was more similar to that in humans. Given 
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that the data shown in Chapters II and III indicate that some transporters (e.g. P-gp, BCRP) play 
a larger role in ARV disposition than others (e.g. MRP1, OCT3), the 4-fold differences in MDR1 
protein expression between mice/human and NHPs are particularly important. Understanding the 
relationship between animal and human transporter expression and ARV distribution patterns 
will streamline the developed of targeted ARVs and prevent the inappropriate extrapolation of 
data from one species to another.  
 We were severely limited in our ability to recruit eligible subjects for this study, 
primarily because the ARV regimens we used in the animal models were rapidly replaced with 
newer regimens in clinical practice over the course of the study. Although we were able to 
generate data for each of the ARVs investigated, the small sample size of five subjects (n=1 for 
most ARVs) precluded performing any robust statistical analysis or reliable interspecies scaling 
for variables like mucosal accumulation or T-cell co-localization. A related limitation is the 
potential lack of relevance for clinical practice, as most treatment naïve HIV patients are being 
started on newer regimens. Though we cannot necessarily extrapolate the distribution of these 
drugs to newer agents from the same class (e.g. RAL to DTG), it is not unreasonable to assume 
that the species differences observed here, particularly for drug transporter expression, would 
hold true for similar drugs. Expanding the inclusion criteria of the study to allow for newer 
regimens would allow us to test these assumptions directly, and provide additional clinical 
relevance.  
 
Opportunities for Targeted Therapies 
 The development of novel therapies that achieve optimal GALT exposure will require 
full characterization of ARV exposure at this site. Though the work in this dissertation provides 
an experimental foundation for this work, there are many opportunities to hone our 
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understanding of the PK/PD relationship in this tissue. As MSI technology improves, increased 
spatial resolution will become available and allow for ARV quantitation at a cellular level. 
Single-cell data can supplement the work performed here to understand the relationship between 
ARV exposure in the intracellular versus extracellular environment, and whether or not there are 
certain cell populations that have reduced exposure. Additionally, more rigorous analyses should 
be performed on multiple tissue slices from a single anatomic site in order to understand how 
ARV exposure in GALT changes along the length of the ileum or rectum. These evaluations 
should also include tissues taken at multiple times along the dosing interval to determine what, if 
any, changes occur secondary to plasma exposure at steady-state.  
Importantly, alternative PD surrogates and cell types should be explored in addition to 
HIV RNA expression. In particular, a marker of HIV replication that is able to be detected by IR-
MALDESI (thus overcoming the limitations of RNAscope) would be enormously helpful when 
co-localizing ARV-virus distribution. Proteins produced during the HIV life cycle (e.g. Nef, 
Gag, Env) represent a promising set of potential PD endpoints, as they are more likely to 
represent true HIV replication over RNA. Unfortunately, the size of even the smallest of these 
proteins is outside of our current analysis window (200-800m/z) and we would thus be unable to 
detect whole protein by IR-MALDESI. However, peptide fragments from these proteins can be 
found on the surface of antigen-presenting cells as a result of lysosomal degradation.159,160 If a 
small, conserved peptide sequence that can be adequately ionized and analyzed by IR-MALDESI 
is identified, our estimate of viral localization can be refined. As a candidate peptide sequence 
that meets these criteria has yet to be identified, alternative approaches to measuring downstream 
viral expression can be useful. The viral capsid protein p24 is often utilized as a surrogate for 
HIV protein expression, and IHC protocols staining for this marker have already been optimized. 
125 
 
Not only would p24 staining provide a more relevant marker of infection, we could also compare 
the distribution this antigen to RNA as an additional validation step. Additionally, understanding 
ARV distribution into more specific T cell subsets can also help narrow down targets for 
optimized exposure. A comprehensive assessment of ARV disposition in GALT will help to 
clarify the mechanisms of persistence and define targets for optimized therapy.  
Finally, a statistically robust method to isolate ARV signal from cells and tissues should 
be developed and implemented. As discussed in Chapter II, subtracting ARV signal on the basis 
of heme distribution alone likely underestimates actual ARV exposure in tissues. Further, though 
cholesterol is a useful biomarker to isolate “on-tissue” ARV response, cholesterol contained 
within the blood plasma (though small in comparison to the amount in tissues) may confound 
results. A method that takes into account the relative contribution of each of these biomarkers to 
refine correlation between variables would be useful. Specifically, applying a statistical method 
that can interpolate tissue-specific signal based on heme and/or cholesterol response within a 
single voxel will reduce the over-correction secondary to our current methods.  
Perhaps the most straightforward approach to this interpolation is to estimate the amount 
of drug present within each heme-containing voxel based on the known plasma concentration of 
each drug. For example, in an animal with a MVC plasma concentration of 50ng/mL and an 
estimated blood volume of 10µL/voxel, we can estimate that in voxels containing both heme and 
MVC signal, approximately 50pg of MVC is contained in blood. This value can then be 
subtracted from the total amount in the voxel to provide a more reasonable concentration 
estimate. The limitations of this approach include the fact that it is susceptible to error 
propagation from upstream measurements of plasma concentration as well as error in the 
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estimates of blood volume in a given voxel. This error propagation can be accounted for using 
bootstrapping techniques, but the limitation remains.   
Alternatively, rather than specify a specific value to subtract from each voxel, our current 
“all-or-nothing” approach can be modified to account for variation in heme signal. By building a 
continuum of cutoff values we can correct for the fact that some voxels show more heme signal 
than others. For instance, in voxels containing both heme and ARV where heme signal is above a 
theoretical “high” threshold, ARV signal from that voxel would be reduced by 50%. In cases 
where heme shows a “moderate” intensity, ARV signal would be reduced by 30%. In this way, 
we can account for the fact that greater ARV intensity would be expected in voxels with greater 
heme signal, and mask each ARV in a consistent way. By applying these modified correction 
algorithms, we can better understand true ARV exposure at the site of action. 
 The work performed here and elsewhere98,100 suggests that drug transporters are an 
important variable in defining ARV exposure in GALT. We performed a rigorous analysis of 
nine efflux and uptake transporters for the purposes of generating method and interspecies 
comparisons, and attempted to use expression data from all of these proteins in combination to 
predict ARV exposure (Chapter III). However, a more step-wise approach to identifying specific 
transporters to target or avoid in order to increase ARV tissue exposure would provide precision 
evidence to be used in drug development. This can be accomplished initially through the use of 
transporter knockout mice, which have already been used to implicate P-gp and BCRP as 
important transporters for CNS penetration.62 A similar approach using IR-MALDESI to assess 
the impact of knocked-out transporters on ARV GALT distribution would be feasible and 
provide more precise data. Another approach would be to co-administer ARVs with transporter-
specific inhibitors to assess whether increased GALT exposure can be accomplished in a more 
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clinically feasible setting, and whether this increased exposure has any effect on HIV replication. 
The ultimate goal of this work would be to identify specific transporters to target or avoid to 
maximize GALT penetration and reduce or eliminate replication. Once these have been 
identified, novel therapies can be developed to exploit these effects in a similar fashion to 
ritonavir use as a CYP3A4 inhibitor to increase plasma exposure of protease inhibitors.  
 The development of any novel ARV or ARV formulation will require testing in 
preclinical species before use in humans. The data generated in Chapter IV show that the 
agreement between animal models and humans depends on the variable being evaluated. As 
mentioned previously, although the present study evaluated ARV distribution across three 
species, the regimens used are no longer clinically relevant. Because any novel therapy is more 
likely to have properties related to new versus old ARVs, it is important to define these 
relationships using more modern drugs (e.g. DTG vs RAL, TAF vs TDF, etc.). Therefore, 
ongoing or future studies in humans should be performed that include these newer regimens. 
Additionally, once a sufficient sample size for each ARV has been achieved, interspecies scaling 
factors should be developed for both distributional variables (mucosal accumulation, HIV co-
localization) as well as transporter expression (gene and protein). Once scaling factors are 
developed, they can be applied in the development process to inform go/no-go decision making. 
An ideal scenario would be generating a series of characteristics that are known to favor GALT 
exposure (similar to “Lipinksi’s rule of five”) that would allow for easy extrapolation of animal 
data to humans to predict efficacy. Taken together, these strategies will build on the work 
performed here to inform efforts to eliminate HIV replication in GALT. 
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Implications for Eradication Research 
 This aims of this dissertation addressed a relatively narrow field of research questions, 
focusing on depth over breadth. However, the implications of the data generated here are far-
reaching and will inform the wider field of HIV eradication research. The results summarized in 
Chapter II provide strong support for the hypothesis that ongoing HIV replication occurs in 
tissues, and is secondary to reduced ARV exposure. This is an important finding, as previous 
studies provided only indirect evidence of this relationship.56 This finding provides much needed 
insight into the interplay between active replication and latency, which remains the primary 
obstacle to cure. The relative contribution of each of these mechanisms to total HIV persistence 
remains undefined, but this work suggests that complete HIV eradication will require elimination 
of both latent virus and ongoing replication in tissue reservoirs. 
 To that end, the methods and concepts addressed here can easily be applied to the 
latency-reversing agents (LRAs), many of which are small molecules. As discussed in Chapter I, 
the success of an LRA is dependent on it reaching adequate concentration at the site of action, 
which includes lymphoid tissues. The pharmacologic principles governing ARV disposition and 
active HIV replication also apply to LRAs and latently-infected cells. Current methods for 
assessing the efficacy of LRAs, such as the quantitative viral outgrowth assay (QVOA), are 
difficult to perform and likely underestimate the true size of the reservoir161, making evaluations 
of LRA efficacy difficult and variable.105,162 The ability to perform PK/PD assessments at the 
tissue or cellular level from LRA-dosed animals would provide an additional avenue for 
eradication research. We have already demonstrated our ability to detect and quantify LRAs in 
tissue using IR-MALDESI78, and evaluations are underway to assess the efficacy of these agents 
at inducing viral gene expression. 
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 There are many putative HIV reservoirs outside of the GALT10–13 that remain unstudied. 
GALT was chosen for this dissertation based on the clinical consequences of persistence at this 
site, as well as the relative ease of collecting human tissue for interspecies comparisons. We have 
already shown in preliminary experiments that ARV distribution is heterogeneous in tissues such 
as the lymph node163, but homogenous in others like the testes.75 Whether or not these trends 
hold true for every ARV, or whether viral gene expression will continue to occur preferentially 
in areas of low ARV exposure in each of these tissues will need to be determined. It should be 
noted that variables such as sample preparation, IR-MALDESI conditions, cell types, or PD 
endpoints will need to be tissue-specific to generate the most useful data. However, these data 
form a sound experimental framework upon which to build future studies. Finally, the 
interspecies work described in Chapter IV can be used to inform the development of non-ARV 
agents including LRAs, several of which are known to be utilized by or affect the expression of 
drug transporters.164 
 
Conclusion 
 This dissertation describes an innovative use of clinical pharmacology to characterize 
ARV disposition in a putative HIV reservoir. We use a novel technology to visualize ARV 
distribution in tissues, perform a multi-modal analysis of the factors influencing observed 
distribution, and determine how well the results from pre-clinical models predict similar data 
from human subjects. These data provide theoretical and practical frameworks to inform the HIV 
field, and have the potential to streamline the development of novel therapies for HIV 
eradication. 
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APPENDIX 2.1: EFFLUX TRANSPORTER CO-LOCALIZATION VALUES 
 
 Drug 
Ileum Rectum 
Mice 
All Macaques 
Mice 
All Macaques 
BLT hu-HSC-Rag BLT hu-HSC-Rag 
MDR1 
TFV - - 
0 
(-0.05,0.19) 
0.14 
(0.01,0.43) 
0.10 
(-0.05,0.19) 
0 
(-0.05,0.06) 
FTC - - 
0 
(-0.05,0.12) 
- - 
0.02 
(0,0.05) 
RAL - - 
0.29 
(-0.02,0.34) 
- - 
0.18 
(0.01,0.20) 
EFV  - 
0.04 
(-0.06,0.29) 
 - 
0.16 
(0.01,0.28) 
MVC 
0.01 
(-0.09,0.24) 
0.13 
(0.02,0.24) 
0.11 
(0.04,0.14) 
0.14 
(0,0.35) 
- 
0.06 
(0,0.29) 
ATZ 
0.03 
(-0.09,0.23) 
0.23 
(0.10,0.36) 
0.16 
(0.04,0.19) 
0.12 
(-0.03,0.54) 
0.28 
(n=1) 
0.05 
(0,0.22) 
BCRP 
TFV - - 
0 
(-0.01,0.03) 
0.11 
(-0.07,0.39) 
0.05 
(-0.05,0.16) 
0.01 
(-0.08,0.04) 
FTC - - 
0 
(-0.01,0) 
- - 
0 
(-0.01,0.05) 
RAL - - 
0 
(-0.03,0.03) 
- - 
0.07 
(0,0.21) 
EFV  - 
0 
(-0.02,0.04) 
 - 
0.07 
(0,0.31) 
MVC 
0.10 
(-0.04,0.34) 
0.02 
(-0.08,0.13) 
0 
(-0.01,0.02) 
0.11 
(-0.12,0.35) 
- 
0.02 
(0.02,0.02) 
ATZ 
0.08 
(-0.06,0.13) 
0.05 
(0,0.11) 
0 
(-0.01,0) 
0.02 
(-0.05,0.55) 
0.33 
(n=1) 
0 
(0,0) 
MRP2 
TFV - - 
0 
(-0.03,0.16) 
- - 
0 
(0,0.04) 
FTC - - 
0 
(-0.01,0.08) 
- - 
0.01 
(0,0.02) 
RAL - - 
-0.02 
(-0.06,0.21) 
- - 
0.02 
(0.02,0.03) 
EFV  - 
0 
(-0.06,0.07) 
 - 
0.02 
(0.01,0.03) 
MVC - - 
0 
(0,0) 
- - 
-0.03 
(-0.03,-0.03) 
ATZ - - 
0 
(-0.01,0) 
- - 
0 
(0,0) 
MRP1 
TFV - - 
0 
(-0.04,0.04) 
0.02 
(-0.04,0.36) 
0.02 
(-0.01,0.13) 
0.08 
(-0.02,0.18) 
FTC - - 
0.01 
(-0.05,0.06) 
- - 
0.02 
(-0.01,0.08) 
RAL - - 
-0.02 
(-0.03,0) 
- - 
0.17 
(0,0.27) 
EFV  - 
0.01 
(0,0.14) 
 - 
0.14 
(0,0.25) 
MVC 
0.06 
(-0.04,0.32) 
0.05 
(-0.02,0.13) 
0.04 
(0.04,0.04) 
-0.01 
(-0.05,0.15) 
- 
0.28 
(0.28,0.28) 
ATZ 
0.02 
(0,0.04) 
0.17 
(0,0.34) 
0.04 
(0.03,0.05) 
0.02 
(-0.08,0.50) 
0.03 
(n=1) 
0.28 
(0.28,0.28) 
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APPENDIX 3.1: GENE EXPRESSION ASSAYS USED FOR EACH SPECIES 
 
Gene Name Species Catalog Number 
ABCB1 Mouse Mm00440736_m1 
ABCC1 Mouse Mm00456156_m1 
ABCC2 Mouse Mm00496899_m1 
ABCC4 Mouse Mm01226381_m1 
ABCG2 Mouse Mm00496364_m1 
SLCO2A1 Mouse Mm00459638_m1 
SLC29A1 Mouse Mm01270577_m1 
SLC22A2 Mouse Mm00457295_m1 
SLC22A3 Mouse Mm00488294_m1 
GAPDH Mouse Mm99999915_g1 
ABCB1 Macaque Rh02788239_m1 
ABCC1 Macaque Hs01561502_m1 
ABCC2 Macaque Rh02788077_m1 
ABCC4 Macaque Rh02858818_m1 
ABCG2 Macaque Rh02788848_m1 
SLCO2A1 Macaque Rh02858210_m1 
SLC29A1 Macaque Rh02794207_m1 
SLC22A2 Macaque Hs01010723_m1 
SLC22A3 Macaque Hs01009568_m1 
GAPDH Macaque Rh02621745_g1 
ABCB1 Human Hs00184500_m1 
ABCC1 Human Hs01561502_m1 
ABCC2 Human Hs00166123_m1 
ABCC4 Human Hs00988717_m1 
ABCG2 Human Hs01053790_m1 
SLCO2A1 Human Hs00194554_m1 
SLC29A1 Human Hs01085704_g1 
SLC22A2 Human Hs01010723_m1 
SLC22A3 Human Hs01009568_m1 
GAPDH Human Hs02758991_g1 
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APPENDIX 3.2: TRANSPORTER GENE EXPRESSION AMONG MOUSE DOSING 
COHORTS (ILEUM) 
 
 
Appendix 3.2: Transporter Gene Expression Among Mouse Dosing Cohorts (Ileum) Gene 
expression is represented as fold change of GAPDH for uninfected (white) and infected (gray) 
animals from multiple dosing cohorts. Data shown are median (line) and interquartile range 
(box) with range (whiskers). Dashed lines are the values for the non-dosed control animals (n=2). 
EFV=hu-HSC-Rag dosed with EFV; ATZ=hu-HSC-Rag mice dosed with ATZ; TFRM=hu-
HSC-Rag mice dosed with TFV, FTC, RAL, MVC; BLT= all BLT mice. N=6 for all groups. * 
represents p<0.05 
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APPENDIX 3.3: TRANSPORTER GENE EXPRESSION AMONG MOUSE DOSING 
COHORTS (RECTUM) 
 
 
Appendix 3.3: Transporter Gene Expression Among Mouse Dosing Cohorts (Rectum) Gene 
expression is represented as fold change of GAPDH for uninfected (white) and infected (gray) 
animals from multiple dosing cohorts. Data shown are median (line) and interquartile range 
(box) with range (whiskers). Dashed lines are the values for the non-dosed control animals (n=2). 
EFV=hu-HSC-Rag dosed with EFV; ATZ=hu-HSC-Rag mice dosed with ATZ; TFRM=hu-
HSC-Rag mice dosed with TFV, FTC, RAL, MVC; BLT= all BLT mice. N=6 for all groups. * 
represents p<0.05 
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APPENDIX 3.4: TRANSPORTER PROTEIN EXPRESSION BY WESTERN BLOT 
AMONG MOUSE DOSING COHORTS 
 
Appendix 3.4: 
Transporter Protein 
Expression by Western 
blot Among Mouse Dosing 
Cohorts. Densitometry data 
from each blot was 
quantified for each 
transporter in a-h, where 
protein expression is 
represented as a fold change 
over GAPDH for uninfected 
(white) and infected (gray) 
animals. Data shown are 
median (line) and 
interquartile range (box) 
with range (whiskers). 
EFV=hu-HSC-Rag dosed 
with EFV; ATZ=hu-HSC-
Rag mice dosed with ATZ; TFRM=hu-HSC-Rag mice dosed with TFV, FTC, RAL, MVC; 
BLT= all BLT mice. N=6 for all groups.  
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APPENDIX 3.5: TRANSPORTER PROTEIN EXPRESSION BY PROTEOMICS 
AMONG MOUSE DOSING COHORTS (ILEUM) 
 
Appendix 3.5: 
Transporter Protein 
Exprssion by 
Proteomics Among 
Mouse Dosing 
Cohorts (Ileum) 
Protein concentrations 
are presented as 
pmol/mg total protein 
for each cohort of 
uninfected (white) and 
infected (gray) mice. 
Values for non-dosed 
control animals (n=2), 
when detectable, are 
shown as dashed lines. 
EFV=hu-HSC-Rag dosed with EFV; ATZ=hu-HSC-Rag mice dosed with ATZ; TFRM=hu-
HSC-Rag mice dosed with TFV, FTC, RAL, MVC; BLT= all BLT mice. N=6 for all groups.* 
represents p<0.05 
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APPENDIX 3.6: TRANSPORTER PROTEIN EXPRESSION BY PROTEOMICS 
AMONG MOUSE DOSING COHORTS (RECTUM) 
 
Appendix 3.6: Transporter Protein Expression by Proteomics Among Mouse Dosing 
Cohorts (Rectum) 
Protein concentrations 
are presented as 
pmol/mg total protein 
for each cohort of 
uninfected (white) and 
infected (gray) mice. 
Values for non-dosed 
control animals (n=2), 
when detectable, are 
shown as dashed lines. 
EFV=hu-HSC-Rag 
dosed with EFV; 
ATZ=hu-HSC-Rag 
mice dosed with ATZ; 
TFRM=hu-HSC-Rag 
mice dosed with TFV, 
FTC, RAL, MVC; BLT= all BLT mice. N=6 for all groups.* represents p<0.05 
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APPENDIX 3.7: HUMAN CONTRIBUTION TO TOTAL TRANSPORTER POOL 
Appendix 3.7: Human Contribution To Total Transporter Pool Original gene expression 
values for each mouse were multiplied by the fold change value for human expression for the 
transporters ABCB1 (a) and 
ABCC4 (b). The resulting 
value was added back to the 
original expression value to 
account for the contribution of 
human gene expression. For 
example, an original mouse 
expression value of 0.03 was 
multiplied by 2.5 (as it was 
found that human gene 
expression was 2.5-fold higher 
than mouse gene expression). 
The result of 0.075 was added 
back to 0.03 to get 0.105, 
which represents total gene 
expression for this transporter. 
Gene expression is represented as fold change of GAPDH for uninfected (gray) and infected 
(red) animals from multiple dosing cohorts. Data shown are median and range. NHP=non-human 
primate. * represents p<0.05 
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APPENDIX 3.8: LINEARITY OF PEPTIDE DETECTION IN PROTEOMIC ASSAY 
 
 
 
Appendix 3.8: Linearity of Peptide Detection in Proteomics Assay Five-fold dilution of SILs 
(a) resulted in linear peak area intensities across dilution range. (b) 3-fold dilution of a 
representative peptide of known starting concentration (MRP1 from cell lysate standard) resulted 
in linear quantitation across dilution range.  
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APPENDIX 4.1: COMPLETE INCLUSION/EXCLUSION CRITERIA 
 
Inclusion Criteria:  
1. Healthy HIV-positive female subjects between the ages of 18 and 65years, inclusive on the 
date of screening, with an intact gastrointestinal tract, uterus, and cervix. Healthy is defined 
as no clinically relevant abnormalities that would interfere with the interpretation of results, 
or pose unnecessary risk onto volunteers due to study procedures. 
2. All subjects must have an undetectable viral load (<40copies/mL) at the time of screening or a 
documented undetectable viral load within the preceding 3 months of screening. 
3. All subjects must be receiving one of the study regimens as part of their regular HIV care for at least 
6 months preceding the date of enrollment. 
4. Subjects must not have a history of GI disease (e.g. Crohn’s disease, irritable bowel syndrome, 
ulcerative colitis, diverticulitis, colon cancer) or have a history of GI surgery. 
5. All subjects must have a negative serum pregnancy test at screening and negative urine 
pregnancy tests on days of sampling and should be using at least one of the following 
methods of contraception from the screening visit through 72 hours prior to inpatient 
admission (at which time the women will be asked to remain abstinent until after their 
follow-up visit): 
a. Systemic hormonal contraceptive (oral, depot, transdermal or implant) 
b. IUD placed at least 1 month prior to study enrollment 
c. Bilateral tubal ligation (Sterilization)  
d. Vasectomized male partners 
e. Condom + Spermicide 
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f. *Unless engaged in sexual activity with female only sex partners or abstinent for at 
least 3 months prior with no intention of becoming sexually active during the study 
period.  Any history of recent or present concomitant male sex partners will be 
addressed and ruled out in the context of screening participants for eligibility for the 
protocol 
6. Body Mass Index (BMI) of approximately 18 to 37 kg/m2; and a total body weight > 45 kg 
(99 lbs). 
7. Evidence of a personally signed and dated informed consent document indicating that the 
subject has been informed of all pertinent aspects of the trial. 
8. Willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other 
trial procedures. 
9. Subject must have documentation of a normal pap smear within 36 months of the screening 
visit, no procedures for abnormal cervical/vaginal pathology in the last six months, at least 
one prior gynecological visit as part of subject’s routine medical history. 
10. Not receiving any known CYP3A4 inducers (rifampin, carbamazepine, St. John’s wort) or 
inhibitors (ketoconazole, non-DHP calcium channel blockers, macrolide antibiotics) other 
than those contained in their HIV regimen for at least 6 months prior to enrollment. 
11. Subject must be willing to abstain from sexual intercourse, douching, and all intravaginal and 
intrarectal objects and products for at least 72 hours prior to enrollment until study 
completion.  
12. Subject must be Hepatitis B surface antigen negative as documented on screening labs.  
13. Subject must not be actively involved in the conception process. 
14. Subject must be able to swallow pills and have no allergies to any component of the study 
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products (i.e. bowel preparation regimen) 
 
Exclusion Criteria 
1. Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, 
gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease 
(including documented drug allergies, but excluding untreated, asymptomatic, seasonal 
allergies at time of dosing). 
2. Subjects with a history of hysterectomy or cervical resection that would preclude obtaining a 
cervical biopsy. 
3. Subjects who are pregnant, possibly pregnant or lactating. 
4. Subjects with a presence of abnormal vaginal discharge bleeding at screening. 
5. History of febrile illness within five days prior to enrollment. 
6. A positive urine drug screen for illicit substances (e.g. cocaine, methamphetamines) that 
would increase risk associated with sedation. 
7. Active Hepatitis B infection as determined by positive Hepatitis B surface antigen (HBsAg). 
8. An untreated-positive test for syphilis, gonorrhea, Chlamydia, or trichomonas at screening, 
Tests for these STIs will be performed on samples from both the vaginal and rectal orifices.  
9. Any laboratory chemistry or hematology result Grade 3 or greater according to the DAIDS 
Laboratory Grading Tables  
10. Treatment with an investigational drug within 4 months preceding the first dose of trial 
medication.   
11. History of regular alcohol consumption exceeding 14 drinks (1 drink = 5 ounces (150 mL) of 
wine or 12 ounces (360 mL) of beer or 1.5 ounces (45 mL) of spirits) per week. 
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12. Participation in a clinical trial involving vaginal or rectal biopsies within 6 months preceding 
enrollment. 
13. Blood donation of approximately 1 pint (500 mL) within 56 days prior to dosing.  
14. History of sensitivity to heparin or heparin-induced thrombocytopenia. 
15. Allergy to lidocaine or Monsel’s solution. 
16. Allergy to latex. 
17. Abnormal pap smear in the past 36 months 
18. Any degree of ectopy or abnormality evident during the pelvic exam at screening. 
19. Any condition which, in the opinion of the investigator, is likely to interfere with follow-up 
or ability to take the bowel preparation appropriately. 
20. Unwilling or unable to comply with the dietary and concomitant drug restrictions in regard to 
study drug administration as outlined in the study procedures and prohibited medications 
sections. 
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APPENDIX 4.2: HUMAN EFFFLUX TRANSPORTER CO-LOCALIZATION VALUES 
 
ARV TRANSPORTER ILEUM RECTUM 
TFV (n=5) 
MDR1 
-0.05 
(-0.08, -0.03) 
0 
(-0.02, 0.21) 
BCRP 
-0.04 
(-0.05, -0.03) 
0.06 
(0.03, 0.14) 
MRP2 
-0.03 
(-0.03, -0.03) 
0 
(-0.01, 0.03) 
MRP1 
0 
(0, 0) 
-0.03 
(-0.03, 0.11) 
FTC (n=5) 
MDR1 
- 0 
(-0.01, 0.02) 
BCRP 
- 0.14 
(0.03, 0.15) 
MRP2 
- -0.01 
(-0.02, -0.01) 
MRP1 
- 0.09 
(-0.01, 0.17) 
RAL (n=1) 
MDR1 -0.03 -0.07 
BCRP -0.04 0.15 
MRP2 -0.05 0 
MRP1 0.18 0.23 
EFV (n=1) 
MDR1 0.03 0.02 
BCRP -0.02 0.18 
MRP2 -0.06 0.08 
MRP1 -0.03 0.07 
MVC (n=1) 
MDR1 0.21 - 
BCRP 0.09 - 
MRP2 -0.03 - 
MRP1 0.16 - 
ATZ (n=2) 
MDR1 - 0.19 
BCRP - 0.01 
MRP2 - -0.05 
MRP1 - 0.04 
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HIV replication has been shown to persist in certain anatomic sites, known as active viral 
reservoirs, despite treatment with highly-active antiretroviral therapy (HAART).25,129 
Understanding the factors that contribute to the formation and propagation of these active viral 
reservoirs is essential to the design of targeted therapies for HIV eradication. It has been 
suggested that sub-therapeutic drug concentrations in certain tissues resulting from poor drug 
penetration may provide a favorable environment for reservoir formation and drug-resistant viral 
variants.56 Several groups, including our own, have assessed antiretroviral (ARV) penetration 
into tissues by directly measuring drug concentrations using liquid chromatography/mass 
spectrometry (LC-MS) of homogenized whole tissue123 or  isolated mononuclear cells56,165. 
Though these methods can provide useful quantitative data, they do not have the ability to 
spatially define the distribution of drug within the tissue, as either the entire sample is consumed 
in the homogenization process or spatial information is lost during cellular isolation. This is a 
critical limitation of these methodologies, as our preliminary data have shown that ARV 
distribution across tissue is not uniform.163  
 Mass spectrometry imaging (MSI) offers an alternative strategy for quantifying ARV 
distribution into tissues and cells that maintains the sensitivity and specificity of LC-MS while 
preserving the spatial distribution of analytes within tissue. Through step-wise interrogation of 
discrete sample locations, MSI simultaneously collects information that can be concatenated into 
images of multiple molecules and their respective metabolites. This attribute is an important 
advantage for the combinatorial nature of HAART and has already led to the implementation of 
MSI in the drug development process.74  One approach to MSI that is particularly well suited to 
the analysis of small molecules is infrared matrix-assisted laser desorption/electrospray 
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ionization (IR-MALDESI)166, which we have previously demonstrated allows detection of ARVs 
in human tissue.77,107  
 Here, we utilize IR-MALDESI to characterize ARV distribution in 11 non-human 
primate tissues implicated as viral reservoirs.26,167–169 Further, we quantify the variability of ARV 
exposure between tissues and compare this to LC-MS and immunohistochemistry (IHC) data, 
allowing for absolute quantification of observed ARV signal abundance and identification of the 
tissue compartments or cellular populations where a drug may be concentrating. These data are 
the first quantitative images of ARV distribution in a macaque, an important species for studies 
of HIV/SIV therapy, and show that MSI is a promising approach for evaluating ARV disposition 
in HIV reservoirs.170 
One healthy male rhesus macaque (Macaca mulatta) was given 7 daily oral doses of 200 
mg efavirenz (EFV). This dose of EFV equates to roughly 60 mg/kg and is consistent with 
standard treatment doses for SIV.171,172 Prior to necropsy, blood plasma and cerebrospinal fluid 
were collected.  The animal was euthanized by pentobarbital overdose 24 hours after the final 
dose of EFV, and necropsy was performed by the pathology staff at the California National 
Primate Research Center. Tissue samples from the GI tract (ileum, colon, rectum), central 
nervous system (CNS:cerebellum, basal ganglia), lymph nodes (axillary, iliac, mesenteric, 
inguinal), and spleen were snap frozen on dry ice, and stored at -80°C until analysis.138  
Calibration of IR-MALDESI response to EFV from the dosed tissue was conducted by MSI of 
tissues from non-dosed (“blank”) macaques (BioreclaimationIVT, Baltimore, MD), matching 
dosed tissue samples where possible, upon which a set of EFV standards were pipetted. Prior to 
imaging, 10 µm sections of each tissue (dosed and non-dosed) were sliced and thaw mounted on 
a single glass microscope slide uniformly coated with internal standards and the tissue sections 
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were spotted with 100 nL of 0-5000 pg EFV before placing the sample slide in the IR-MALDESI 
imaging source.  Serial 10 µm sections were set aside for LC-MS/MS and IHC analysis. 
The IR-MALDESI MSI approach for analysis of tissue samples has been described 
previously.107,166 Briefly, tissue samples maintained at -10°C in the source chamber were ablated 
at a spot-to- -Opolette 2371; Opotek, 
Carlsbad, CA, USA) that resulted in the complete desorption of neutral molecules for a given 
volume element, or voxel. The desorbed neutral molecules were then ionized by an orthogonal 
electrospray plume and sampled into a high resolving power Thermo Fisher Scientific Q 
Exactive (Bremen, Germany) mass spectrometer for synchronized analysis.107 To generate 
images from mass spectrometry data, raw data from each voxel was converted to the mzXML 
format using MSConvert software.173 These mzXML files were interrogated using MSiReader, a 
free software developed for processing MSI data, from which measurements such as tissue 
surface area can be made and images of analyte distribution can be generated.115  
For LC-MS/MS analysis of efavirenz concentrations, serial 10 µm tissue sections were 
homogenized in 1 mL of 70:30 acetonitrile:1 mM ammonium phosphate (pH 7.4) using a 
Precellys 24 tissue homogenizer (Bertin Technologies, Montigny-le-Bretonneux, France). A 
Shimadzu HPLC system performed chromatographic separation and an AB SCIEX API 5000 
mass spectrometer (AB SCIEX, Foster City, CA, USA) equipped with a turbo spray interface 
was used as the detector. The samples were analyzed with a set of calibration standards (0.02-
20ng) and QC samples. Precision and accuracy of the calibration standards and QC samples was 
within acceptance criteria of 15%. Homogenate LC-MS/MS quantification of EFV for each 
tissue section was compared to the summed MSI response on a per-mass-tissue basis using the 
MSI-derived tissue surface area, the known section thickness, and an assumed tissue density of 
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1.06 g/cm3. The MSI quantitation and LC-MS/MS analysis were performed by different 
individuals at separate institutions, and no data were shared before analyses were completed. The 
LC-MS/MS data underwent quality control by a designated individual not directly involved in 
this study to ensure accuracy.  
To verify tissue quality and assess architecture for comparison to EFV distribution by 
MSI, serial sections of frozen tissue were sliced at 10 µm thickness, thaw mounted on glass 
slides, and fixed in 100% ethanol for 10 minutes. After fixation, the tissues were stained with 
hematoxylin and eosin (H&E) using standard histological techniques. IHC analysis was 
performed on similarly prepared frozen tissue slices using human primary antibodies for CD3 
(clone LN10, Leica Biosystems, Buffalo Grove, IL) followed by staining with secondary 
antibodies. All stains were performed using the Leica Bond automated tissue stainer (Leica 
Biosystems). MSI revealed heterogeneous intra-tissue EFV distribution into several anatomic 
sites. Figure 1 showcases these findings for representative tissues. When MSI images were 
compared with IHC staining, interesting spatial distributions were noted. For example, EFV was 
concentrated in the mucosa and lamina propria of the colon (1A), which corresponds to high 
CD3+ cell density on IHC. However, this distribution was not observed in the ileum (1B).  The 
inguinal lymph node showed EFV in some, but not all, primary follicles (1C).  EFV concentrated 
in the grey matter of the cerebellum (1D), and showed a homogeneous distribution in the spleen, 
testes, and axillary lymph node (1E). The heterogeneity of EFV distribution is quantified in 
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Table 1 by the dynamic range in MSI response (expressed in the base-10 units of decibels, dB) 
to each tissue type that can be observed from the images of Figure 1. The dynamic range of EFV 
response was lower in tissues such as the basal ganglia and lymph nodes reflecting more 
Figure 1: EFV Distribution into Macaque Reservoir Sites Representative MSI images 
are shown on the left, with adjacent CD3+ cell staining of serial tissue slices for colon 
(A), ileum (B), inguinal lymph node (C), cerebellum (D), and spleen (E). MSI signal 
intensity is shown next to each image on a concentration-dependent scale. The bottom of 
the scale (0) represents no EFV present, while the top of the scale reflects the highest per-
voxel EFV signal observed within each slice. Brighter colors represent higher EFV 
concentrations.  
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homogeneous EFV distribution, whereas  tissues such as the colon (37.6 dB) and rectum (26.8 
dB) had much larger differences between minimum and maximum concentrations that suggest 
greater biological differences in drug uptake. 
 
Table 1: Variability of EFV MSI Response Within Dosed Macaque Tissues 
 
Tissue Type Maximum Median Minimum Dynamic range 
    ng/voxel   dB 
Cerebrum 1.8E+04 5.0E+03 6.5E+02 14.5 
Basal ganglia 1.8E+03 9.2E+02 4.8E+02 5.8 
Lymph node: Axillary 3.0E+04 4.2E+03 2.0E+03 11.8 
Lymph node: Mesenteric 9.8E+03 2.6E+03 1.1E+03 9.5 
Lymph node: Inguinal 2.7E+04 1.6E+03 8.1E+02 15.2 
Lymph node: Iliac 4.0E+03 9.3E+02 3.4E+02 10.7 
Spleen 4.2E+04 5.1E+03 1.4E+03 14.6 
Ileum 1.4E+04 3.7E+03 2.5E+03 7.5 
Colon 8.7E+06 1.4E+04 1.5E+03 37.6 
Rectum 1.6E+06 1.2E+04 3.4E+03 26.8 
Testes 2.7E+03 5.9E+02 3.7E+02 8.6 
 
                 *EFV concentration within each voxel was quantified using calibration standards and averaged  
          across the entire tissue slice. These averages and the maximum and minimum concentrations for 
          each slice are reported. 
         **Relative standard deviation was calculated 
Inter-tissue EFV quantitation is summarized in Table 2. LC-MS/MS analysis 
demonstrated a 20-fold variability in total tissue EFV exposure, with concentrations ranging 
quantification, though agreement varies between tissue types. EFV concentrations were found to 
be in agreement (<30% difference) between MSI and LC-MS/MS for half of the tissues after 
correction for tissue size. In tissues such as the lymph nodes, concentrations varied by as little as 
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8%. Tissues of the GI tract demonstrated less agreement between techniques, with variations up 
to -70%. Table 2 also compares EFV exposure in tissue and in plasma. EFV achieved high 
exposure in the CNS, where tissue concentrations were 6.8-7.6 logs higher than in the CSF. EFV 
exposure was consistent among the lymph nodes, with 1.7-2.2 log increases over plasma 
observed. In the GI tract, EFV exposure was 3.6 logs higher than plasma in the colon and 
rectum, and 2.7 logs higher in the ileum.     
Table 2: Comparison of EFV Quantitation in Macaque Tissues using MSI and LC-MS/MS 
Tissue Type LC-MS/MS 
 
LC-MS/MS 
Log Increase 
Over Plasma 
or CSF* 
MSI 
tissue) 
MSI Log 
Increase 
Over 
Plasma or 
CSF* 
Difference*
* 
(%) 
Cerebellum 6.86 7.6 3.09 6.8 -54.89 
Basal ganglia 2.01 6.4 1.67 6.2 -16.80 
Lymph node: 
Axillary 
3.91 2.0 3.33 1.8 -14.91 
Lymph node: 
Mesenteric 
3.82 2.0 3.12 1.8 -18.48 
Lymph node: 
Inguinal 
4.80 2.2 2.86 1.7 -40.38 
Lymph node: Iliac 2.82 1.7 3.06 1.7 8.40 
Spleen 5.01 2.2 3.61 1.9 -27.83 
Ileum 8.41 2.7 3.20 1.8 -61.94 
Colon 20.77 3.6 6.12 2.4 -70.54 
Rectum 20.69 3.6 8.22 2.7 -60.26 
Testes 1.22 0.8 2.91 1.7 138.94 
Day 8 Plasma 
(ng/mL) 
541 n/a n/a n/a n/a 
Day 8 CSF 
(ng/mL) 
3.30 n/a n/a n/a n/a 
*To compare tissue concentrations to plasma or CSF, tissue concentrations (µg/g) were converted to ng/mL assuming 
a tissue  
density of approximately 1g/mL, then divided by the plasma or CSF concentration and converted to log units 
**Difference between methods was calculated by subtracting LC-MS/MS concentrations from MSI concentrations, 
dividing by the  
LC-MS/MS concentration and multiplying by 100% 
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 The persistence of HIV replication within anatomic reservoirs necessitates the use of 
tissue pharmacology to inform the design of effective treatment strategies. This will require 
knowledge of tissue penetration to sites of action, as underscored by recent findings that the 50-
90% reduction of EFV in mononuclear cells isolated from reservoir tissues relative to PBMCs 
was associated with persistent viral replication in these tissues.56 This finding, in combination 
with the fact that EFV receives widespread clinical use as a component of Atripla® (a fixed dose 
combination of tenofovir, emtricitabine, and efavirenz dosed once daily) and is frequently 
included in HIV treatment and cure research regimens for macaques, led us to choose EFV for 
our evaluations.   
The observed ARV drug distribution within these putative viral reservoirs reveals 
important information regarding tissue pharmacology that can inform treatment strategy. The 
heterogeneous penetration of EFV into the lymphoid follicles suggests that further quantification 
of effective drug exposure in these tissues is required.  Conversely, the abundance of EFV signal 
in the CD3+ cell populations of the gut is evidence that adequate EFV concentrations are likely 
reached in this compartment. Both of these findings are consistent with previous studies that 
have examined EFV tissue concentrations by LC-MS.165  The EFV distributions observed here 
would not have been possible with traditional LC-MS of tissue homogenates or isolated 
mononuclear cells:  the heterogeneity of EFV distribution within tissue slices as measured by the 
dynamic range of response (Table 1) is only measurable using MSI. Moreover, our MSI analysis 
provides evidence that the use of plasma or CSF as a surrogate for tissue concentrations may be 
inappropriate without detailed quantification of these relationships. The increased CNS tissue 
concentrations compared to the CSF (Table 2) and the concentration of EFV within the grey 
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matter of the cerebellum (Figure 1) agree with brain microdialysis data showing that CNS drug 
concentrations are higher than CSF concentrations.174,175   
 The variability in the extent of EFV distribution between tissue types suggests that 
biological processes, more than the cellular populations present, drive the movement of EFV into 
tissues. The non-homogenous distribution of EFV in tissues such as the colon may be 
attributable to the physicochemical properties of EFV, or to active transport mechanisms. Our 
previous work identifying variables affecting ARV exposure in the female genital tract (another 
putative viral reservoir) found that the efflux transporters MRP1 and MRP4 were associated with 
ARV penetration into this compartment.52 While EFV is not a known substrate of these 
transporters, other drug transporters such as MDR1 or BCRP may affect its disposition and 
explain the areas of EFV concentration seen here.176,177 
There are several limitations to this analysis which should be addressed, the most 
important of which is our limited sample size. As this study was conducted in a single animal, 
the variability in tissue drug distribution between animals remains unknown and remains to be 
evaluated. Further, the assessment of EFV distribution shown in Figure 1 is based on individual 
slices of tissue under steady-state conditions. Repeated sectioning may reveal additional 
biological variability.   Although EFV has a long plasma half-life and relatively flat blood 
plasma concentration-time curve, EFV exposure over the dosing interval could not be 
determined due to the fact that sampling was only performed at the end of the dosing interval.  
Additionally, we were unable to determine the relationship between drug and viral dynamics in 
this uninfected animal, though we selected tissues with previous evidence supporting persistent 
HIV infection.26,167–169 Finally, only CD3 was used for an IHC correlate to drug distribution. 
Though visualization of the overall T cell compartment is informative, future work will relate 
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ARV localization to CD4+ T cell distribution, as these cells are the most relevant for HIV 
infection. 
This is the first study to apply MSI to ARV distribution in potential tissue reservoirs for 
HIV infection. Using IR-MALDESI, we have confirmed that ARV tissue distribution is 
heterogeneous, and that the distribution of a single ARV can vary greatly between tissues within 
an individual. By comparing to the gold standard of tissue quantification, LC-MS/MS, our 
analysis confirms the importance of MSI for drug quantification.  Future work will address 
existing limitations of our approach. For MSI, this will entail a systematic exploration of factors, 
such as matrix effects or electrospray ionization capacity, which may influence the quantitative 
agreement with LC-MS for different tissue types and drug exposure. IR-MALDESI is sensitive 
to a wide variety of endogenous lipids (profiles of which vary between tissue types) that are 
ablated and analyzed simultaneously with EFV. Any suppression of EFV response as a result of 
tissue-specific ablation and ionization conditions is intended to be taken into account by 
performing EFV calibrations on matching or closely related blank tissue types and evaluating IR-
MALDESI response to an internal standard. However, a more thorough investigation of these 
effects must be undertaken to improve analytical agreement. Additionally, lower limits of 
detection for all antiretrovirals and their active metabolites within a drug regimen must be 
attained in order to link tissue drug exposure and suppression of viral replication. We will also 
evaluate ARV distribution in SIV/HIV infected samples to determine the effect of ARV 
disposition on viral expression. Despite these limitations, these data show that MSI is a critical 
tool for the disposition of ARVs within putative active HIV reservoirs, which is an important 
step toward understanding how to eradicate HIV infection. 
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ABSTRACT PRESENTED AT THE AMERICAN SOCIETY OF CLINICAL 
PHARMACOLOGY AND THERAPEUTICS 2017 CONFERENCE, WASHINGTON, 
D.C.  
 
Imaging Antiretroviral Distribution Within Gastrointestinal Tissues Across Pre-Clinical 
Species: Implications For Hiv Eradication 
Corbin G. Thompson, Elias P Rosen, Michelle Mathews, Nicole White, Craig Sykes, Yuri 
Fedoriw, Paige Charlins, Leila Mulder, Martina Kovarova, Lourdes Adamson, David C 
Muddiman, Ramesh Akkina, Victor Garcia, Paul Luciw, Angela DM Kashuba 
 
HIV replication within the gut may be propagated by reduced antiretroviral (ARV) exposure. 
Mass spectrometry imaging (MSI) provides biodistribution data that LC-MS cannot. Here, we 
use MSI to visualize ARV distribution within gut tissues from two species, and assess 
colocalization with HIV target cells and drug efflux transporters. 
Two humanized mouse (n=49) and one primate (NHP, n=12) models were given combination 
ARVs. One 10µm slice from frozen ileum and rectum was analyzed by MSI.  Serial slices were 
analyzed for CD3+ T cell and efflux transporter (MDR1, BCRP, MRP1, MRP2) localization by 
IHC. Colocalization of ARV and IHC imaging was performed in Matlab using Pearson 
correlation (r).  
ARV distribution was heterogeneous (Figure, column 1, NHP ileum) with 2-fold greater mucosal 
accumulation in NHP vs mice. ARV-T cell correlation ranged from 0.007 to 0.55, was 19-fold 
higher in NHP vs mice and 11-fold higher in the NHP rectum versus the ileum. Transporter 
colocalization was highest for MDR1 (range 0.06-0.62) in both species. 
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Large interspecies differences in ARV distribution were noted.  Colocalization suggests efflux 
transporter expression results in lower ARV exposure in HIV target cells in the ileum, which 
may contribute to low level HIV replication. These data will inform the development of targeted 
therapies for HIV eradication.  
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PHARMACOLOGY OF HIV AND HEPATITIS C THERAPY, WASHINGTON, D.C.  
 
Quantitative Proteomic Analysis of Drug Transporter Expression in the GI Tract of 
Multiple Animal Models of HIV Infection 
 
Corbin G. Thompson1, John K. Fallon1, Paige Charlins3, Leila Mulder3, Martina Kovarova1, 
Lourdes Adamson2, Paul Luciw2, J. Victor Garcia1, Ramesh Akkina3, Philip C. Smith1, and 
Angela DM Kashuba1 
1University of North Carolina at Chapel Hill, Chapel Hill, NC, USA  
2University of California, Davis, CA, USA 
3Colorado State University, Fort Collins, CO, USA 
The persistence of HIV in tissue reservoirs such as the GI tract may be reduced or eliminated 
with optimized exposure of antiretrovirals (ARVs) at the site of action. Drug transporters affect 
ARV tissue disposition and can be exploited to maximize ARV exposure, but quantitative 
measures of drug transporter protein expression across preclinical species are not available. In 
this study, we use proteomics to obtain absolute transporter concentrations and assess agreement 
with corresponding gene and immunometric protein data. We also examine the effect of HIV 
infection on transporter expression in the GI tract.  
 
Animals from two humanized mouse (hu-HSC-Rag (n=18); BLT (n=7)) and one primate (rhesus 
macaque, (NHP, n=3)) models were infected with HIV or SHIV for 4-6 weeks before being 
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dosed to steady-state with combination ARV treatment. Ileum and rectum were collected at 
necropsy and analyzed for protein expression of ARV efflux (MDR1, BCRP, MRP1, MRP2, and 
MRP4) and uptake (ENT1, OATP2A1, OCT3) transporters using quantitative targeted absolute 
proteomics (QTAP) and Western blot (WB). Transporter mRNA was measured by qPCR. Gene 
and protein expression were compared against historical data from uninfected animals, and 
comparisons between anatomic sites and animal models were made using ANOVA on ranks. 
Agreement between analytical techniques was assessed by linear regression. Data are presented 
as median concentration.  
 
QTAP analysis showed a 1.7 log increase in MDR1 expression in the ileum of infected mice 
versus infected macaques (49.9 vs 1.6 pmol/mg protein; p<0.001), and significantly higher 
OATP2A1 concentrations in macaque vs mouse rectum (10.4 vs undetectable pmol/mg 
protein;p=0.002). Transporter concentrations were similar between ileal and rectal tissues with 
the exception of ENT1, which was significantly higher in mice ileum versus rectum (1.1 vs 
undetectable pmol/mg protein;p=0.002). Gene expression was generally consistent between 
infected and uninfected animals (p>0.05), however ABCC4 gene expression was significantly 
higher in infected versus uninfected mice (97.4 vs 0.02 x 104 fold change vs GAPDH; p<0.001). 
There was little agreement between QTAP and qPCR or WB, with R2 values ranging from 0.001 
(MDR1 QTAP vs qPCR) to 0.34 (MRP1 QTAP vs WB). 
 
This evaluation is the first to determine absolute protein concentrations of drug transporters 
across pre-clinical species. We observed significant differences in MDR1 and OATP2A1 
concentrations between species, suggesting that the tissue exposure of their substrates, including 
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many ARVs, may not be equal between these models. Further, the lack of differences in 
transporter expression between infected and uninfected animals suggests that HIV infection does 
not confound ARV distribution studies.  Finally, the lack of agreement between analytical 
techniques indicates that resources may need to be focused on generating high-throughput, 
downstream measures of protein expression. Taken together, these data inform the use of pre-
clinical models for studying ARV distribution and the design of targeted therapies for HIV 
eradication.  
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Multispecies Differences in Drug Transporter Expression and Localization in GI Tissue 
Corbin G. Thompson1, Elias P. Rosen1, Paige Charlins3, Leila Mulder3, Martina Kovarova1, Yuri 
Fedoriw1, Paul Luciw2, J. Victor Garcia1, Ramesh Akkina3, and Angela DM Kashuba1 
1University of North Carolina at Chapel Hill, Chapel Hill, NC, USA  
2University of California, Davis, CA, USA 
3Colorado State University, Fort Collins, CO, USA 
HIV replication may persist during treatment within tissue reservoirs, including the 
gastrointestinal (GI) tract. Differences in drug transporter expression and localization may alter 
ARV exposure and confound the ability to translate study results between animal models, and to 
humans. Here, we characterize the expression and localization of transporters relevant to ARVs 
in 3 animal models. 
Three cohorts of uninfected animals (rhesus macaques (NHP, n=3); humanized mice (BLT, n=6 
and hu-HSC-Rag, n=18)) were dosed to steady-state with a combination of ARVs including 
tenofovir (TFV), emtricitabine (FTC), and raltegravir (RAL). Ileum and rectum were collected at 
necropsy and analyzed for gene (qPCR) and protein (Western blot) expression and localization 
(immunohistochemistry (IHC)) of ARV efflux (ABCB1, ABCG2, ABCC1, ABCC2, and ABCC4) 
and uptake (SLC29A1, SLCO2A1, SLC22A3) transporters. Tissue concentrations were analyzed 
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by LC-MS and normalized to plasma. Species comparisons were performed using ANOVA. Data 
are reported as mean fold expression vs GAPDH. 
In the ileum, gene expression differed significantly between BLT and hu-HSC-Rag mice for 
ABCB1 (5.02 vs 23.4 x 10-4;p=0.005), ABCC2 (0.11 vs 0.19;p=0.01), and ABCC4 (4.56 vs 1.91 x 
10-6;p=0.005). Protein expression did not differ between these 2 models (p>0.05). Iliac NHP 
gene expression was increased over mouse for ABCB1 & ABCC4 (1.7 & 3.3 log;p<0.01) and 
decreased for SLC22A3 (3.2 log;p<0.01). In the colorectum, gene differences were again 
observed between BLT and hu-HSC-Rag mice for ABCB1 (2.08 vs 26.3 x 10-4;p<0.001), 
SLC29A1 (0.07 vs 0.04;p=0.019), and ABCG2 (0.11 vs 0.05;p=0.001). No interspecies 
differences were seen. In all species, IHC showed MDR1 localization on the luminal surface of 
ileac and rectal mucosa and a lack of MRP2 expression. hu-HSC-Rag TFV tissue concentrations 
were 13 & 8-fold greater than BLTs and NHPs (p<0.05). 
This is the first study comparing the expression and localization of these transporters across 
animal models. Observed variability in expression suggests model-dependent ARV tissue 
penetration (e.g. decreased ABCB1 and increased ABCC4 expression in BLT mice explain the 
observed decrease in TFV exposure). Multi-log increases in ABCB1 expression between NHP 
and mice may impact the disposition of many ARVs that use ABCB1 for transport (e.g. TFV and 
RAL). Ultimately, these data can be coupled with ARV exposure data to inform inter-species 
drug scaling for targeting HIV reservoirs. 
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Spectrometry Imaging 
 
Corbin G. Thompson1, Eli Rosen2, Craig Sykes1, Yuri Fedoriw1, Paul Luciw3, David C. 
Muddiman2, and Angela DM Kashuba1 
1University of North Carolina at Chapel Hill, Chapel Hill, NC, USA 2North Carolina State 
University, Raleigh, NC, USA 3University of California at Davis, Davis, CA, USA  
 
HIV infection persists despite long-term antiretroviral (ARV) treatment. Inadequate ARV 
exposure in certain anatomic sites may contribute to continued viral replication within tissue 
reservoirs.  Detailed evaluations of the contribution of ARV disposition to the formation and 
persistence of these reservoirs would greatly inform HIV cure efforts. Recent studies have 
demonstrated differential ARV penetration into suspected reservoirs using tissue homogenates; 
however this method of evaluating ARV exposure in tissues is limited in its scope and ability to 
describe within-tissue ARV distribution. Mass spectrometry imaging (MSI) allows for the 
visualization of small molecule biodistribution within anatomic sites. Here, we use a novel MSI 
technique to characterize the distribution of two commonly prescribed ARVs within the lymph 
node, which has been implicated as an active viral reservoir.  
 
163 
 
A single uninfected rhesus macaque was dosed to steady-state with 30mg/kg tenofovir disoproxil 
fumarate (TDF) given subcutaneously, and 200mg efavirenz (EFV) given orally once daily. At 
necropsy, an inguinal lymph node was removed and frozen on dry ice. A single ten micron slice 
from each tissue was analyzed using an infrared matrix-assisted laser desorption electrospray 
ionization (IR-MALDESI) source coupled to a Thermo Q-Exactive mass spectrometer.  MSI 
data were analyzed using MSiReader software. In order to relate observed IR-MALDESI 
findings to tissue architecture, serial sections were fixed and stained with hematoxylin and eosin 
(H&E). 
 
IR-MALDESI imaging revealed non-homogenous ARV distribution within the tissue 
compartment. TFV and EFV were both detected in the lymph node, though their respective 
signals showcased unique tissue distribution. Visual inspection of the supporting H&E stain 
show that TFV signal was concentrated throughout the medullary sinuses, while EFV signal was 
predominantly visualized near a small section of the lymph node capsule.  
 
This is the first report of visualizing ARV distribution within a tissue implicated as a viral 
reservoir. Observed distributional patterns identified by IR-MALDESI, when coupled with H&E 
stains from serial slices, agree with tissue homogenate studies that have shown that TFV and 
EFV achieve measurable concentrations in the lymph nodes. The distinct distributional pattern of 
EFV compared to TFV suggests that ARV exposure within viral reservoirs cannot be assumed to 
be the same between individual agents. Further, TFV’s apparent preference for the vascularized 
medullary sinus over the lymphoid follicles may suggest inadequate concentrations at the site of 
action. Importantly, the distributional variation observed between TFV and EFV would not have 
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been captured with standard analytical methods and showcases the advantage of using MSI for 
future studies. Because the tissues evaluated in this study were removed from a dosed animal, the 
observed results are likely representative of ARV disposition during in vivo dosing scenarios. 
This study provides sound proof of concept for future evaluations defining drug distribution in 
animals and humans. 
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APPENDIX 6: GRANTS AND AWARDS  
 
 
September 2016 ASCPT Presidential Trainee Award 
 Scholarship awarded to top abstracts at the ASCPT conference 
 
November 2015 International Antiviral Society Young Investigator Award 
Scholarship given on the basis of abstract quality. Provides free 
attendance at CROI 2016 
 
2015-2016  AFPE Pre-Doctoral Fellowship in Pharmaceutical Sciences 
National award given to doctoral students who demonstrate promising 
research proposals 
 
November 2014 International Antiviral Society Young Investigator Award 
Scholarship given on the basis of abstract quality. Provides free 
attendance at CROI 2015 
 
August 2014  DPET Research Day Travel Award 
Divisional travel award given to the top three poster presenters at DPET 
Research Day  
 
2014-2015  AFPE Pre-Doctoral Fellowship in Pharmaceutical Sciences 
National award given to doctoral students who demonstrate promising 
research proposals 
 
2012-2013  AFPE-Rho Chi First Year Graduate School Fellowship 
National award given to two graduating pharmacy students who are 
pursuing a graduate degree 
 
2012-2013  UNC Eshelman Fellowship 
   For selected incoming students into the graduate program at UNC 
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